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ABSTRACT OF THE DISSERTATION
Guanine Nucleotide Synthesis and The Enteric Nervous System
by
Jonathan Ian Lake
Doctor of Philosophy in Biology & Biomedical Sciences
(Molecular Cell Biology)
Washington University in St. Louis, 2015
Professor Robert Heuckeroth, Chair
Professor David Ornitz, Co-Chair
There are currently no prevention strategies for Hirschsprung disease (HSCR), a potentially
lethal birth defect caused by the failure of the enteric nervous system (ENS) to develop
completely, resulting in an aganglionic segment of intestine. HSCR can result from one or a
combination of partially-penetrant mutations in genes affecting the enteric neural crest-derived
cells (ENCDCs) that colonize the intestine to form the ENS. While the genetics of HSCR and
ENS development has been extensively studied, little is known about environmental risk factors
for HSCR. To investigate maternal medication exposure as a possible HSCR risk factor, we
conducted a chemical screen in zebrafish embryos for drugs that inhibit ENS development.
Among several identified inhibitors of ENS development, we selected the antimetabolite
immunosuppressant medication mycophenolic acid (MPA) and its prodrug mycophenolate
mofetil (MMF) for further study. Here we demonstrate that maternal MPA or MMF exposure
impairs ENS development in mice through MPA-mediated inhibition of inosine–5’monophosphate dehydrogenase (IMPDH), which catalyzes the rate-limiting step of de novo
guanosine monophosphate (GMP) synthesis. This inhibition results in reduced ENCDC
proliferation that then impairs colonization of the intestine. We also show that MMF exposure is
sufficient to cause permanent ENS defects and greatly enhances the penetrance and severity of
aganglionosis in the Sox10 and Ret mouse models of HSCR. Prompted by this interaction
xiii

between IMPDH inhibition and ENS development and by the proximity of an essential IMPDH
gene, IMPDH2, to a mapped HSCR susceptibility region, we sequenced IMPDH2 in a cohort of
HSCR patients. We detected a single individual heterozygous for a nonsynonymous variant,
P123R, and show that it produces an enzyme with slightly reduced activity. Furthermore, we
deleted Impdh2 in neural crest derivatives in mice, resulting in major developmental defects
including drastically reduced ENCDC colonization of the intestine. However, heterozygosity for
a null allele of Impdh2 did not affect the penetrance of either Sox10 or Ret mutations. These
studies reinforce the importance of ENCDC proliferation to ENS development, demonstrate a
dramatic gene-drug interaction, and provide the first evidence that maternal medications may
increase HSCR risk.

xiv

Chapter 1: Introduction
Hirschsprung disease (HSCR), or congenital megacolon, is a birth defect affecting
1 in 5000 infants (1) in which a portion of the enteric nervous system (ENS) fails to form.
HSCR is lethal if not surgically treated and is an oligogenic disease with incomplete
penetrance and variable severity. The incomplete penetrance of HSCR mutations is
generally attributed to either interactions between multiple mutations or to random
developmental noise. While the human genetics of HSCR and developmental pathways
of ENS development have been very heavily studied, the contribution of environmental
factors to this birth defect’s penetrance may be overlooked. Investigating the effect of
environmental factors on ENS development could lead to prevention or mitigation
strategies for HSCR. To date, little attention has been paid to the possible role of
nongenetic factors on HSCR, though animal data and some limited human data suggests
that the fetal microenvironment exerts an influence. Since medications represent a group
of compounds that have known biological relevance, often have well-understood
mechanisms, and are actively used by people, they are an ideal tool with which to screen
for environmental exposures that influence phenotype.
The studies described here attempt to address this gap. In Chapter 2, I review the
genetics and cell biology of ENS development and the pathological processes that occur
in HSCR (2.3–2.10). I also discuss areas of ENS development and HSCR pathology
where mechanisms remain unexplained or data appears contradictory (2.11). I then
review the evidence from animal models and human studies that supports a role for geneenvironment interactions in ENS development and HSCR (2.13).
1

In Chapter 3, I describe a chemical screen in developing zebrafish that I
conducted together with other lab members and our detection of mycophenolic acid
(MPA) as an inhibitor of ENS development. I then describe my subsequent investigation
into the mechanism of MPA’s effects on ENS development and demonstrate gene-drug
interactions in mouse models of HSCR.
While the chemical screen was intended to detect compounds that affect ENS
development, it also prompted us to examine the genes in target pathways, the most
prominent being the genes encoding inosine 5’ monophosphate dehydrogenase (IMPDH),
the target of MPA. In Chapter 4, I examine the developmental role of one of the genes
that encodes this enzyme, Impdh2, in the mouse ENS using conditional deletion within
the neural crest. There, I demonstrate that Impdh2 expression in the neural crest is
essential for development of the craniofacial skeleton and for colonization of the bowel
by ENS progenitors.
In Chapter 5, I investigate the possible relationship between genetic variation in
the human IMPDH2 gene and HSCR, since this gene is located in a chromosomal region
associated with HSCR susceptibility. Sequencing of a cohort of HSCR patients revealed
one rare IMPDH2 variant that reduces its enzymatic activity, but mouse experiments did
not support an Impdh2 interaction with HSCR model mutations.
Together, these studies demonstrate the requirement for a basic metabolic process,
de novo guanine nucleotide synthesis, in ENS precursors, reinforce the critical role of
proliferation in this developmental process, and demonstrate proof-of-principle geneenvironment interactions in ENS development.

2

Chapter 2: Enteric Nervous System Development:
Migration, Differentiation, and Disease.
This chapter has been published as a review article by Jonathan I. Lake and Robert O.
Heuckeroth in American Journal of Physiology - Gastrointestinal and Liver Physiology 2013,
Volume 305, Issue 1, pp. G1-G24

2.1 Summary
The enteric nervous system (ENS) provides the intrinsic innervation of the bowel and is
the most neurochemically diverse branch of the peripheral nervous system, consisting of two
layers of ganglia and fibers encircling the entire gastrointestinal tract. The ENS is vital for life
and is capable of autonomous regulation of motility and secretion. Developmental studies in
model organisms and genetic studies of the most common congenital disease of the ENS,
Hirschsprung Disease (HSCR) have provided a detailed understanding of ENS development. The
ENS originates in the neural crest, mostly from the vagal levels of the neuraxis, which invades,
proliferates, and migrates within the intestinal wall until the entire bowel is colonized with
enteric neural crest-derived cells (ENCDCs.) After initial migration, the ENS develops further by
responding to guidance factors and morphogens that pattern the bowel concentrically,
differentiating into glia and neuronal subtypes, and wiring together to form a functional nervous
system. Molecules controlling this process are required for ENS development in humans,
including GDNF and its receptor RET, endothelin-3 and its receptor EDNRB, and transcription
factors such as SOX10 and PHOX2B. Important areas of active investigation include
3

mechanisms that guide ENCDC migration, the role and signals downstream of EDNRB, and
control of differentiation, neurochemical coding, and axonal targeting. Recent work also focuses
on disease treatment by exploring the natural role of ENS stem cells and investigating potential
therapeutic uses. Disease prevention may also be possible by modifying the fetal
microenvironment to reduce the penetrance of HSCR-causing mutations.

2.2 Introduction
The gastrointestinal tract requires finely tuned control over muscular activity and fluid
secretion to efficiently break down macroscopic food particles, efficiently extract nutrients, and
maintain a healthy luminal microbiome. An important arbiter of these processes is the enteric
nervous system (ENS), a network of neurons and glia within the wall of the bowel that controls
most aspects of intestinal function. In humans, the ENS contains about 500 million neurons of
more than 15 functional classes comprising a wide range of neurotransmitters, projection
patterns, and electrical properties (71). When the ENS is missing (aganglionosis) or defective,
children develop constipation, vomiting, abdominal pain, growth failure, and may die. Because
ENS development and function are complex, the regulatory molecules that control ENS
morphogenesis are also diverse. Disruption of one or more of these signals contributes to a
spectrum of diseases. The ENS is derived from the neural crest (NC), a highly migratory and
proliferative cell population originating at the junction of the neural plate and the adjacent
ectoderm. NC cells invade the bowel and migrate through the mesenchyme in a process that is
lengthy in both distance traveled and time required. Failure of enteric neural crest-derived cells
(ENCDCs) to colonize the distal bowel causes Hirschsprung disease (HSCR), a common (1 in
5000 live births) and life-threatening developmental disorder. Because enteric neurons are

4

required to actively relax intestinal smooth muscle, aganglionic bowel is tonically contracted
causing functional obstruction. HSCR is a non-Mendelian genetic disease with partial penetrance
and variable expressivity. Several excellent reviews of HSCR genetics (2, 111) and ENS
developmental biology (12, 40, 79, 81, 89, 90, 120, 140), have been published recently, but these
fields are advancing rapidly. Here, we will review recent studies in the field in the context of
existing models of ENS development and genetics and highlight areas that require additional
investigation.

2.3 The time course of ENS development
ENS precursors originate in the vagal and sacral segments of the neural tube. The vagal
NC is the major source of ENS precursors (217), while the sacral NC makes a small contribution
to the distal bowel (28, 52) and anterior trunk NC makes a small contribution to the foregut ENS
(57). Because vagal NC are most extensively studied and form the vast majority of the ENS, we
will focus our discussion on vagal NC while highlighting a few important differences in sacral
ENCDC biology. At embryonic day 9.5 (E9.5) in mouse (108) and prior to week 4 in human
embryos (63), pre-enteric neural crest-derived cells (pre-ENCDCs) invade the foregut and begin
their long rostrocaudal journey down the bowel. By E14 in mice and week 7 in humans (66), this
linear migration is complete (Figure 2.1). In mice and humans, ENCDC also undergo inward
radial migration after initially colonizing the bowel (103), forming the two layers of ganglia that
comprise the myenteric and submucosal plexi (Figure 2.2). Unless otherwise indicated we will
refer to mouse gestational ages. As the enteric neural crest-derived cells (ENCDCs) migrate,
they proliferate extensively, and then differentiate into neurons and glia and condense into
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ganglia to form a network throughout the bowel. Recent data also suggest that ENS stem cells
are present in both fetal and adult mammals raising interest in the possibility of autologous stem
cell therapy for treatment of Hirschsprung disease and other intestinal motility disorders (14,
138, 139). Formation of the ENS therefore requires extensive cell migration, controlled cell
proliferation, regulated differentiation, directed neurite growth and the establishment of a
network of interconnected neurons. Given these complex cellular events, each of which must be
guided by specific molecular signals, it is not surprising that the genetics of ENS disease is
complicated.

2.4 Human genetics of Hirschsprung Disease and associated syndromes
Most cases of HSCR are sporadic and occur as an isolated anomaly, but approximately
20% are familial and 30% have either cytogenetic abnormalities or additional developmental
defects that constitute a recognizable clinical syndrome. Currently, at least ten distinct genetic
syndromes are strongly associated with HSCR, and many other disorders affecting genes without
a clear role in ENS development occasionally include HSCR. These are beautifully discussed in
recent reviews (2, 111). There is also a strong male predominance (4:1 male/female ratio) in
children with HSCR restricted to the rectum and sigmoid colon (i.e., short segment disease) and
a weaker male predominance in children with long segment disease. Sibling recurrence rates for
HSCR vary from 1% to 33% depending on the gender of the proband, the length of
aganglionosis, and the gender of the new child. This is consistent with the hypothesis that
affected females and those with longer aganglionic regions are likely to carry greater genetic
liability than males with short segment HSCR. These complex genetic patterns are to be
expected given the developmental pathways needed to form the ENS and the many molecules
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Figure 2.1: Initial Colonization of the Mouse Gastrointestinal Tract by Enteric Neural
Crest-Derived Cells
During neural tube closure, neural crest cells (black) delaminate from the vagal region of the
dorsal neural tube and migrate (arrows denote direction) in the ventral stream to the region
adjacent to the foregut, which expresses glial cell line-derived neurotrophic factor (GDNF) (A).
After these pre-ENCDCs invade the foregut, they migrate rostrocaudally, proliferate, and
differentiate first into neurons (green) and later into glia (purple: earliest glial marker BFABP)
(B, C, D, E). As this process proceeds, the bowel lengthens and changes shape, first from a
straight line (B) to a single bend with midgut and hindgut closely apposed (C) followed by
growth of the cecal appendage and further lengthening of the entire bowel (D, E). From E11E12, ENCDCs invade the colon by crossing the mesentery and transiting the cecum (C). The
cecal and trans-mesenteric populations then fuse to form the ENS in the rostral colon (D) and the
trans-mesenteric population populates the terminal colon as the smaller sacral ENCDC
population enters the bowel and migrates caudorostrally (E). Regions of peak Gdnf (red) and
endothelin-3 (Edn3) (blue) production are shown (A,B,C,D, E). The peaks of Gdnf expression
partially but imperfectly mirror the extent of ENCDC migration, while peak Edn3 expression is
centered at the cecum. A smaller domain of Gdnf expression in the antimesenteric side of the
terminal colon may attract ENCDCs across the mesentery (C). Human ENS development
proceeds through a similar process.
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Figure 2.2: Primary and Secondary Migration of Mouse ENCDCs
While the wavefront of ENCDCs in the bowel moves steadily rostrocaudally, individual
ENCDCs have complex and unpredictable behaviors. At and immediately behind the wavefront
(A, middle and right), ENCDCs migrate in chains and are often closely associated with the
caudally-projecting neurites of immature neurons, which extend up to the wavefront. ENCDC
connections are transient, and cells often swap neighbors within a chain or detach to switch
chains or divide. The onset of neuronal lineage differentiation occurs very close to the wavefront
(A, left) and these cells retain some of their motility as they begin to extend neurites. In
colonized regions in mice (B, cross sectional illustration) a secondary centripetal migration of
ENCDCs is triggered by trophic factors and the morphogens that control the patterning of the
bowel wall. Netrin 1 and Netrin 3 are attractive to ENCDCs and are expressed in the epithelium,
outer mesenchyme, and pancreatic buds, triggering the secondary migration of ENCDCs toward
these structures. This broad attractive signal is probably refined by repulsive signals from sonic
hedgehog (SHH) in the epithelium and later bone morphogenetic protein 4 (BMP4) expression in
the inner mesenchyme, which SHH induces. A layer of BMP antagonist Noggin expressing cells
is located just inside the primary ENCDC migration layer, which may protect that region from
the influence of BMP4. The precise timing of these signals in relation to each other and the
secondary migration process has not yet been established. A similar secondary migration occurs
in humans, but this process appears to proceed differently in birds.
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that guide this development. Many mouse models with varying degrees of bowel aganglionosis,
hypoganglionosis, and other defects have been isolated or engineered (Table 2.1), many of which
are caused by disruption of orthologs of human HSCR genes.

2.5 Critical molecular mediators of ENS development:
The process of ENS development is controlled by cell surface receptors and their ligands,
transcription factors that regulate their expression, morphogens, and proteins that transmit
signals from the cell surface the cytoskeleton and the nucleus. Very brief summaries of these
proteins are provided before discussing their role in cell biology and development.

2.6 The RET/GFRα1/GDNF Pathway:
RET is a transmembrane tyrosine kinase receptor that is expressed in ENCDCs as they
migrate through the bowel. It is the signaling receptor for four ligands (glial cell line-derived
neurotrophic factor (GDNF), neurturin, artemin and persephin) that activate RET by binding to
the glycosylphosphatidylinositol linked GDNF family of Receptors (GFRα1, GFRα2, GFRα3
and GFRα4 respectively). RET signaling supports ENS precursor survival, proliferation,
migration, differentiation, and neurite growth (80, 92, 95, 146, 192, 219). Heterozygous
inactivating mutations in RET occur in about 15% of children with sporadic HSCR, and 50% of
children with familial HSCR (2, 111). A common intronic enhancer polymorphism (RET+3 or
rs2435357) is an important risk factor for HSCR that impairs RET expression (58). This
polymorphism underlies many cases of HSCR because of its high prevalence in the population.
In both mice and humans, total RET deficiency causes complete intestinal aganglionosis,
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highlighting the central role of RET signaling in ENS development (175, 177). RET’s coreceptor
GFRα1 and ligand GDNF are the critical RET activators during fetal development, and loss of
Gdnf and Gfra1 causes nearly identical phenotypes to Ret in mutant mice. Indeed, these genes
may be involved in rare cases of HSCR. Constitutively active mutations in RET cause the
hereditary cancer syndromes multiple endocrine neoplasia type 2 (MEN2A and MEN2B) and
familial medullary thyroid carcinoma (FMTC). MEN2A is genetically heterogeneous and
paradoxically associated with HSCR despite mutations that constitutively activate RET. In
contrast, MEN2B is almost always caused by the same M918T mutation and causes
ganglioneuromas to form within the ENS, impairing bowel function.

2.7 EDNRB, ET-3 and ECE1:
Another signaling pathway, centered on endothelin receptor B (EDNRB) and its ligand
endothelin-3 (ET-3) is required for ENS development in the colon. EDNRB is a G-protein
coupled receptor expressed in neural crest derivatives including the developing ENS.
Hypomorphic or null-mutations in EDNRB, EDN3 (encoding the prepropeptide for ET-3), or the
ligand-processing protease ECE can cause Hirschsprung disease, usually in the context of
Waardenburg syndrome type 4 (WS4), a disorder that includes pigmentation defects,
sensorineural deafness, dysmorphic facial features and aganglionic megacolon in humans.
Spontaneous mutation of EDNRB has also occurred in domesticated mice, rats, and horses,
producing a similar phenotype.
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2.8 Transcription factors important for ENCDC colonization of the bowel:
Several transcription factors play critical roles in early ENS development. In part they
are important because they influence the expression of RET (SOX10, PAX3, PHOX2B) (118,
119, 124, 154) or EDNRB (SOX10) (228), but this is clearly not their only role. While these
transcription factors are critical for cells in multiple organ systems, we will concentrate on their
roles in ENS development.
SOX10 is an SRY-related HMG-box transcription factor expressed in the neural tube
prior to NC delamination, in migratory ENCDCs, and in mature enteric glia. In humans,
heterozygous mutations in SOX10 cause WS4 with a highly penetrant HSCR component (1, 10,
63). Experiments with homozygous Sox10-null mice revealed apoptotic cell death of neural crest
cells prior to their entry to the foregut (109). Haploinsufficiency for Sox10 appears to decrease
the number of ENCDCs that initially colonize the bowel, eventually resulting in colonic
aganglionosis. In addition to these requirements for survival, appropriate population size, and
ENS gene transactivation, SOX10 has a critical role in maintaining ENCDCs in an
undifferentiated state. Overexpression and loss-of-function experiments in primary cell culture
(19, 112) and in chick embryos (137) indicate that SOX10 prevents precursors from
differentiating into neurons.
PHOX2B is a homeodomain transcription factor expressed in the neural crest-derived
autonomic nervous system, including the developing ENS and adult enteric neurons. PHOX2B is
required for Ret expression in mouse pre-ENCDCs (154), and heterozygous PHOX2B
polyalanine-expansion mutations cause congenital central hypoventilation syndrome (CCHS,
central sleep apnea) in people, a syndrome that may include Hirschsprung disease (Haddad
syndrome) (2, 11).
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Other transcription factors implicated in ENS development include PAX3 and ZFHX1B.
In humans, heterozygous PAX3 mutations cause Waardenburg syndrome without HSCR (158),
but PAX3 is required for development of the ENS in mouse (118). PAX3 also activates Ret
transcription in concert with SOX10. ZFHX1B (ZEB2/SIP1) mutations cause HSCR in the
context of Mowat-Wilson syndrome, which also includes microcephaly, mental retardation, and
dysmorphic facial features (31, 204). In mice, ablation of Zfhx1b within the neural crest prevents
ENCDC migration beyond the proximal duodenum (163). NKX2-1 and HOXB5 also physically
associate with RET’s promoter and increase its expression (124, 227). Their necessity in vivo
remains uncertain in the mouse, though mutations in both genes have been detected in the DNA
of some HSCR patients (75, 131).
Several other transcription factors have been linked to the ENS in model systems, but
have unexpected mutant phenotypes or an unknown relevance to human disease. ASCL1
(MASH1) and HAND2 (dHAND) are transcription factors required for the development of
subsets of autonomic neurons. In Ascl1-/- mice, ENCDCs colonize the bowel, but develop into a
sparse and abnormal ganglionic network (15) and do not form serotonergic neurons (15) or
esophageal neurons (85). Loss of Hand2 (93) results in a complex phenotype involving a failure
of multiple aspects of ENS development. Both Ascl1 and Hand2 will be discussed in the context
of neuronal subtype specification.

2.9 Morphogens in ENS development
Organization of the ENS requires the establishment of two ganglion cell networks in
precise locations within the bowel wall (Figure 2.2B). Neurons and glia cluster together into
ganglia, and then neurons extend neurites that initially fasciculate before innervating targets.
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Molecules controlling ENS morphogenesis are relatively poorly understood, but several classic
morphogens are now known to have important roles in ENS development. Some specific trophic
factors are also critical for subsets of enteric neurons, but their absence does not cause intestinal
aganglionosis or malformed ganglia.
The hedgehog pathway is involved both indirectly and directly in the developing ENS.
Hedgehog proteins have important roles as morphogens. For example, localized sonic hedgehog
(SHH) expression is critical for defining anterior-posterior patterning of digits in the limb (10)
and dorsoventral patterning in the spinal cord (50). Similarly in the bowel, localized expression
of hedgehog proteins in epithelium is essential for concentric patterning of the bowel wall (165).
The hedgehog ligands SHH and Indian hedgehog (IHH) are expressed by the gut epithelium
during bowel development (13, 165, Figure 2.2B). However, loss of SHH or IHH have very
different effects in mice, despite signaling though the same receptor and transduction machinery.
Targeted mutation of Shh results in excessive numbers of enteric neurons and improper
colonization of villi by enteric neuron cell bodies, whereas loss of Ihh causes dilated segments of
bowel and aganglionosis in parts of the GI tract (165). Oddly, ectopic expression of the
hedgehog pathway’s transcriptional effector GLI in developing mice produced an effect similar
to loss of Ihh (216). These disparate phenotypes in mice with hedgehog signaling pathway
mutations are incompletely understood. It is possible that Ihh and Shh mutant phenotypes differ
because of important temporal or spatial expression requirement for these proteins. Some of
these phenotypes are consistent with known hedgehog effects on ENCDCs since SHH promotes
proliferation, inhibits neuronal differentiation, and prevents premature centripetal invasion of
ENCDCs into the future submucosa (64, 187).
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A second role for hedgehog in the developing ENS is indirect. Hedgehog signaling
induces bowel mesenchyme to secrete bone morphogenetic protein 4 (BMP4), another important
modulator of ENS patterning. During initial ENCDC migration, BMP4 expression is induced in
a ring of mesenchyme adjacent to the epithelium. Noggin, a BMP antagonist, is secreted by cells
surrounding the BMP4 producing mesenchyme (82) and presumably reduces the effect of BMP4
on migratory ENCDCs (67). Interestingly, BMP effects on ENCDC migration differ between
mouse and chick. In organotypic and explant cultures of embryonic mouse bowel, inhibiting
BMP4 signaling with noggin enhances ENCDC migration (67), while chick embryos that
overexpress noggin in the mesenchyme inhibit ENCDC migration (82). However, BMP4 clearly
enhances neuronal aggregation in both organisms (38, 64, 82), and is probably important for the
clustering of ENCDCs into definitive ganglia. BMP4 also induces the fasciculation of neurites in
cell and organotypic culture systems. BMP effects on aggregation and fasciculation appear to be
mediated through the addition of the polysaccharide polysialic acid (PSA) to neural cell adhesion
molecule (NCAM) expressed by ENCDCs and enteric neurons (62, 67).
Netrins, diffusible ligands involved in central nervous system (CNS) and peripheral
nervous system (PNS) patterning, are also involved in the radial migration of the ENS that
occurs after initial colonization of the bowel. In mice, Netrins 1 and 3 are produced by the outer
bowel mesenchyme in the presumptive myenteric region and by the intestinal mucosa and
pancreatic buds (103), which are also invaded by ENCDC during this secondary migration
(Figure 2.2B). Deleted in colon cancer (DCC), a netrin receptor, is expressed in migrating
ENCDCs and is required for netrins to attract ENCDCs, since Dcc-/- mice do not develop a
submucosal plexus. Enteric neurons also produce netrins after they differentiate (167), attracting
extrinsic fibers from the vagus nerve. Interestingly, laminin, an extracellular matrix molecule
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that accumulates in the epithelial basal lamina and around enteric ganglia, converts the attractive
effect of netrins on vagal axons to repulsion (166). It is unclear if this repulsion of fibers also
applies to migrating ENCDCs, but if it does then such an effect could contribute to the cohesion
of ganglia and the exclusion of ENCDCs from the epithelium.
Semaphorins are diffusible ligands involved primarily in axon growth cone repulsion. In
the developing colon and cecum, Sema3A is expressed by the inner mesenchyme, while the
coreceptor for Sema3A, neuropilin-1, is expressed in all ENCDCs (4). Despite its wide
expression, Sema3A appears to specifically affect sacral ENCDCs and the extrinsic axons that
they migrate upon. Normally, sacral ENCDCs are sequestered until embryonic day 13.5 within
the pelvic ganglia that flank the end of the colon. They begin migrating up the colon, closely
associated with extrinsic nerve fibers, just before the arrival of the vagal ENCDC wavefront
(110, 209). In Sema3A-/- embryos, sacral ENCDCs migrate into the colon early, demonstrating
that Sema3A serves as a repulsive cue (4).
Retinoic acid (RA) is a diffusible morphogen produced locally in tissues by the
retinaldehyde dehydrogenase (RALDH) enzymes. Mice lacking Raldh2 die prior to ENS
development, but viability can be prolonged by exogenous RA supplementation. These partially
rescued embryos lack ENCDCs entirely (148), indicating a clear role for RA in ENS
development. In vitro, Retinoic acid has dramatic effects on both ENCDCs and differentiating
enteric neurons. For example, RA is required for the efficient migration of ENCDCs, and acts by
reducing levels of phosphatase and tensin homolog (PTEN) protein, a critical negative regulator
of ENCDC migration and proliferation that we will discuss below. RA also induces shorter
neurites in enteric neurons, a response opposite to that of most other neurons (174). Because RA
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is essential for normal ENS development, mouse embryos with impaired RA production due to
deficiency in its dietary source, Vitamin A, also have defects in ENS development (65).

2.10 Intracellular signaling molecules in the developing ENS
The trophic factors and morphogens that control ENS development depend on complex
intracellular signaling pathways for their action (Figure 2.3). This implicates a large number of
additional proteins whose function in the ENS has not been directly tested, and whose expression
patterns are not always restricted to the neural crest. For example, SHH, IHH, and GLI activity
implicates important functions for the Patched (PTCH1 or PTCH2) receptor and for Smoothened
(SMO). Similarly, BMP4 activity implies important roles for SMADs, and RA activity implies
that at least some of the retinoid receptors and metabolizing enzymes (RARα, RARβ, RARγ,
RXRα, RXRβ, RXRγ, RALDH1, RALDH2, RALDH3, ADH, RDH, CYP26A, CYP26B,
CYP26C, STRA6) will have essential functions that still need to be evaluated. This situation is
not confined to morphogen pathways and also applies to signals downstream of critical ENS
development genes. To illustrate the complexity of these signaling pathways, we will briefly
review the intracellular consequences of RET signaling, some of which have been directly
demonstrated in ENCDCs and others inferred from non-ENCDC RET-expressing tissues and
studies in cell culture.
The RET gene produces two protein isoforms, RET9 and RET51, which differ in their
intracellular domains and have some distinct signaling properties in different cell types. After
stimulation by a GDNF-family ligand complexed with the appropriate GFR coreceptor, RET
dimerizes and becomes autophosphorylated. Phosphorylated RET activates many intracellular
signaling pathways including phosphatidylinositol 3-kinase (PI 3-kinase) (146, 182),

16

Figure 2.3: Molecules and Pathways Implicated in ENS Development
The roles of molecules and pathways discussed in this review are shown in the contexts of
ENCDC migration (top), neuronal differentiation (bottom left), and glial differentiation (bottom
right). Markers used to distinguish these developmental stages are listed outside the cells.
Intracellular signaling molecules with important activating or inhibitory roles in RET signaling
within ENCDCs are boxed (red: inactivating, green: activating). Transcription factors with
known (color) or likely (gray) roles in ENS development are shown in nuclei. Important
mechanisms that remain unresolved are highlighted with black question marks including the
mechanism and targets of endothelin-3 (ET-3)/endothelin-receptor type B (EDNRB) signaling in
ENCDCs, the conditions that specify each subtype of neuron, the factors other than GDNF that
control axonal targeting and circuit formation, and the role of neurogenesis in adults. RA,
retinoic acid; PSA-NCAM, polysialic acid-neural cell adhesion molecule; ECE1, endothelinconverting enzyme 1; PP1, protein phosphatase 1; PTEN, phosphatase and tensin homolog;
ENCDC, enteric neural crest-derived cell.
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extracellular-regulated mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase
(JNK), p38 MAPK, phospholipase Cγ (PLC-γ), and the small GTPase Rac (70). These pathways
are activated by adapter complexes that bind to phosphorylated RET intracellular domains. cSRC also binds directly to activated RET and contributes to PI 3-kinase activation (59, 60).
Important docking tyrosines known to be required for ENS development include tyrosine 981,
the docking site for SRC, and tyrosine 1015, which activates phospholipase C-gamma. Tyrosine
1062 of the RET9 isoform is especially critical for ENS development (102, 211), and serves as a
docking site for adapter proteins SHC and GRB2, mediating activation of the MAPK and PI3K
pathways. Negative regulators of RET are also required for normal ENS development and
maturation. Mice lacking Sprouty2, a negative regulator of receptor tyrosine kinase signaling,
have hyperganglionosis, esophageal dysmotility, and intestinal motility defects due to
hypersensitivity of RET to GDNF signaling (189). Another recent study implicates KIF26A, an
atypical kinesin, in the negative regulation of RET through the binding and inhibition of GRB2.
Mice lacking Kif26a develop megacolon and hyperganglionosis, and appear to have defects in
neurite growth despite an overactive GDNF/RET signaling system (226). Overactivation of RET
also occurs in the context of MEN2A, which is occasionally co-incident with HSCR. This
paradoxical situation demonstrates that the same mutation can have activating effects in one
system (i.e., oncogenesis) and inactivating effects in another (ENS development). One possible
mechanism for this is that some MEN2A mutations, which result in inappropriate intermolecular
disulfide bond formation, activate RET via constitutive dimer formation but disrupt RET
structure and prevent its efficient expression at the cell surface (188). Protein trafficking to the
cell surface may be more efficient in some cells than in others, or perhaps the rapid rate of
ENCDC division does not permit the accumulation of poorly trafficked but hyperactive protein.
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Of the pathways activated downstream of RET, the PI 3-kinase pathway appears to be
most critical for ENCDC migration. Studies of ENCDC migration in the presence of PI 3-Kinase
inhibitors have demonstrated the importance of this pathway for migration towards GDNF (146).
PI3-kinase

phosphorylates

phosphatidylinositol

(4,5)-bisphosphate

(PIP2)

to

generate

phosphatidylinositol (3,4,5)-triphosphate (PIP3), which recruits the kinases PDK1 and AKT to
the membrane. In addition to targets downstream of AKT, PIP3 accumulation increases the local
activity of the Rho GTPases RAC1 and CDC42 through their guanine nucleotide exchange
factors, contributing to cell motility and neurite extension (83). This process also recruits the
partitioning defective (PAR) complex of polarity proteins (PAR3/PAR6/PKCζ), which influence
axon specification and growth. PKCζ, an atypical protein kinase C, is then activated by PIP3 and
PDK1 and may locally inhibit glycogen synthase kinase beta (GSK3β), which must be disabled
for definition and efficient growth of axons. In differentiating enteric neurons, inhibition of
PKCζ or GSK3β increased the number of neurons developing multiple axons and decreased
neurite growth (202). PKCζ and GSK3β inhibition also reduced ENCDC invasion of the colon in
organ culture assays, suggesting a role for polarity effectors in the migration of undifferentiated
ENCDCs or a role for neurite growth in the colonization process.
Molecules that inhibit the PI 3-kinase cascade are also involved in ENS development.
PTEN is a tumor suppressor protein that reverses the reaction catalyzed by PI3-kinase,
preventing activation of downstream effectors. In the ENS, PTEN serves as a “brake” on
ENCDC migration, proliferation, and growth. One recent study genetically ablated Pten within
the mouse neural crest, which caused intestinal hyperganglionosis and megacolon. These animals
also have overactivation of AKT and other downstream targets of the PI3-Kinase pathway within
the ENS (162). Enteric neuron hyperplasia began at embryonic day 16, several days after the
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colonization of the colon by ENCDCs. Another recent study complements these postcolonization findings, showing that PTEN levels must be reduced within migratory ENCDCs at
the wavefront for efficient migration (65). Furthermore, in cultured cells responding
chemotactically to GDNF, PTEN was polarized away from the leading edge of the cell and
PTEN overexpression impaired ENCDC migration.

2.11 Progress in answering persistent questions in ENS developmental biology
Despite dramatic advances in our understanding of the molecular and cellular mechanisms of
ENS development, many important questions remain only partially addressed.
2.11.1 Why do ENS precursors migrate through the bowel?
It has been difficult to identify a master mechanism that controls the migration of
ENCDCs. Clearly, The GDNF-RET-GFRα1 signaling pathway is critical for the migration of
ENCDCs out of explants (146, 219) and for their directional migration through Boyden chamber
membranes (65). GDNF is also mitogenic to ENCDCs and, at later stages of development,
trophic for differentiating enteric neurons. The expression of RET in the vagal NC begins at or
before E9, prior to the invasion of the foregut (57). At the same time, the foregut mesenchyme
begins to express Gdnf mRNA, so the GDNF protein can attract pre-ENCDCs adjacent to the
foregut (146). In addition, Gdnf expression along the gut mesenchyme appears to be
spatiotemporally patterned. At E9.5, Gdnf mRNA is abundant in the stomach. By E10.5, Gdnf
mRNA extends to the cecum and is most intense in this region. At both these time-points, the
ENCDC wavefront is rostral to the Gdnf expression peak. However, the cecum sustains the
highest level of Gdnf mRNA until ENCDCs complete their colonization of the terminal colon
(146). This suggests a role for a gradient of GDNF in promoting ENCDC migration, at least up
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to the point where ENCDCs pass through the cecum, after which GDNF chemoattraction cannot
explain their continued migration since Gdnf mRNA levels are lower in more distal bowel.
GDNF is clearly chemoattractive to ENCDCs in cell and organotypic culture (65, 146, 219), but
the ability of endogenous GDNF to induce directed chemotaxis of ENCDCs within the bowel
mesenchyme has been difficult to demonstrate in vivo. In addition to attracting pre-ENCDCs into
the foregut, another place where long-range GDNF signals might have an important role is
during the entry of the very first ENCDCs into the colon at E11 in mouse. A recent study has
determined that most of these pioneer cells actually enter the colon by crossing the mesentery
between the closely apposed midgut and hindgut (Figure 2.1C). Unlike the majority of ENCDCs,
which migrate though the bowel wall, these cells exit the midgut and migrate across the
mesentery as isolated cells. This study also showed that a thin band of antimesenteric colon
mesenchyme expresses Gdnf mRNA at this time point and that the mesenteric crossing process
requires GFRα1, suggesting that a long-range gradient of GDNF attracts these ENCDCs into the
colon. By combining organ culture and a mouse line expressing a photoconvertible fluorescent
protein in ENCDCs, the authors were able to mark these cells and demonstrate that the ENS in
the distal colon is derived almost entirely from ENCDCs that cross the mesentery.
A model that explains many aspects of vagal ENCDC migration within the bowel
mesenchyme (170, 193) is based on the observation that neural crest cells only migrate
efficiently through the bowel when at high densities and proliferating. According to this model,
migration need not be directed toward a particular attractive signal at the end of the bowel.
Instead, the only mechanisms required to produce a directionally migrating wavefront of cells are
a proliferating cell population, a limited “carrying capacity” of the local microenvironment, and
random motility of ENCDCs. Proliferation in one region proceeds until a limiting cell density is
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reached, and then stops. The translocation of the wavefront proceeds mostly by the proliferation
and random movement of cells at the wavefront (181). Thus, migration of individual cells need
not be directional for a moving wavefront to develop (180).
There is ample evidence to support this model. The first experiments demonstrating a
neural crest origin for the enteric ganglia showed that removing the vagal neural crest abolished
ganglia throughout the digestive tract, and that partial ablation produced partial aganglionosis,
always in the distal region of the bowel (217). Indeed, mechanically reducing the numbers of
ENCDCs in bowel explants reduces the population’s migration speed (218) and reduces their
invasion of the colon (53). ENCDC proliferation is also required for wavefront advance (181). In
addition, there is strong evidence that ENCDC migration is not intrinsically unidirectional
through the bowel, since ENCDCs grafted at the caudal ends of aneural bowel can migrate
caudorostally (181, 220), and vagal neural tube grafted into the sacral level of the neuraxis of
chick embryos results in ENCDCs that efficiently migrate caudorostrally through the bowel (27).
Finally, it is likely that the bowel microenvironment has a limited carrying capacity for
ENCDCs. Even in the absence of any other limiting factors, availability of GDNF limits the
proliferation of ENCDCs above a maximal density (80, 208).
The proliferation dependent model cannot explain all aspects of ENCDC colonization.
According to simulations based on this model, purely random diffusion would be sufficient to
create a migrating wavefront (180), but observations of migrating ENCDCs demonstrate
complex and nonrandom patterns of movement (Figure 2.2A). ENCDCs migrate in contact with
one another in structures that, near the wavefront, resemble caudally projecting “chains” of cells.
Time-lapse imaging of fluorescent ENCDCs in organ culture reveals that the ENCDCs in these
chains climb upon each other and have unpredictable trajectories (218). ENCDCs can detach
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from chains, sometimes forming new chains, or can advance along an existing chain (54)..
However, the overall structure of the chains and the spaces between them are persistent over time
despite the dynamic behavior of each ENCDC. These complex behaviors strongly suggest
additional signals governing ENCDC guidance that remain to be discovered. Furthermore, early
neuronal differentiation begins almost immediately behind the wavefront, and neurites grow
along chains of ENCDC. The nascent neuronal cell bodies also migrate along these neurites,
which generally project rostrocaudally (86, 220). At the wavefront itself, migration trajectories
of ENCDCs are also predominantly caudal (151, 218), suggesting that wavefront ENCDCs
migrate toward a local cue. It is possible that the ENCDC population generates a gradient of
GDNF by consuming or competing for GDNF. Endocytosis or simply receptor binding of GDNF
by ENCDCs may deplete most of the available GDNF behind the wavefront, creating a local
gradient that travels with the wavefront.

Another phenomenon that might contribute to the directed migration of wavefront cells is
contact inhibition of locomotion. Recent experiments in Xenopus neural crest demonstrated that
directional migration of neural crest cells is inhibited by contact with other neural crest cells, but
not with other cell types (32). Furthermore, the authors found that non-canonical Wnt signaling
(planar cell polarity) at cell-cell contacts mediates this repulsion. Disrupting this pathway
inhibits directional migration (34). This pathway, in turn, is dependent on the function of primary
cilia on neural crest cells and is disturbed in Bardet-Beidel Syndrome (BBS), an HSCRassociated condition caused by ciliary gene dysfunction (168). The caudally-directed migration
of individual ENCDCs at the wavefront could be driven by such a mechanism. Some aspects of
colonization might be explained by this behavior, such as the failure of vagal ENCDCs to
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colonize already colonized bowel, but others such as chain migration seem incompatible with
this mechanism.
The proliferation dependent and contact-mediated repulsion models of migration may
explain some otherwise perplexing non-cell-autonomous effects of ENS gene mutations. Mouse
chimera and grafting experiments have shown that mixing migration-capable neural crest cells
with a sufficient number of neural crest cells with genetic lesions in Ret (16), Ednrb (107), or
Sox10 (106) impairs migration of wild-type ENCDC enough to cause distal aganglionosis in
chimeric embryos and grafted bowel tissue. Wild-type ENCDC were also able to rescue the
migration of Ednrb null mutant ENCDCs in some chimeric embryos. Since RET, EDNRB and
SOX10 are primarily expressed within ENCDCs, the observed non-cell-autonomous effects
exerted on neighboring normal ENCDCs are surprising. These results are consistent with a
proliferation dependent model of migration, which predicts that if some part of the migratory
population is defective for proliferation or survival, as is the case in these models, incompetent
cells at the leading edge of the wavefront can inhibit the progress of the cells in the more
proximal bowel by reducing the size of the proliferating cell population and blocking progress
forward. Similarly, the ability of normal ENCDCs to rescue the migration of mutant ENCDCs
may be rooted in an increased overall population size or proliferative capacity. However, it may
also occur because wild type cells actively invade aganglionic bowel forming a substrate for
mutant cells to migrate on via chain migration or migration along neurites.
Several processes occur simultaneously during colonization of the bowel, including some
that fit a proliferation model (wavefront movement), some that appear more chemotactic
(movement of individual cells at the wavefront), and some related to cell or matrix adhesion
(fiber-climbing and chain-migration). Determining experimentally which of these processes are
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critical for colonization has been difficult, largely because mechanisms responsible for directed
migration, proliferation, and neurite growth share many molecules and pathways, making any
experimental separation difficult. Despite this difficulty, roles for several molecules involved in
neuronal polarity and cell motility have been demonstrated. As discussed previously, inhibiting
the neuronal polarity effectors GSK3β and PKCζ impairs ENCDC migration (202). Also,
chemical inhibition of the RAC and CDC42 GTPases or the RHO effectors ROCKI/II in the
cecum and colon reduced both migration and neurite growth without affecting proliferation
(185). In another study, genetic ablation of Rac1 and Cdc42 in the early neural crest impaired
neural crest cell proliferation and thereby prevented colonization of the distal bowel by
ENCDCs, but did not cause migration defects in early NC cells emigrating from the neural tube
(69). While both studies implicate Rho-family GTPases in ENS development, they suggest
different roles of these molecules in different stages of neural crest development.
Finally, we should not neglect the critical role of the extracellular matrix (ECM) and the
ENCDC proteins that interact with the ECM during bowel colonization. The ECM provides both
a mechanical substrate and important signals for ENCDC migration and differentiation. During
the process of ENCDC migration, the bowel mesenchyme matures from a uniform-appearing
population of mesenchymal cells into layers with distinct morphologies and ECM molecule
expression patterns (147). Maturation occurs in a bidirectional wave from rostral and caudal ends
of the bowel, and occurs more quickly than ENCDC colonization, so the ECM in contact with
ENCDCs is constantly changing. Laminin influences axon guidance, as noted previously, and
also enhances neuronal differentiation (43) Since newly differentiated neurons migrate more
slowly than undifferentiated ENCDCs (86), the high levels of laminin in the colon may
contribute to distal bowel aganglionosis.
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Important roles have also been assigned to several ECM-interacting molecules. β1
integrin (Itgb1) is important for ENCDC migration, and its loss from ENCDCs results in colonic
aganglionosis and structural abnormalities of the ENS (24). Integrins are cell surface receptors
for ECM molecules that participate in both adhesion and signaling. β1 integrins are necessary for
optimal ENCDC migration on fibronectin, which is present throughout the bowel and is enriched
in the hindgut. β1 integrin is especially critical for migration on the ECM molecule tenascin-C,
which is expressed at high levels in the hindgut and otherwise inhibits ENCDC migration (21).
β1 integrin is also important for transducing signals from the ECM, and dysregulation of these
signals impairs ENS development. PHACTR4, a protein recently shown to be required for
directed ENCDC migration, interacts with the actin cytoskeleton and protein phosphatase 1
(PP1). PHACTR4, though its interaction with PP1, modulates β1 integrin signaling and activates
the actin-severing protein cofilin, contributing to the formation of directionally stable
lamellipodia (225). This manifests as hypoganglionosis in Phactr4humdy/humdy mutant mice, which
lack interaction between PHACTR4 and PP1. During development, these embryos have less
directed ENCDC migration at the wavefront, despite having a normal random migration velocity.
Adhesion between an individual ENCDC and other ENCDCs is also important for
migration. The homophilic adhesion molecules N-cadherin, NCAM, and L1CAM are expressed
by migrating ENCDCs, and loss of either N-cadherin or L1CAM results in delayed ENCDC
migration and potentiates aganglionosis (5, 24, 206), though neither is sufficient to cause
aganglionosis by themselves. Finally, as previously discussed in the context of BMP signaling,
the posttranslational addition of polysialic acid to NCAM influences ENCDC aggregation and
migration efficiency (62, 67).

26

Migration and proliferation differ significantly between ENCDCs derived from the vagal
and sacral neural crest. Sacral crest-derived ENCDCs migrate in isolation rather than in chains
(209), always moving along extrinsic neuronal fibers that project into the hindgut. Although
sacral ENCDCs arrive in the terminal hindgut at the same time as vagal ENCDCs, they continue
to migrate caudorostrally through vagal crest-colonized bowel. In contrast, vagal ENCDCs will
not enter previously colonized bowel (97). The proliferative capacity of sacral ENCDCs is also
very different from vagal ENCDCs. While sacral ENCDCs normally comprise about 10-20% of
the most distal region of the ENS (28, 209), their population only slightly expands if the vagal
neural crest is mechanically ablated in chick embryos (26) and the hindgut is otherwise devoid of
ENCDCs. Vagal-to-sacral transplantation experiments in the chick (27) have demonstrated at
least some of these differences in behavior reflect intrinsic differences between sacral and vagal
neural crest rather than different signals along the migration routes. While vagal and sacral
ENCDCs express the same ENCDC-specific markers (3, 49), an RNA microarray comparing
vagal and sacral chick neural tube explants (49) indicated that sacral-derived crest expressed less
RET mRNA than vagal crest, and their behavior was partially transformed to that of vagal crest
by RET overexpression. A study in mice where the vagal wavefront was significantly delayed
(neural-crest specific Ednrb deletion) confirmed the finding that RET expression was reduced in
sacral ENCDCs (61). Notably, In the Ret-/- and Gfra1-/- mouse models of total intestinal
aganglionosis (57, 30) and a conditional Ednrb ablation model of colonic aganglionosis (61),
rare intrinsic neurons can be found within the most distal bowel. These almost certainly represent
the remnants of the sacral ENCDC population. Since these neurons are rare and their numbers
approach neither the expected sacral-derived densities observed in the chick nor those estimated
in mouse organ culture experiments (28, 209), it seems likely that mutations affecting vagal
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ENCDCs also affect sacral ENCDCs, which likely accounts for their absence in the terminal
colon of HSCR patients. To our knowledge, it is not known whether the aganglionic segment of
HSCR-affected terminal colon contains any residual neurons, but they would likely be difficult
to detect using routine diagnostic histology and would not form a functional ENS.
2.11.2 What is the function of EDNRB in ENS development?
Although EDNRB/EDN3 signaling is essential for efficient colonization of the colon and
clearly influences ENCDC differentiation and migration, many of the cellular and molecular
effects of EDNRB/EDN3 signaling on the developing ENS remain confusing. Total loss of
EDNRB signaling results in colonic aganglionosis, abnormalities of the ENS in the small bowel
(33), and a developmental delay in ENCDC migration (55). This is a much milder phenotype
than is associated with a loss of RET signaling. There are two primary processes that EDNRB
affects within ENCDCs: it prevents premature neuronal differentiation and it is required for
efficient migration within the colon. Here we will summarize the well-established actions of
EDNRB and discuss some apparently contradictory observations demonstrating species specific,
region specific, and cell-type specific roles for EDNRB in the ENS.
In culture, there is significant evidence that the EDNRB ligand ET-3 maintains ENCDCs
in an undifferentiated state (19, 92, 213). ET-3 alone does not appear to cause proliferation, but
ET-3 treatment causes overpopulation of the developing ENS in avian gut explants (143) and
acts together with GDNF to increase the proliferation of undifferentiated mouse ENCDCs (8).
ET-3 administration to cultured enteric progenitors maintains their expression of SOX10 and
their undifferentiated state (19), suggesting that EDNRB signaling might be required to prevent
premature loss of SOX10 protein. These observations are consistent with a role for ET3/EDNRB signaling in repressing neuronal differentiation that might otherwise be triggered by
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the high GDNF levels in the cecum and rising laminin levels in the colon (55). Since neurons are
post-mitotic, enhanced neuronal differentiation will reduce the proliferative drive that supports
bowel colonization by ENCDCs. The similarity of the phenotypes that result from EDNRB or
SOX10 mutations (colonic aganglionosis) and their genetic interaction when mutated (discussed
below) further suggests that EDNRB and SOX10 are components of a common pathway that
keeps ENCDCs undifferentiated. In mouse ENCDCs, Ednrb expression is directly regulated by
SOX10 binding to promoter elements upstream of Ednrb (228), possibly forming a positive
feedback loop contingent on ET-3 signaling.
It is unclear whether increased neuronal differentiation occurs in vivo when EDNRB
signaling is defective. The best evidence, from homozygous null Edn3 mouse embryos, showed
an increase in the percentage of wavefront ENCDCs positive for neuron-specific βIII tubulin,
indicating an increase in early neuronal differentiation (19). However, in a recent study that used
a conditional allele of Ednrb allowing specific ablation from the neural crest, the wavefront did
not display an increased proportion of ENCDCs positive for the neuronal marker Hu (55). In
another study of Ednrb-null rat embryos, the wavefront also failed to display an increase in
peripherin positive cells (116). This same study showed that rat enteric neural crest stem cells
(NCSCs), a defined subpopulation of crest-derived cells in the gut, respond to ET-3 in culture by
differentiating into myofibroblast-like cells. It is unclear whether differences between cell types,
the mutation status of Edn3 or Ednrb, the neuronal markers chosen, or the species studied
account for these differing results suggesting the need for additional investigation of the role of
EDNRB signaling in the ENS.
Despite the fact that ENCDCs lacking Ednrb have a migratory delay throughout ENS
development, ENCDCs have a specific requirement for EDNRB signaling as they migrate
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through the colon. In grafting experiments performed in organotypic culture, neural crest cells
from normal bowel colonized normal embryonic colon, but did not invade embryonic colon from
mice with Edn3 mutations (101). Edn3 mRNA appears to be expressed in a spatially and
temporally regulated manner that tracks the migration of ENCDCs, and EDNRB signaling is
required during a very narrow temporal window roughly corresponding to colonic migration. At
E10, Edn3 mRNA is expressed throughout the midgut, but levels become elevated in the cecum
at E10.5 and this domain of expression extends into the hindgut at E11, when ENCDCs are
migrating through the cecum (8). This is identical to the temporal interval when EDNRB
signaling is required for ENS development (E10.5 to E12.5) as shown using a tetracyclineregulated Ednrb knock-in mouse (178). Like the effects on differentiation, some of the effects of
ET-3/EDNRB signaling on migration are also contradictory and difficult to interpret. One issue
is that ET-3 appears to have divergent effects on ENCDC migration under different conditions.
ET-3 impairs GDNF’s chemoattractive effects on ENCDCs in explants cultured in collagen gels
(8, 116, 143), but appears to encourage migration through the colon in explant cultures (143),
and to partially rescue colon colonization when RET signaling is dysfunctional (203). EDNRB
antagonists also cause colonic hypoganglionosis or aganglionosis in culture (143, 212), and acute
chemical inhibition of EDNRB in colonic ENCDCs produces immediate retraction of cell
processes and loss of motility that occurs too quickly to result from effects on differentiation
(55). In addition to its expression in ENCDCs, EDNRB is expressed to some degree in the
mesenchyme (8) of mouse bowel. This observation, combined with the finding that laminin-α
expression by enteric smooth muscle cells is negatively regulated by ET-3 (213) suggested that
EDNRB signaling in the mesenchyme might be necessary to create a colonic microenvironment
permissive to ENCDC colonization. However, mesenchymal expression of EDNRB is not
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conserved in the chick (143, 144). Furthermore, neural-crest specific ablation of Ednrb produces
the same ENS phenotype as a null allele (56) and colonic aganglionosis in rats lacking Ednrb can
be rescued with a transgene that expresses functional EDNRB specifically in ENCDCs (78),
indicating that neural crest cells are the critical targets of the ET-3 signaling required for ENS
development.
The importance of each second messenger pathway activated downstream of EDNRB is
also unclear. One disease-causing mutation in EDNRB has been linked to a selective loss of
Gαq/Gα11 coupling and intracellular Ca2+ signaling (100, 161) while two others have been shown
to perturb Gαi coupling and prevent the reduction in cyclic-AMP levels that occurs with Gαi
activation (68). Of these possibilities, there is more evidence for EDNRB signaling through
cyclic-AMP in ENCDCs. Indeed, neural crest-restricted deletion of Gαq/Gα11 did not result in any
ENS defects (51). In primary enteric progenitor cell culture, the anti-differentiation actions of
ET-3 were mimicked by inhibition of the cAMP-regulated protein kinase A (PKA), and
suppressed by increasing cyclic-AMP (8). In the same study, a protein kinase C inhibitor did not
appear to inhibit the effects of EDNRB stimulation, which would be likely if some of the actions
of EDNRB were mediated through Gαq/Gα11. Interestingly, cAMP-dependent and cAMPindependent activation of PKA downstream of BMP signaling have important roles controlling
differentiation of another neural-crest derived population, noradrenergic sympathetic neurons
(129). However, inhibiting PKA activity is probably not uniformly beneficial to the developing
ENS. PKA has been shown to phosphorylate RET at a serine residue (70) important for
lamellipodia formation in culture. Targeted mutation of this site to prevent phosphorylation
results in distal colonic aganglionosis and ENCDC migration defects (6). Moreover, the same
study demonstrated that PKA inhibition reduced ENCDC migration in the colon. This
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requirement of PKA activity for migration is difficult to reconcile with the evidence for
inhibition of cAMP signaling required to maintain ENCDCs in an undifferentiated state.
Intermediate levels of PKA activation or fine temporal or spatial control of cAMP or PKA may
be required for normal ENS development. Further study of the ET-3/EDNRB signaling pathway
in ENCDCs is necessary to better understand these important molecules.
2.11.3 What controls neuronal versus glial differentiation of ENS precursors and what
controls neuronal subtype specification?
Although appropriate differentiation into the many neuronal classes and into glia and is
absolutely critical for ENS function, the signals that control these cell fate decisions are less well
understood than the process of initial ENS colonization by the multipotent ENCDCs.
ENCDC, neuron, or glial cell?
Presumably, an ENCDC must decide whether to self-renew or differentiate into a
neuronal or a glial progenitor. While SOX10 has a central role in maintaining ENCDCs (19,
112), it is not sufficient for maintaining an undifferentiated state, since both ENCDCs and adult
enteric glia express SOX10. Notch signaling is implicated in gliogenesis in other areas of the
PNS, but appears to have a different role in the ENS. Mice with neural crest incapable of
receiving Notch signals develop a hypocellular ENS as newborns, accompanied by reduced
Sox10 expression in migrating ENCDCs and inappropriately high level of neuronal
differentiation in the population of migrating ENCDCs. Thus, in the developing ENS, Notch is
required to prevent premature neuronal differentiation and depletion of undifferentiated
ENCDCs. One signal recently demonstrated to be important for enteric glial development is the
secreted factor LGI4, which is produced by migrating ENCDCs in the bowel and glia
themselves. Mutations in Lgi4 or its receptor ADAM22 reduce the number of enteric glia and
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alter ENS structure (150). BMP signaling may be involved in specifying enteric glia, since it
induces glial differentiation of ENCDCs in vitro and these developing glia become dependent on
glial growth factor 2 (Ggf2, a NRG1 isoform) signaling through ErbB3 for survival (39). RA
signaling also increases neuronal differentiation and the proliferation of cells with early neuronal
markers, but not at the expense of glia (174).
Neurogenesis in the ENS is asynchronous
Cells expressing early neuronal markers (Tubb3/Tuj1 and HuC/HuD) and bearing long
processes appear in the ENS almost immediately after colonization begins (86, 221). A core
population remains as undifferentiated ENCDCs and are presumably responsible for propagating
the ENCDC wavefront down the bowel. Other cells express pan-neuronal markers and extend
neurites but remain in the cell cycle and continue to migrate. Still others exit the cell cycle during
specific intervals (a neuron’s “birth date”), and differentiate into diverse enteric neuron subtypes.
Neuronal birth dating is a technique that exploits labels such as BrdU or tritiated thymidine that
are permanently integrated into the DNA of replicating cells. The label is administered at one
selected time point and development is allowed to continue. Neuronal precursors that incorporate
the label and then become postmitotic retain high levels of the label, while cells that continue to
divide dilute the label to undetectable levels. Thus, this technique marks cells preparing for their
final division. In the mouse, serotonergic neurons are born earliest (embryonic days 9-15), and
birth of cholinergic neurons peaks at E14 and continues until E17. Birth dates for dopaminergic,
peptidergic, nitrergic, and GABA-ergic neurons peak at E14 in the myenteric plexus and close to
P0 in the submucosal plexus, extending into postnatal life for up to two weeks after birth (41,
156). While the expression of a neurochemical phenotype occurs some time after a given
neuron’s birth, the tight association between the time of cell cycle exit and neurochemical
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phenotypes suggests that the timing of cell cycle exit may control some aspect of neurochemical
fate. Alternatively, an upstream mechanism that remains unknown may determine both birth date
and ultimate fate.
Signals and genes affecting neuronal subtypes
There are relatively few genetic models that lack subsets of enteric neurons. This is likely
due to the difficulty of identifying subtle ENS phenotypes, which may not lead to life threatening
bowel dysfunction. A prominent exception is serotonin (5-hydroxytryptamine, 5-HT) producing
neurons that are absolutely dependent on the transcription factor ASCL1. Serotonergic and, to a
lesser extent, calretinin-expressing neurons also require the norepinephrine transporter (NET,
Slc6a2) to develop in proper numbers (125). Another transcription factor required for terminal
differentiation of enteric neurons is HAND2, a basic helix-loop-helix transcription factor needed
for heart and neural crest development. Hand2 is not required for ENCDC migration down the
bowel, but its deletion results in profound defects in overall ENS structure (93), reductions in
neuronal density (93, 48), severe bowel distension likely caused by ENS defects (123) and either
subtype-selective (93, 123) or a more general failure (48) to differentiate into functional neurons.
Overexpression studies demonstrate that HAND2 is sufficient to both support neurogenesis (93)
and specify vasoactive intestinal peptide (VIP) expression in cultured chick ENCDCs, while
early neural crest-specific deletion of mouse Hand2 results in a loss of VIP-expressing neurons
(93). In a mouse model where Hand2 is deleted in a specific subset of ENCDCs, (123) precursor
proliferation, gliogenesis, and the specification of many (cholinergic, nitrinergic, and calretininexpressing) but not all neuronal subtypes were impaired within the population derived from
Hand2 deleted ENCDCs, Reductions in numbers of specific neuronal subtypes (nitrergic and
calretinin-expressing but not substance P-expressing) also result from haploinsufficiency for and
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hypomorphic alleles of Hand2 (47). Since Hand2 is expressed and experimentally deleted in
both undifferentiated ENCDCs and differentiating neurons and glia, the precise stage where loss
of Hand2 alters neuronal subtype specification or gliogenesis is not yet known.
Another signal critical for specific cell populations in the ENS is neurotrophin-3 (NT-3),
which signals through the p75 neurotrophin receptor and the TrkC receptor. Mice lacking NT-3
or TrkC had significantly fewer neurons throughout the ENS, with a particular deficit in the
submucosal plexus (42). Calcitonin gene-related peptide (CGRP) reactive submucosal neurons
are most sensitive to loss of NT-3/TrkC signaling. However, this signaling pathway does not
appear to uniquely identify a single type of neuron. BMP2 and BMP4 signaling also influence
neuronal subtype and enhance the development of this TrkC+ population (38, 41). When the
BMP inhibitor Noggin was expressed ectopically in all enteric neurons in vivo, the overall
neuronal density in the ENS increased markedly, but the number and proportion of TrkC+
neurons was reduced. Conversely, a transgene expressing BMP4 increased the proportion of
TrkC+ neurons in the adult ENS. These studies implicate BMP signaling in both specification of
a particular neuronal subtype (TrkC+) and limiting the numbers of other neurons (TrkC-). In
particular, the density and proportion of early-born classes of neuron were increased and of lateborn classes were decreased when BMP signaling was inhibited by the Noggin transgene (41).
In accordance with the effects of BMPs on glial differentiation in culture, the same Noggin
transgene also reduced the density and proportion of glia in the ENS (39).
Early neuronal activity shapes late-differentiating neurons
Since enteric neurons are “born” asynchronously, the activity of early-born neurons has
the potential to shape developmental decisions in later-born neuronal populations. Serotonin
producing neurons are one of the earliest-born populations in the ENS (156) and the 5-HT
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produced by these cells has a significant effect on the development of later-born neuronal
populations (126). ENCDCs express many classes of serotonin receptors and 5-HT promotes the
neuronal differentiation of ENCDCs in culture. Mice with enteric neurons unable to synthesize
5-HT develop fewer neurons of several late-born classes including dopaminergic, GABA-ergic,
and a subset of nitrergic neurons. Serotonergic neurons, in turn, require the norepinephrine
transporter for proper development, which suggests that norepinephrine uptake may shape
neuronal differentiation. Recent work has also demonstrated that nascent enteric neurons are
electrically active very early in the colonization process (87), and that inhibition of this activity
reduces the number of early-born nitrergic neurons close to the ENCDC wavefront (88),
suggesting that the interdependence of different types of enteric neuron is not limited to the lateborn populations. Finally, neuronal activity may be important for ENCDC colonization of the
bowel, since Tetanus and Botulinum neurotoxins slow neurite extension and ENCDC migration
(201).
Lineage restriction and decision points
There are a few known progenitor states that mark major decision points in the enteric
neuron generation program. One important mark of lineage restriction is the transiently
catecholaminergic (TC) class of immature enteric neuron. Neurons expressing catecholaminergic
markers are common early in the colonization process, but definitive catecholaminergic neurons
represent a small fraction of the mature ENS. The early, transiently catecholaminergic (TC)
lineage encompasses many terminal fates, but it includes all future serotonergic neurons (7) and
excludes certain fates, including late-born CGRP-producing neurons (15). TC status is clearly a
marker of an important decision-making step, but the factors controlling this decision remain
unknown, though Ascl1 may contribute since it is required for development of the TC lineage
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(15). Also, since TC cells produce norepinephrine and both TC-cells and the TC-derived lineage
express the norepinephrine transporter, the TC-lineage may influence its own developmental fate
by signaling through norepinephrine.
2.11.4 What controls neurite outgrowth and axon pathfinding in the ENS?
The ENS is controlled by the organized connections between neurons of different types
in different regions. In the CNS and other regions of the PNS, target-derived trophic factors
ensure that specific neuronal subtypes are matched qualitatively and quantitatively to their
targets. This system works well because axon tips and neuronal cell bodies are usually distant
from each other and in quite distinct environments. In contrast, ENS neurons often have a
similar environment at the axon tip and cell body (e.g. for cells whose soma and neurites remain
within the myenteric plexus) making it difficult to imagine how target derived trophic factors
might direct the proper wiring of the adult ENS. While distribution of neuronal classes clearly
differs between different areas of the ENS, each ganglion is indistinguishable from its immediate
oral or aboral neighbor. Few conditions leading to defects in targeting of neuronal projections
have been demonstrated in the ENS at least in part because there has until recently been no
simple way to track neurites of single enteric neurons. One study has demonstrated that the
targeting of projections from myenteric nitrergic neurons is controlled by GDNF during perinatal
and postnatal development. When GDNF was ectopically expressed in enteric glia using the glial
fibrillary acid protein (GFAP) promoter, NADPH diaphorase positive (a marker of nitric oxide
synthase) fibers redistributed densely around enteric glia, suggesting a role for GDNF in axon
targeting for this subtype of enteric neuron (208). In contrast, neither cholinergic nor
serotonergic neuron fibers redistributed toward enteric glia in these GDNF overexpressing mice.
A recent study used ligand regulated Cre recombinase and a fluorescent recombination reporter
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to label single enteric neurons in fetal bowel (173). Using this system, they were able to detect
very subtle structural ENS defects and demonstrated that enteric neurons require the planar cell
polarity signaling components Celsr3 and Fzd3 for proper wiring. Further study and innovative
methods will be required to better understand the maturation of the nascent ENS into functional
circuits.
2.11.5 What is the normal role of cell death in the developing and mature ENS?
Programmed cell death in the form of apoptosis plays a critical role matching neuron
numbers to target size and ensuring correct targeting of neurites in the developing vertebrate
CNS and other regions of the PNS. In fact, in most regions of the nervous system more than half
of the neurons generated undergo apoptosis, often after target innervation (25). In contrast,
during normal ENS development, some apoptosis occurs in pre-ENCDCs (i.e., before these cells
enter the bowel) and this may be important for limiting ENS density in the proximal bowel
(205). However, after ENCDC entry into the bowel, programmed cell death in the form of
apoptosis does not appear to play a role in ENS development in wild type mice. In contrast, cell
death does occur in the ENS of mice with specific gene defects. In support of this statement,
activated caspase-3 (a marker of cells undergoing apoptosis) is extremely rare in the fetal,
newborn, and adult ENS (80) of wild type mice. Rare instances of nuclear fragmentation and
death have been observed in migrating SOX10+ ENCDCs (45), although these events are so
infrequent that they are unlikely to influence the size of the ENCDC population. Moreover, Bax-/and Bid-/- mice, which have defective apoptosis in other developing neuronal populations, have
an essentially normal ENS (80). Thus, programmed cell death appears to be involved in
regulating the number of ENCDC precursors that initially arrive in the bowel, but seems unlikely
to control later developmental processes such as neuronal subtype ratios and ENS wiring.
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However, it should also be noted that ENCDC apoptosis is a critical consequence of complete
Ret and Sox10 deficiency. Furthermore, under certain circumstances, an unusual form of cell
death occurs in the ENS. When GFRα1 is genetically ablated after ENCDC migration is
complete, neurons undergo non-apoptotic cell death, and do not display ultrastructural signs of
necrosis or autophagy (198). A subsequent study also demonstrated that a similar atypical
ENCDC death occurs in the colons of mice with reduced Ret expression (Ret9/-) (199), a model
that very closely resembles RET mediated HSCR in humans. Thus, this atypical cell death may
prove to be a critical contributor to the most common form of HSCR.
2.11.6 Applying our understanding of ENS development to human disease
These exciting advances in our understanding of the mechanisms of ENS development
raise new hope that novel strategies can be developed to reduce the frequency and severity of
human intestinal motility disorders. Managing HSCR remains a challenge in the modern era.
One to 10% of children with HSCR still die despite advances in surgical treatment and postoperative management (2, 159). Furthermore, long-segment aganglionosis can necessitate the
removal of enough small bowel to cause short gut syndrome resulting in long term dependence
on parenteral nutrition, which has serious risks of infection and liver damage. Several other less
well understood clinical conditions are caused by altered ENS activity. For example, chronic
idiopathic intestinal pseudoobstruction (CIIP), a condition where intestinal motility is abnormal
but neurons are present, can also be caused by structural and functional ENS defects that may or
may not be obvious on routine clinical biopsies. Based on murine models where the ENS is
formed, but the bowel does not function properly, pseudoobstruction of neuronal origin is likely
to be due to a variety of failures in post-colonization ENS development such as neurotransmitter
selection, axonal targeting, or synaptogenesis. For example, RET activating mutations that cause
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MEN2B and mutations in FLNA (77) cause dysmotility, but the motility defects remain
incompletely characterized. In contrast to the major defects that may underlie chronic
pseudoobstruction, even more subtle changes to the physiology of the ENS may contribute to
irritable bowel syndrome and other “functional” motility disorders. In fact, genetic lesions that
alter the structure of the ENS can produce or modify bowel inflammation, suggesting that
developmental abnormalities of the ENS can contribute to the severity of inflammatory bowel
disease (29, 134). Understanding neuronal cell fate decisions and the wiring process that
generates the normal ENS will help us better understand how these pathophysiological events
impair intestinal function, and may suggest novel clinical interventions for intestinal motility and
inflammatory diseases.
2.11.7 Why is HSCR partially penetrant and why does the extent of aganglionosis vary
between individuals?
Human birth defects including HSCR result from genetic defects, non-genetic factors or
interactions between genes and “fetal environmental” factors. In some cases, single-gene defects
are the major risk factor for HD occurrence and have very high penetrance. However, no known
HSCR associated gene defect is fully penetrant. A partial explanation for this observation is that
genetic interactions critically influence HD penetrance. For example, there is a well-established
genetic interaction between EDNRB and RET mutations in both humans and in mice. Alleles of
each gene that produce mild phenotypes or no phenotype in isolation can cause severe disease in
compound heterozygous mice and humans (36, 136). In mice, non-penetrant and weaklypenetrant alleles of Ednrb (or Edn3) can also worsen the severity of the ENS phenotype resulting
from Sox10 mutations (33, 183). In addition to RET coding mutations, a common intron one
polymorphism that reduces RET expression (RET+3 or rs2435357) is highly associated with
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sporadic HSCR and modifies the penetrance of HSCR in various predisposing syndromes (58,
152, 160). Recent studies have also implicated neuregulin 1 (NRG1) as a modifier of RETdependent HSCR risk (76). Additionally, genes at several other chromosomal loci may influence
HSCR risk in people with RET mutations (17, 72, 74, 190), though identifying the specific genes
has been challenging.
Genetic interactions cannot explain all of HSCR’s variability, since HSCR-like
phenotypes in many inbred animal models are partially penetrant and of variably severity.
Sox10Dom is an excellent example of this phenomenon (33). “Developmental noise” or random
occurrences at the level of individual ENCDC movement might influence migration processivity
and speed. This could be translated into a variable extent of aganglionosis as the bowel wall
eventually becomes relatively non-permissive to continued invasion (55, 97) after E14 and the
migration wavefront is frozen in position, forming the transition zone between ganglionic and
aganglionic bowel. The non-permissiveness of older bowel is relative rather than absolute, as
illustrated by Tcof1 (Treacher Collins-Franceschetti syndrome 1) mutant mice, where
heterozygous mice do not fully colonize the bowel at E14.5 due to depletion of early neural crest
precursors but continue to migrate, fully colonizing the colon by E18.5 (9). Tcof1 ENCDCs,
however, have abnormally low rates of differentiation and may in fact be more capable of
migrating through older bowel than wild-type ENCDCs. Another situation where ENCDCs
complete their migration despite a significant colonization delay occurs in the rescued Ret9/mouse model. These mice develop colonic aganglionosis after a moderate ENCDC migration
delay and ENCDC death in the colon (199), but in mice that also overexpress the pro-survival
protein Bcl-XL, the colon is eventually fully colonized even though ENCDC migration is not
rescued and is incomplete at E13.5. In these situations, it seems that abnormal “hardier”
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ENCDCs are capable of compensating for a developmental delay that would normally contribute
to aganglionosis (197).
2.11.8 Why is HSCR more common in males than in females?
Another perplexing issue in the study of HSCR and ENS development is the male bias
for penetrant disease. Interestingly, the male bias is much more pronounced in patients with
short-segment disease (5.5:1) than in those with longer regions of aganglionosis (1.75:1) (2).
Conceptually, this makes sense if we consider male sex as a mild predisposing factor for
aganglionosis. Among syndromic HSCR cases, length of aganglionosis mostly correlates with
penetrance of a mutation (160), and strongly penetrant mutations are not dependent on a weak
modifier like sex. The molecular basis of this sex bias has been difficult to determine, despite
several genetic models of colonic aganglionosis that demonstrate a similar predominance of
affected males (33, 136, 199). Mutations in one X-linked gene, L1CAM, are rarely associated
with HSCR and a group of syndromes involving multiple nervous system abnormalities and
hydrocephalus. Murine studies have demonstrated that null mutations in L1cam can interact with
Sox10 mutations to increase the penetrance of aganglionosis and result in more severe pathology
(206). Since L1CAM mutations cause syndromic disease, they are unlikely to account for the
male predominance in isolated HSCR unless a new and much less severe variant is found to be
associated with HSCR. Another possible explanation for the male bias is suggested by the lower
levels of colonic Edn3 and Ece1 expression in males compared to females during the time that
ENCDC colonize distal bowel (203). However, the reasons for this difference remain unclear as
neither testosterone nor Müllerinan inhibitory factor (MIF) had any measurable effect on either
ENCDC migration or gene expression. Adding ET-3 to cultured Ret mutant male mouse bowel,
however, increased the extent of colonization in vitro suggesting that EDNRB signaling is
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limiting in male mice. Clarifying the mechanisms behind these sex differences will require a
better understanding of sexual dimorphism at the level of gene-expression with more detailed
analysis of cis and trans regulatory elements (e.g. for Edn3 and Ece1) and the epigenetic marks
that control gene expression for critical regulators of ENS development.
2.11.9 Why does Down syndrome predispose to HSCR?
Down syndrome (Trisomy 21) is the most common genetic disorder that predisposes to
HSCR. Overall occurrence of HSCR in Down syndrome is low (about 1%), and the common
RET +3 polymorphism is highly associated with HSCR among children with Down syndrome,
suggesting that some level of RET dysfunction is required for penetrant disease (160). Despite
the fact that HSCR occurs in Down syndrome with a low penetrance relative to single-gene
syndromes like WS4 and Mowat-Wilson syndrome, Down syndrome contributes to 2-10% of
HSCR cases (2) because it is quite common (about 1 in 800 births). Increased chromosomal copy
number of genes expressed in the ENS or surrounding tissues could be important for the HSCRpredisposing effect of trisomy 21. However, no genes confirmed to be important to ENS
development reside on chromosome 21, though some candidates have been identified (135). One
of these is DSCAM, an immunoglobulin-superfamily cell adhesion molecule expressed widely in
the CNS and the developing ENS (214). A high-resolution copy number study of individuals
with partial trisomy 21 and birth defects including HSCR demonstrated a shared 13-megabase
region containing DSCAM that was duplicated in the 3 study participants with HSCR (113). It
will be interesting to see whether DSCAM or other genes from this critical region impair ENS
development if overexpressed.
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2.12 Stem cells in the ENS: therapeutic possibilities and natural roles
During ENS colonization, ENCDCs serve as stem cells for the ENS and engage in both
self-renewing replication and terminal differentiation into neurons and glia. Similar cells exist in
the adult and newborn bowel in humans and rodents (Reviewed in 90, 98). Understanding these
cells is critical for any future attempts to use them in therapy for HSCR, gastroparesis, achalasia,
intestinal pseudoobstruction syndrome or possibly CNS disorders. Some stem cell types that
have been transplanted into the rodent bowel are not neural crest derivatives, but instead begin as
embryonic stem cells (99) or CNS neural stem cells (NSCs), which can improve gastric
emptying in a mouse model of gastroparesis (141) when transplanted into the pylorus. However,
we will focus our discussion on stem cells derived from the ENS.
Cultures of multipotent and self-renewing enteric neurospheres can be established from
embryonic and postnatal mouse bowel (20, 186). Human enteric neurospheres have also been
grown from full-thickness bowel explants (1, 138) and endoscopic mucosal biopsy samples (139)
of children with HSCR and others of various ages. These human cells can colonize embryonic
bowel (127, 139), differentiate into some types of neuron and glia in appropriate positions, and
restore some contractile function (127) in grafting studies. Many criteria have been used to
enrich cells isolated from bowel for ENS stem cells, including RET expression (145), selection
using reporters recapitulating the expression patterns of ENS genes (44, 45, 91), selection for
proliferative capacity in culture (20), and coexpression of p75NTR and the HNK-1 carbohydrate
epitope (207). Another well-defined population of stem cells present in embryonic and postnatal
bowel of rats coexpress alpha-4 integrin and high levels of p75NTR, and is both multipotent and
self-renewing (14, 115) in culture. Many challenges lie between our current capability to expand
a population of progenitors and the prospect of colonizing neonatal aganglionic bowel. To date,
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engraftment and migration of grafted cells through non-embryonic bowel has been quite limited
(139, 196), and it is unclear what functional capabilities these cells could have once engrafted,
although they do extend neuronal processes. One aspect that has received less attention is the use
of ENS-derived stem cells for transplant into the CNS. These ENS-derived stem cells may be an
ideal therapeutic source since they are already capable of differentiating into cells expressing
neurotransmitters lost in adult nervous system diseases. Furthermore, human ENS stem cells
derived from a patient’s own mucosal biopsies are proliferative, neurogenic, and nonimmunogenic without the need for genetic modification. They may be the most easily accessible
neuronal stem cell in the body, and their use in both CNS and ENS transplantation is worth
investigating.
Although much effort has been focused on isolation and growth of ENS-derived stem
cells in culture, these cells may serve a homeostatic role in postnatal ENS development, possibly
in response to injury and aging. Recent work has demonstrated the existence of an extraganglionic cell that responds to 5-HT4 receptor stimulation by proliferating, becoming
immunoreactive for SOX10, Phox2B and HuC/HuD, and very slowly migrating into ganglia
(130). Two recent studies used lineage tracing to demonstrate that enteric glia in the adult rat and
mouse ENS have significant neurogenic potential in culture, but only form neurons in vivo under
very restricted circumstances. Adult cells labeled by an inducible recombinase under control of
SOX10-genomic sequences (Sox10-CreERT2) never became neurons in vivo, except after ENS
injury by benzalkonium chloride (121). However, a simultaneous study by another group
demonstrated that neurogenesis from cells labeled by a GFAP-controlled recombinase (GFAPCre) did not occur after the same type of ENS injury. Furthermore, they did not detect any
proliferative neurogenesis in adult mice and rats exposed to an array of chemical, physical,
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infectious and dietary insults (105). Taken together, these studies suggest that some neurogenesis
in the adult ENS can occur via proliferation of an extraganglionic cell after 5-HT4 receptor
stimulation or possibly through non-proliferative differentiation of an as-yet unidentified
SOX10-positive, GFAP-negative (or GFAP-Cre transgene non-expressing) cell after injury.
Further work will be needed to identify the source cells for both these fascinating processes.
Since neuronal progenitors within the postnatal and adult central nervous system express glial
markers (114), the population currently considered to be uniformly enteric glia may contain a
distinct subpopulation with the capacity to generate neurons.

2.13 Prevention of HSCR and other intestinal motility disorders
While progress is being made toward novel transplantation strategies that might help
treat HSCR or other serious motility disorders, HSCR prevention strategies deserve more
focused study. Given the myriad of molecules and pathways involved in ENS development, it is
very likely that one or more can be affected by some aspect of the prenatal environment.
Currently, counseling for parents of a child with sporadic HSCR is limited to providing
information about the sibling recurrence risk, which varies depending on the sex of the proband
and the length of aganglionosis. RET sequencing in HSCR patients is also becoming more
common, since 1-2 % of children that present with HSCR actually have RET mutations that
cause MEN2A. However, knowing the nature of the mutation does not influence the treatment of
HSCR.
Since treatment for HSCR remains imperfect, and even diagnosed and treated HSCR
causes significant morbidity, identifying environmental factors that could modify disease
penetrance or expressivity would be extremely valuable. The vast majority of sporadic HSCR
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(80%) occurs because ENCDC fail to colonize the final 5-10% of the bowel. At this critical
point, small effects on ENCDC migration efficiency, proliferation, or survival can mean the
difference between a functional colon and aganglionic bowel causing life-threatening disease. By
identifying and eliminating environmental factors that impair ENS development, we may be able
to prevent some cases of short-segment disease and reduce the morbidity of more extensive
aganglionosis. To date, very few associations between environmental factors and ENS
development have been found, but this has not been systematically investigated. Only a few
small clinical studies address whether the prenatal environment affects HSCR risk. One study of
children with trisomy 21, for example, found that consumption of more than 3 cups of coffee a
day and possibly maternal fever were associated with increased HSCR occurrence (195). An
earlier study performed before the identification of any HSCR susceptibility genes also proposed
an association between HSCR and hyperthermia during gestation (128), though a subsequent
study failed to find any correlation (122). More subtle disorders of intestinal motility may also be
rooted in environmental disruption of ENS development. In a recent retrospective study (149),
tricyclic antidepressant use during the first trimester and selective serotonin reuptake inhibitor
(SSRI) use during the second or third trimester of pregnancy was associated with increases in
laxative use (a surrogate for constipation) during early childhood. This is especially interesting
because tricyclic antidepressants inhibit the function of many receptors and transporters
including the norepinephrine transporter, which, as discussed previously, is required for normal
TC-lineage differentiation into serotonergic neurons. In turn, SSRIs might interfere with the
normal role of 5-HT in later neurogenesis.
Animal models and culture studies now provide strong evidence that specific geneenvironment interactions influence ENS development and/or HSCR risk. Treatment of cultured
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fetal mouse colon with the Rho-kinase inhibitor Y-27632 for example, inhibited ENCDC
migration significantly more in Ret+/- explants than in controls (185). Furthermore, oxidative
stress in the early neural crest, induced by injection of pregnant mice with H2O2, reduced the
extent of ENCDC migration into distal bowel in Tcof1+/- embryos while not affecting the extent
of ENCDC bowel colonization in wild-type littermates (9). A dramatic and clinically relevant
gene-environment interaction was also observed in a mouse model of vitamin A deficiency (65).
Mice maintain significant stores of vitamin A in their livers in the form of retinol, so Rbp4-/mice, which cannot mobilize these stores and depend on dietary retinol, were used to assess the
effects of vitamin A depletion during ENS development. Rbp4-/- mice fed a vitamin-A deficient
diet during neural crest development had striking ENCDC migration delays in the colon
compared to Rbp4-/- mice fed a diet containing vitamin A. Additionally, Rbp4-/- Ret+/- mice had a
much more severe delays in ENCDC colonization of the bowel when deprived of dietary vitamin
A, and even manifested a significant developmental delay when fed a vitamin-A sufficient diet.
Similarly, in humans carrying HSCR risk alleles, otherwise subclinical vitamin A deficiency
could synergize with genetic defects to worsen the severity of HSCR or increase the likelihood
that HSCR will occur. Genetic models of HSCR susceptibility that more closely approximate
sporadic HSCR and a careful examination of the signals involved in ENS development will be
critical for identifying and characterizing other environmental insults that impair ENS
development and to test prevention strategies.
Finally, large scale human epidemiologic studies are now appropriate and will be needed
to validate and identify non-genetic factors that increase HSCR risk. Given the strength of the
experimental data demonstrating that non-genetic factors can alter HSCR risk, the known effect
of many medicines on proteins needed for ENS development, and our ability to couple genetic
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and epidemiologic data, this is the ideal time to launch a systematic national or international
case-control study of non-genetic HSCR risk factors. The implications of this work will have
immediate benefit to families since many children with HSCR are now becoming parents, and
families who have one affected child are at dramatically higher risk of having a second child
with HSCR.

2.14 Conclusion
Much of our understanding of ENS development has been informed by developmental
and genetic studies of very severe ENS defects, in a generally successful effort to understand the
etiology of Hirschsprung disease and ENCDC colonization of the bowel. However, we have
highlighted several areas where aspects of both global ENS development (cell motility,
colonization, cell death, gene and environmental interactions) and processes with more restricted
effects (neuronal fate decisions, axon pathfinding, postnatal ENS stem cells) remain unexplained.
To address these gaps in our understanding, it will be necessary to find new and more precise
ways to perturb ENS development in experimental systems and expand the study of subtle and
difficult to identify ENS phenotypes. Understanding normal ENS development and its modes of
failure will translate into better outcomes for those affected by developmental defects of the
ENS, whether these improvements come in the form of more informative genetic counseling,
prevention strategies to mitigate the penetrance and expressivity of mutations, or via stem-cell
therapy.
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Table 2.1
Genes involved in RET and EDNRB signaling
Gene

Ret
receptor
tyrosine kinase

Mouse Model

ENS Phenotype in Mouse

Monoisoformic alleles
that are hypomorphic
in the ENS despite not
having any mutations:
Serine
phosphorylation site
mutation RetS697A
Tyrosine
phosphorylation site
mutations such as
RetY1062F (104)

Homozygous RetmiRet51/ miRet51:
Colonic aganglionosis (84)
Hemizygous Ret9/-: Colonic
aganglionosis (199)

RetRET9(1062F)
RetRET9(Y981F)
RetRET9(Y1015F)
RetRET51(Y1062F)
RetRET51(Y1015F) (102)

Human
Disease
Association(2)

Homozygous: Colonic aganglionosis
(6)
Homozygous: Range of phenotypes
from occasional hypoganglionosis to
total intestinal aganglionosis. Effects
of a given mutation depend on which
isoform is mutated. Mutations
affecting monoisomorphic RET9
have more deleterious effects than
mutations affecting RET51.

Missense MEN2A
mutation RetC620R

Homozygous: Total intestinal
aganglionosis
Heterozygous: Hypoganglionosis
(35)

Dominant negative
allele:
RetRET9-L985P-Y1062F

Heterozygous: Aganglionosis
extending into the small bowel.

Null alleles

Homozygous: Total intestinal
aganglionosis (175)
Heterozygous: Subtle reductions in
neuron size and fiber density. Bowel
contractility is abnormal (80)
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HSCR,
Total
intestinal
aganglionosis,
MEN2A,
MEN2B

Genes involved in RET and EDNRB signaling (continued)
Gene

Mouse Model

Gdnf
neurotrophin,
RET ligand

Null allele

Gfra1
RET
coreceptor

Null allele

ENS Phenotype in Mouse
Homozygous: Total intestinal
aganglionosis (172)
Heterozygous: Reduced enteric neuron
density (80)
Homozygous: Total intestinal
aganglionosis (30)
Heterozygous: Subtle reductions in
neuron size and fiber density. Bowel
contractility is abnormal (80)

Nrtn
neurotrophin,
RET ligand

Null allele

Homozygous: Reduced soma size and
fiber density in the myenteric plexus.
Abnormal motility (94)

Gfra2
RET
coreceptor

Null allele

Homozygote: Reduced fiber density
and abnormal motility (169)

Ednrb
G-protein
coupled
receptor

Null allele: Ednrbs-l
Hypomorphic allele:
Ednrbs

Homozygote: Colonic aganglionosis
with hypoganglionosis of the small
intestine (96)
Heterozygote: hypoganglionosis of the
small intestine (33)
Homozygote: Rare colonic
aganglionosis (136)
Homozygote: Colonic aganglionosis
(155)

Edn3
Null allele: Edn3ls
EDNRB ligand
Ece1
EDN3
Homozygote: Colonic aganglionosis
Null allele:
processing
(215)
protease
Genes involved in ENS development and implicated in syndromic HSCR
BBS1-11
intraciliary
ENS not yet studied in mouse models. Morpholino knockdown
transport
in zebrafish causes ENS precursor migration defects (194)
proteins
KIAA1279
(Kbp)
No mouse model exists. Zebrafish kbpst23 loss-of-function
unclear
mutation reduces axon growth in the ENS (132)
function
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Human
Disease
Association
Mutations
found in
some HSCR
cases

Mutations
found in
some HSCR
cases

HSCR,
WS4

WS4, very
rare
One case of
HSCR with
multiple
birth defects
BardelBiedl
syndrome
(±HSCR)
GoldbergShprintzen
syndrome
(+HSCR)

Genes involved in ENS development and implicated in syndromic HSCR (continued)
Human
Gene
Mouse Model
ENS Phenotype in Mouse
Disease
Association
X-linked
L1cam
congenital
L1 family cell
Transient ENCDC migration delay at
hydrocephal
Null allele
adhesion
E11.5 (5)
us, MASA
molecule
Syndrome
(±HSCR)
Pds5A and
Cornelia de
Pds5B
Homozygotes: Delayed ENS
Lange
cohesin
Null alleles
colonization (223) , partially penetrant syndrome
regulatory
colonic aganglionosis (224)
(One
factor
family)
Congenital
central
Phox2b
hypoventilat
homeodomain
Homozygous: Total intestinal
Null allele
ion
transcription
aganglionosis (154)
syndrome,
factor
Haddad
syndrome
Heterozygous: Colonic aganglionosis
(117)
Dominant Negative
Sox10
Dom
Sox10
Homozygous: Total intestinal
SRY-related
HSCR,
aganglionosis (109)
HMG-box
WS4
Heterozygous: Colonic aganglionosis
transcription
(23)
factor
Null allele Sox10LacZ
Homozygous: Total intestinal
aganglionosis (23)
Zfhx1b (SIP1,
MowatZEB2)
Homozygous: Failure of vagal neural
Wilson
zincNull allele
crest delamination. ENCDCs do not
syndrome
finger/homeoenter the bowel. (164)
(+HSCR)
domain protein
Genes involved in ENS development or associated with HSCR
Aldh1a2
(Raldh2)
Homozygous: Neural crest cells never
retinoic acid
Null allele
enter the bowel (148)
synthesis
enzyme

52

Genes involved in ENS development or associated with HSCR (continued)
Gene
Ascl1
(MASH1)
basic helixloop-helix
transcription
factor
Dcc
receptor for
netrin-1
HOXB5
homeodomain
transcription
factor
Ihh
hedgehog
ligand
Kif26a
negative
regulator of
RET signaling
Lgi4,
Adam22
Secreted factor
and receptor
involved in
glial
development
and
myelination
NKX2-1
homeodomain
transcription
factor
NRG1
ERBB3 Ligand
NRG3
ERBB4 Ligand
Ntrk3 (TrkC)
receptor for
NT-3

Mouse Model

ENS Phenotype in Mouse

Null allele

Serotonergic neurons absent from ENS
(15), no neurons develop in the
esophagus (85)

Null allele
Dominant negative
Tg(enb5), Tg(b3-IIIaCre), mosaic
expression
Null allele

Homozygous: Failure of ENCDCs to
migrate to submucosal plexus and
pancreas (103)
Hypoganglionosis and aganglionosis of
the ENS, Ret expression and migration
reduced in the subset of cells that
express dominant negative HOXB5
(131)
Homozygous: ENS is absent in some
regions of the small bowel and colon
(165)

Null allele

Homozygous: Homozygous:
Myenteric neuronal hyperplasia,
pseudoobstruction (226)

Null alleles

Homozygous: Reduced numbers of
glial cells, impaired glial marker
expression, abnormal ENS structure.
(150)

Human
Disease
Association

Variants
associated
with HSCR
(37, 131)

ENS not studied in mouse models. Protein is detectable in
human but not mouse ENCDCs.

Mutations
found in
some HSCR
cases. (73)

ENS not yet studied in mouse models

HSCR (76)

ENS not yet studied in mouse models

HSCR (191)

Null allele

Reduced numbers of enteric neurons,
evidence for a selective reduction in
late-born CGRP neurons (42)
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Mutations
found in
some HSCR
cases

Genes involved in ENS development or associated with HSCR (continued)
Gene
Ntf3 (NT-3)
neurotrophin,
TrkC/p75NTR
ligand

Pax3
paired-box
transcription
factor

Phactr4
regulator of the
actin
cytoskeleton
and cell
adhesion
PROK1
PROKR1
PROKR2
Prokineticin
and receptors
Shh
hedgehog
ligand
Slc6a2 (NET)
norepinephrine
reuptake
transporter

Mouse Model

ENS Phenotype in Mouse

Human
Disease
Association

Null allele

Reduced numbers of enteric neurons
(42)

Mutations
found in some
HSCR cases

Null allele Pax3Sp

Homozygous: Total intestinal
aganglionosis (118)

Heterozygous
mutations
associated
with
Waardenburg
syndrome
without
HSCR.

Mouse hypomorphic
allele Phactr4humdy

Homozygous: Colonic
hypoganglionosis (225)

ENS not yet studied in mouse models. Receptors are expressed
in cultured human enteric neurosphere-like bodies. (171)

Null allele

Null allele

Tcof1
nucleolar
factor

Null allele

Tlx2
(Hox11L1)
homeodomain
transcription
factor

Null allele

Homozygous: Ectopic neurons
located in mucosa (165)
Homozygous: Decreased neuronal
numbers, selective decreases in
numbers of serotonin and calretinin
reactive neurons (125)
Heterozygotes: Delayed colonization
of the bowel by ENCDCs. Migration
continues between E14 and E18 to
colonize the entire bowel (9)
Homozygous: Myenteric neuronal
hyperplasia, pseudoobstruction (179)
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Mutations
found in some
HSCR cases.

Genes involved in ENS development or associated with HSCR (continued)
Gene

Mouse Model

ENS Phenotype in Mouse

Human
Disease
Association

Tph2
Homozygous: Decreased numbers of
neuronal
myenteric neurons, selective decreases
serotonin
Null allele
in numbers of dopaminergic and
biosynthesis
GABAergic neurons (126)
enzyme
Spry2
regulator of
Homozygous: Myenteric neuron
receptor
Null allele
hyperplasia, pseudoobstruction,
tyrosine
achalasia (189)
kinases
Other genes associated with syndromic HSCR
DHCR7
Smithfinal enzyme in
Lemli-Opitz
ENS not yet studied in mouse models
cholesterol
syndrome
biosynthesis
(±HSCR)
RMRP
mitochondrial
CartilageRNAhairNo viable mouse model
processing
hypoplasia
noncoding
(±HSCR)
RNA
TCF7L2,
Pitt(TCF4)
Hopkins
transcription
syndrome, 1
ENS not yet studied in mouse models
factor involved
case
in Wnt
includes
signaling.
HSCR
Transgenic models where overexpression alters ENS development
Mouse Model Description
ENS Phenotype
Ectopic neuronal and
Increased numbers of enteric neurons and neuronal
Tg(DBH-NT3) ENCDC expression of
hypertrophy (42)
NT-3
Increased numbers of submucosal neurons, increased
Tg(GFAPEctopic glial
numbers of nitrergic neurons, aberrant clustering of
GDNF)
expression of GDNF
nitrergic axons around myenteric ganglia (208)
Global overexpression
Colonic hypoganglionosis with neuronal hypertrophy.
Tg(HoxA4)
of homeodomain
(210)
transcription factor
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Transgenic models where overexpression alters ENS development (continued)
Mouse Model Description
ENS Phenotype
Ectopic and inducible
expression of GLI1,
Megacolon with hypoganglionosis, perinatal and adult
Tg(Mt1-GLI)
activator of genes
death. Severity is related to expression level (216)
downstream of
hedgehog pathway
Ectopic neuronal
Increased numbers of enteric neurons, with a selective
Tg(NSEexpression of BMP
decrease in the size of the TrkC expressing
Noggin)
antagonist noggin
population. (38)
Conditional Mutations
Gene
Mouse Model*
ENS Phenotype
Cdh2 (NCadherin)
Tg(Ht-PA-Cre)
Delayed colonization of the colon. Severe migration
LoxP
homophilic
Cdh2
defects in Cdh2 Itgb1 double-conditional ENCDCs
cell adhesion
(24)
molecule
Dicer1
miRNA
Tg(Wnt1-Cre)
Post-colonization loss of ENS cells (222)
processing
Dicer1LoxP
enzyme
Erbb2
Tg(Nestin-Cre)
EGF-receptor
Erbb2LoxP
family member recombination in
Postnatal loss of colonic neurons (46) , thought to be
without known neural crest and other due to loss of Erbb2 in the epithelium, not the neural
ligand. Hetero- tissues including
crest.
dimerizes with colonic crypt
ERBB3/4.
epithelium.
Ercc1
nucleotide
Tg(Tyr-Cre) Ercc1LoxP Postnatal death of colonic neurons (176)
excision repair
factor
Itgb1 (Beta-1
Integrin)
Tg(Ht-PA-Cre)
Colonic aganglionosis (22)
cell-ECM
Itgb1LoxP
adhesion
molecule
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Conditional Mutations (continued)
Gene
Mouse Model*

Hand2
basic helixloop-helix
transcription
factor

Tg(Wnt1-Cre)
Hand2LoxP

Pofut1
Tg(Wnt1-Cre)
required for
Pofut1LoxP
notch signaling
Pten
phosphatase
Tg(Tyr-Cre) PtenLoxP
and tumor
suppressor
Rac1 and
Tg(Wnt1-Cre)
Cdc42
Rac1LoxP or Tg(Wnt1Rho-family
Cre) Cdc42LoxP
GTPases
Tfam
CNPCre,TfamLoxP
mitochondrial
recombination in
transcription
Schwann cells and
factor
ENS precursors
Zfhx1b
(SIP1, ZEB2)
Tg(Wnt1-Cre)
zincZfhx1bLoxP
finger/homeodomain protein
Genetic Interactions in Model Systems
Genes or alleles
Ret+/-

Ednrbs/s
Ednrbs-l/s

Ret Y1062F/Y1062F

Spry2-/-

Ednrbsl/sl

Ret+/miRet51

ENS Phenotype
Tg(Wnt1-Cre), Hand2LoxP/LoxP (93) : Disrupted
patterning of nascent enteric ganglia and fiber
network, reduction in neuronal density. Failure of
neurons to colocalize Tuj1 and Hu markers, selective
loss of VIP-immunoreactive neurons.
Tg(Wnt1-Cre), Hand2LoxP/null: Loss of markers of
terminal neuronal differentiation (Hu, microtubuleassociated protein 2) and some neuronal subtypes
(nNOS, dopamine β-hydroxylase). Fetal death at E14
(48). More severe phenotype may be the result of
heterozygosity for null allele (47).
Hypoganglionosis (153)

Hypertrophy and hyperplasia of enteric neurons (162)

Failure of ENCDCs to proliferate and colonize distal
bowel (69)
Postnatal death of specific subsets of enteric neurons
(200)

Aganglionosis of the entire bowel distal to the
stomach and rostral duodenum. (163)

ENS Phenotype
Highly penetrant aganglionosis in double-mutant
animals. (136) In isolation, Ret+/- is not penetrant, and
these Ednrb genotypes have extremely low
penetrance.
Partial rescue of nitrergic neuron density in the
stomach. No effect on the remainder of the ENS.
(142)
Partial rescue: double mutant embryos have a shorter
aganglionic segment than Ednrbsl/sl single mutants (8)
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Genetic Interactions in Model Systems (continued)
Genes or alleles
ENS Phenotype
s/+
Ednrb
Double mutant embryos have more penetrant
Ednrbs/s
aganglionosis (33) , a more severe ENCDC
Dom/+
Sox10
s-l/+
Ednrbl
developmental delay, and more pre-ENCDC cell death
Ednrbs-l/s-l
than Sox10Dom/+ embryos (183)
ls/ls
Edn3
Double mutant embryos have a more severe ENCDC
Sox10Dom/+
Edn3ls/+
developmental delay than Sox10Dom/+embryos (183)
Double mutant embryos have a more severe ENCDC
developmental delay and more extensive
Sox10LacZ/+
Zfhx1b-/+
aganglionosis than Sox10LacZ/+embryos (184) . The
Zfhx1b-/+genotype does not cause aganglionosis by
itself.
Double mutant embryos have a more severe ENCDC
developmental delay, more extensive aganglionosis,
Sox8LacZ/+
LacZ/+
Sox10
and more pre-ENCDC cell death than
Sox8LacZ/LacZ
Sox10LacZ/+embryos (133). Sox8 mutations do not
affect ENS development in isolation.
Double mutant embryos have a more severe ENCDC
developmental delay, more extensive aganglionosis,
L1cam+/Sox10LacZ/+
and more pre-ENCDC cell death than Sox10LacZ/+
L1cam-/Y
embryos (206). L1cam mutations individually produce
transient delays in ENS development.
Gene-environment interactions
Environmental
Genetic factor
ENS Phenotype
factor
Aganglionosis of the colon and small bowel. Rbp4-/Vitamin A deficiency mice depleted of vitamin A and Ret+/- Rbp4-/- fed
Ret+/- Rbp4-/during gestation
vitamin A also developed aganglionosis, but less
severely. (65)
More severe ENCDC migration delay than Tcof1
Tcof1+/H2O2 exposure at E7.5 mutation alone. H2O2 had no effect on ENCDC
migration in wild-type mice. (9)
Genes affecting ENS development. Genes involved in HSCR disease or known to be important
to ENS development are listed and their mutant phenotypes described. In addition, genetic
interactions and gene-environment interactions that have been demonstrated in the mouse are
listed. While many of the genes with well-documented roles in the ENS are also HSCR
susceptibility genes, most are rare. Conversely, the normal ENS developmental role of several
HSCR susceptibility genes in has not been explored. Human gene symbols are listed when
mouse models have not been studied. Otherwise, mouse symbols are listed. While the Hoxb5
dominant negative mouse is a transgenic, it is listed together with the loss-of-function mutations
due to the possible association of HOXB5 with HSCR. The conditional mutations are listed here
when they provided additional information about the role of each gene in ENS development.
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*Tg(Wnt1-Cre), Tg(Ht-PA-Cre), lines result in recombination in the neural crest, while
the Tg(Tyr-Cre) line results in recombination in a subset of the vagal neural crest including the
ENS. Human chromosomal regions with as-yet unidentified susceptibility loci and the genetic
interactions that have been identified in humans are not included in this table. BMP, bone
morphogenetic protein; CGRP, calcitonin gene-related peptide; ECM, extracellular matrix;
EDNRB, endothelin receptor type B; ENCDC, enteric neural crest-derived cell; E7.5, E11.5,
E14, and E18, embryonic days 7.5, 11.5, 14, and 18; MEN2A and MEN2B, multiple endocrine
neoplasia 2A and 2B; nNOS, neuronal nitric oxide synthase.
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Chapter 3: Hirschsprung-like disease is exacerbated
by reduced de novo GMP synthesis
This chapter describes the rationale and results of our broad attempt to detect
environmental factors that impair enteric nervous system (ENS) development using a chemical
screen in zebrafish. This screen led to the detection of several inhibitors of ENS development
including mycophenolic acid. The systemic effects of MPA and its prodrug mycophenolate
mofetil (MMF) on ENS development were then confirmed in the mouse, and we demonstrated
using in vivo and primary culture systems that MPA impairs ENS development primarily
through its antiproliferative effects on enteric neural crest-derived cells (ENCDCs). Finally, we
demonstrate a profound gene-environment interaction between mouse mutation models of
Hirschsprung disease and MMF exposure, the first demonstration that Hirschsprung disease
phenotypes can be enhanced by an environmental exposure.
Since these experiments indicate that MPA/MMF exerts its antiproliferative effects on
ENCDCs through its inhibition of inosine 5’-monophosphate dehydrogenase (IMPDH) and de
novo guanine nucleotide synthesis, these experiments also form the rationale for our subsequent
investigations into the Impdh2 gene in the developing mouse ENS and the possible association
between the IMPDH2 gene and human Hirschspung disease.
The contents of this chapter have been published: Lake JI, Tusheva OA, Graham BL,
Heuckeroth RO. Hirschsprung-like disease is exacerbated by reduced de novo GMP synthesis.
The Journal of Clinical Investigation 2013;123(11):4875–4887.
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3.1 Summary
Hirschsprung disease is a partially penetrant oligogenic birth defect that occurs if enteric
nervous system (ENS) precursors fail to colonize distal bowel during early pregnancy. We
hypothesized that non-genetic factors might contribute to this disease. Here we show that
mycophenolate, an inhibitor of de novo guanine nucleotide biosynthesis, and eight other drugs
identified using a zebrafish screen impair ENS development. Murine studies in vivo confirm
that mycophenolate selectively impairs ENS precursor proliferation, delays precursor migration,
induces bowel aganglionosis, and increases the penetrance and severity of Hirschsprung-like
pathology in Sox10 and Ret mutant mice. Mycophenolate also reduces ENS precursor migration,
lamellipodia formation, proliferation, and survival in vitro. Using X-inactivation mosaicism for
the purine salvage gene Hprt, we show that reduced ENS precursor proliferation most likely
causes mycophenolate-induced migration defects and aganglionosis. Mycophenolate is the first
medicine identified that causes major ENS malformations and Hirschsprung-like pathology.
These studies demonstrate a critical role for de novo guanine nucleotide biosynthesis in enteric
nervous system development and suggest that some cases of Hirschsprung disease may be
preventable.

3.2 Introduction
Hirschsprung disease (HSCR) is a common (1 in 5000) birth defect where the enteric nervous
system is missing from distal bowel (aganglionosis). Because the ENS controls intestinal
motility, HSCR causes severe constipation, abdominal distension, bilious vomiting, growth
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failure and life-threatening infection (1). Survival requires surgical excision of aganglionic
bowel. After surgery, however, enterocolitis (i.e., bowel inflammation) occurs commonly (35%),
and ~5% of affected children still die from HSCR. Infrequently, long-segment HSCR
necessitates intravenous nutrition with accompanying life-threatening infections. Most children
with HSCR (80%) have only a short segment of aganglionosis, suggesting that slightly enhanced
bowel colonization by ENS precursors could prevent disease. New strategies are needed to
enhance bowel colonization by ENS precursors and to reduce HSCR occurrence.
While HSCR undoubtedly requires genetic defects (2), almost all predisposing mutations
have partial penetrance and variable expressivity. For example, inactivating RET mutations occur
in 15-20% of sporadic and 50% of familial HSCR, but only about half of children with
inactivating RET mutations have HSCR (2). Genetic interactions also influence HSCR risk (3–6),
however, much variability in occurrence and severity of HSCR and other human birth defects
remains unexplained. We hypothesized that non-genetic factors might affect HSCR occurrence.
If so, then some cases of HSCR might be preventable by changes in prenatal care.
HSCR is caused by failure of distal bowel colonization by enteric neural-crest derived cells
(ENCDCs) during week four to seven of human gestation (7–9). Normally, ENCDCs proliferate
vigorously and migrate rostrocaudally to colonize the entire intestine. A similar process occurs in
mice from embryonic day 9.5 (E9.5) to E13.5 and in zebrafish from 36-96 hours post fertilization
(hpf). Many genes (7, 10) in addition to RET are needed for ENS development including
SOX10, PHOX2B, EDNRB, EDN3, GDNF, intracellular signaling molecules (11, 12),
cytoskeletal components (13, 14), and adhesion proteins (15–17). 30% of children with HSCR
have additional birth defects and at least 30 genetic syndromes are HSCR-associated (2). The
diverse molecular mechanisms supporting ENS development suggest that many non-genetic
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factors could influence ENCDC bowel colonization and HSCR occurrence by modifying the
activity or abundance of needed molecules. Furthermore, chemical perturbation of the
developing ENS may identify new pathways involved in ENCDC migration, self renewal,
proliferation, or survival.
To identify medicines that might increase HSCR risk, gain new insight into HSCR genetics,
and identify new modulators of ENS developmental biology, we conducted a zebrafish chemical
screen. Here we show that mycophenolic acid (MPA), a commonly used immunosuppressant,
caused ENS developmental defects in fish and impaired ENCDC colonization of the bowel in
mice via inhibition of inosine monophosphate dehydrogenase (IMPDH), the rate limiting enzyme
in de novo GMP synthesis. Guanine nucleotides are essential for DNA replication, transcription,
and for > 200 GTP-dependent proteins. Our analyses suggest that reduced ENCDC proliferation
after GTP depletion is the primary cause of MPA induced bowel aganglionosis (Supplemental
Figure 3.1) and show that IMPDH inhibition can greatly increase the penetrance and severity of
genetic defects affecting the ENS. These studies reinforce the central role of ENCDC
proliferation in bowel colonization and raise the intriguing possibility that drugs, nutritional
deficiencies, or gene polymorphisms that reduce cell proliferation during early pregnancy may
increase HSCR occurrence.

3.3 Results
3.3.1 Medications that inhibit ENS development
Zebrafish were treated with 1508 individual drugs from the Johns Hopkins Clinical
Compound

Library

(18)

(Supplemental

Table

3.1,

available

at

http://www.jci.org/articles/view/69781/sd/1) for the entire duration of ENCDC colonization of
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the bowel (34 to 96 hours post fertilization (hpf)). Using Elavl3/4 (HuC/HuD)
immunohistochemistry to visualize neurons (19), we identified 9 compounds that consistently
impaired ENS development, are systemically administered, and were not overtly toxic at doses
impacting the ENS (Table 3.1). Dose-response studies permitted determination of TD50 for ENS
defects for these drugs. We analyzed mycophenolic acid (MPA) in more detail because MPA
dramatically impaired fish ENS development (Figure 3.1A-C), is commonly used in humans, has
a well-understood molecular mechanism, and has a TD50 within human therapeutic levels (20).
3.3.2 MPA impaired mammalian ENS development
MPA inhibits IMPDH, a protein detected in all E10.5-E12.5 bowel cells (Supplemental
Figure 3.2), that is slightly more abundant in ENCDCs than in neighboring mesenchyme. To
determine if MPA impairs mouse ENS development, we injected pregnant dams with MPA daily
from E10.5 through E12.5 and analyzed fetal bowel at E13.5. Since we expected that MPA
metabolism and effects might vary depending on genetic background, we used both the outbred
CF1 strain due to its high fertility and large litters and the C57Bl/6 (B6) standard laboratory
strain. CF1 fetuses tolerated 100 mg/kg/day (36% of adult human therapeutic dose allometrically
scaled to mice (21)), but no B6 fetuses survived >25 mg/kg/day. In both strains, MPA caused
dose-dependent reductions in the extent of ENCDC colonization of the bowel (Figure 3.1D-E) as
indicated by the extent of TuJ1-positive neurites in the colon. While we have previously
demonstrated that the caudal extent of TuJ1 reactivity indicates the position of the ENCDC
wavefront (12), these structures might not be tightly associated after MPA treatment. To directly
assess the position of the wavefront, we mated B6 females to Wnt1-Cre Rosa26EYFP/EYFP males,
marking all neural crest-derived cells with enhanced yellow fluorescent protein (EYFP). We
examined the position of the most distal staining in the bowel using EYFP, TuJ1 and SOX10
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Table 3.1: Compounds that inhibited ENS development in zebrafish
Compound
Artesunate

TD50 in Cmax in Indication
zebrafish mammals
ENS
500 nM 1-3 µM Antimalarial

Benzbromaron 600 nM
e
CinchophenA

6-8 µM

Uricosuric

Primary
mechanism

Target
molecule

Unknown

Unknown

Inhibits uric acid URAT1
reabsorption

<100 nM unknown Analgesic/antiinflammatory
(veterinary)
1.8 µM
82 µM
Antihelminthic
(veterinary)

Possibly
cyclooxygenase
inhibition
Closantel
Possibly
mitochondrial
uncoupling
Diclazuril
1 µM
5 µM
Antifungal (veterinary) Unknown
Flubendazole 2 µM
20 nM
Antihelminthic
Inhibits
(veterinary)
microtubule
assembly
Lovastatin
0.4 µM
0.1 µM
Antihyperlipidemic
Inhibits
(Mevinolin)
cholesterol
biosynthesis
Mycophenolic 1 µM
1-10 µM Immunosuppressant
Inhibits de novo
Acid
GMP synthesis
Oxibendazole 200 nM 30 nM
Antihelminthic
Inhibits
(veterinary)
microtubule
assembly
A – Dose response not performed.
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Unknown
Unknown
Unknown
beta-tubulin
(invertebrate)
HMG-CoA
Reductase
IMPDH
beta-tubulin
(invertebrate)

Figure 3.1
MPA inhibited ENS development in developing zebrafish and mouse. Developing
wild-type zebrafish were exposed to DMSO or MPA from 34 hpf to 96 hpf and larvae (N>200)
were immunostained for (A) neuronal marker HuC/D (elavl3/4) (filled arrowheads = most caudal
enteric neuron, empty arrowheads = vent, scale bar = 250 µm), (B) merged with transmitted
light. (C) Average uncolonized distal intestine is plotted vs. MPA dose and compared to control
(Kolmogorov-Smirnov test). MPA exposure by maternal intraperitonal injection from E10.5E12.5 impairs enteric neuron colonization of the mouse hindgut at E13.5 (D) as visualized by the
neuronal marker TuJ1 (left side = ileocecal junction, dotted line = colon outline, scale bar = 1
mm). The position within each E13.5 colon of the most caudal (E) neuronal process (marked by
TuJ1) or (F) ENCDC cell body (ascertained by the lineage-marker EYFP or by SOX10 staining
in EYFP-negative littermates) in each E13.5 fetus is plotted for each MPA dose and mouse strain
(thick lines = mean, statistical tests are ANOVAs and t-test). *** = P < 0.001, ** = P <0.01, * =
P <0.05, ns = not significant.
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immunoreactivity. Both SOX10 and TuJ1 reliably reflected the extent of bowel colonization
seen with EYFP after control or MPA treatment (Supplemental Figure 3.3) confirming that MPA
impaired ENCDC colonization (Figure 3.1F). While MPA treatment reduced fetal size and colon
length (Supplemental Figure 3.3), it also increased the absolute length of uncolonized colon,
suggesting a greater effect of MPA on ENS development than on colon growth.
3.3.3 MPA impaired development of cultured ENCDCs
MPA could reduce migration in vivo by direct effects on ENCDCs or indirect effects on
other fetal cells. To study ENCDCs moving on an acellular, migration-permissive surface, we
cultured E12.5 midgut slices on fibronectin (12). MPA drastically reduced RET-positive cell
migration (Figure 3.2A-B,E) out of bowel explants and reduced the percentage of migrating
ENCDCs with lamellipodia (Figure 3.2F,G-I). MPA also significantly reduced DNA synthesis
(Figure 3.2A-B,D) and induced ENCDC apoptosis (Supplemental Figure 3.4). MPA did not,
however, alter neurite growth in post-mitotic enteric neurons (BrdU-negative, TuJ1-positive)
grown in low density dissociated cell culture (22) (Supplemental Figure 3.5). To confirm that
MPA effects were due to reduced guanine nucleotide levels, we treated cells with guanosine to
restore GTP through the purine salvage pathway. Guanosine efficiently rescued MPA’s effects
on ENCDC migration (3. 2C, E), DNA synthesis (Figure 3.2D), and lamellipodia (Figure 3.2F,
J), indicating that MPA effects are due to IMPDH inhibition.
3.3.4 MPA selectively reduced ENCDC DNA synthesis in vivo
To deliver MPA more consistently than drug injections permit, the prodrug mycophenolate
mofetil (MMF) was given in drinking water at a dose (1 mg/mL) that improves survival in a
mouse lupus model (23). B6 females mated to Wnt1-Cre Rosa26EYFP/EYFP males were MMF
treated from E10.5-E13.5 and injected with BrdU one hour prior to analysis. MMF decreased
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Figure 3.2
MPA reduced ENCDC migration, DNA synthesis, and lamellipodia in explant
cultures. (A-C) Low-magnification confocal micrographs of 24-hour E12.5 midgut explant
cultures immunostained for RET and BrdU (explant is on left side of each panel, scale bar = 250
µm). Guanosine (Guo) (C) completely reverses the proliferation and migration reduction caused
by MPA (B). (D) Quantification of BrdU labeling index and (E) distance migrated by the RETexpressing population after 16 and 24 hours in culture (repeated-measures ANOVA). (F) MPA
reduced the percentage of cells with lamellipodia within the neural crest-derived cell population
(stained with anti-p75NTR) most distant from the explant, an effect also reversed by guanosine
(ANOVA). (G-J) Optical sections of p75NTR and phalloidin stained ENCDCs demonstrate the
changes in cell shape associated with MPA treatment (filled arrowhead shows ENCDC with
lamellipodium; empty arrowhead shows ENCDC without lamellipodia, scale bar = 50 microns).
Insets show detail of ENCDC at the leading edge. *** = P < 0.001, ** = P < 0.01, * = P < 0.05,
ns = not significant.
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distal colon colonization by ENCDCs (Figure 3.3A-D), recapitulating the effect of injected
MPA. SOX10 and RET immunohistochemistry showed that neuronal differentiation in littermate
fetuses was unaffected by MMF (Supplemental Figure 3.6A-C). Since MPA might affect
transcription of mesenchyme-derived signals required for colonization of the bowel, we
measured Gdnf, Edn3, and Ece1 mRNA levels in E13.5 bowel using qRT-PCR, but found no
differences (Supplemental Figure 3.6D). In contrast to our in vitro data, cleaved-caspase 3
positive cells were rare in both ENCDC and surrounding mesenchyme after MMF treatment
(Supplemental Figure 3.7), but were readily detected in limb bud interdigital web. These results
agree with recent studies that showed low but detectable rates of nuclear fragmentation (24) and
cleaved-caspase 3 (25) reactivity in wild-type ENCDCs. While ENCDCs also can die through
unconventional, caspase-independent processes in circumstances such as partial loss of RET
expression (26), ENCDCs in culture readily undergo canonical apoptosis in response to MPA, so
we limited our examination of cell death to cleaved-caspase 3. Consistent with MPA effects on
ENCDCs in culture, MMF reduced proliferation of colon ENCDCs. In contrast to its effects on
ENCDCs, MMF actually increased the fraction of surrounding mesenchymal cells incorporating
BrdU in (Figure 3.3E-G). Since this was unexpected given the reduction in bowel size resulting
from either MPA or MMF treatment (Supplemental Figure 3.3), we counted mitotic figures
within these populations. The mitotic index (Figure 3.3H) was reduced within ENCDCs in
concordance with the reduction in BrdU incorporation. In contrast to BrdU results, however, the
mitotic index in the mesenchyme was not increased, indicating that MMF treated mesenchymal
cells entered S-phase but did not divide at elevated rates. MMF therefore selectively reduced
ENCDC proliferation and distal bowel colonization in vivo without increasing caspase-mediated
apoptosis or altering neuronal differentiation.
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Figure 3.3
MMF treatment reduces ENCDC migration and DNA synthesis in vivo. (A-D) Oral
treatment of pregnant B6 dams with MMF from E10.5-E13.5 reduces the colonization of the
hindgut at E13.5. Stitched maximum-intensity projections of untreated (A), mildly affected (B)
and severely affected (C) fetal colons with EYFP-marked ENCDCs demonstrate MMF’s
inhibitory effect on ENCDC wavefront migration in vivo (dotted lines = outline of bowel, scale
bar = 1 mm). (D) The position within each E13.5 colon of the most caudal ENCDC cell body
(ascertained by EYFP or by SOX10 staining in EYFP-negative littermates) is plotted for each
treatment. (Thick line = mean, statistic is Student’s t-test). (E-F) 8 µm-thick maximum-intensity
projections of EYFP and BrdU labeled E13.5 colons (scale bar = 50 µm) and (G) counting of
BrdU positive cells within these volumes demonstrate a reduced proportion of BrdU positive
ENCDCs and an increased proportion of BrdU-positive mesenchymal cells after MMF treatment
(ANOVA). (H) Counting of mitotic figures shows that the proportion of ENCDCs undergoing
mitosis was reduced, while the mitotic index of the mesenchyme was not significantly changed
(ANOVA on log-transformed values). mes = non-ENCDC mesenchyme. * = P < 0.05, ** = P <
0.01, *** = P < 0.001, ns = not significant.
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3.3.5 MPA reduced ENCDC migration by reducing proliferation
Guanine nucleotide depletion must underlie MPA effects because guanosine rescues
these effects in vitro. GTP is essential for DNA, RNA, and protein synthesis as well as for
GTPases and many other proteins. To distinguish between primary effects of guanine nucleotide
depletion on cell motility versus effects on ENCDC proliferation that secondarily reduce distal
bowel colonization, we determined which effects of GTP depletion are cell autonomous. This is
important since either reduced ENCDC proliferation or reduced cell intrinsic motility could
prevent ENCDC migration into distal bowel (27). We used mice with a null mutation in the
purine salvage gene Hprt (28), which is required for guanosine to rescue GTP depletion (29).
Since Hprt is X-linked, one copy of the Hprt locus is randomly inactivated in each cell of a
female. Thus, in all the cells of Hprt− males or half of the cells of Hprt+/− females, HPRT protein
is absent and guanosine supplementation will not rescue GTP depletion. Leveraging this system
to determine which GTP depletion effects are cell autonomous requires a cellular marker
indicating which X chromosome is active. To achieve this, male mice carrying an X-linked
EGFP transgene (30) were mated to Hprt+/− females, and E12.5 midgut explants were cultured
with 5 µM MPA and 100 µM guanosine, conditions that completely rescue MPA effects in wildtype explants. Four possible genotypes resulted from this mating (enumerated in Figure 3.4A).
One of these genotypes (female X-EGFP+; Hprt+/−) produces an embryo containing a mixture of
cells with normal HPRT activity (EGFP-positive) and EGFP-negative cells with no HPRT
activity. Therefore, each explant from fetuses of this genotype contains a mixture of guanosinerescuable ENCDCs (EGFP-positive) and EGFP-negative cells that cannot convert guanosine to
GMP, GTP, or dGTP. The other three genotypes serve as controls. As expected, MPA and
guanosine treated male (Hprt−/Y) explants had much less migration (Figure 3.4F), less BrdU
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incorporation (Figure 3.4D), and fewer lamellipodia (Figure 3.4H) than wild-type explants,
confirming that HPRT is required for guanosine rescue. In female wild-type explants, ENCDCs
incorporated BrdU equally within EGFP-positive and negative populations as expected. In
contrast, EGFP-negative cells in female heterozygote mosaic (X-EGFP+; Hprt+/−) cultures
incorporated very little BrdU compared to neighboring EGFP-positive cells (Figure 3.4E),
confirming that DNA synthesis is cell-autonomous with respect to GTP depletion and that
guanine nucleotides are inefficiently transferred from rescued wild-type to mutant cells.
Unexpectedly, the overall migration from Hprt+/− explants was equivalent to wild-type
(Figure 3.4F). Moreover, despite absent BrdU incorporation, within Hprt+/− cultures HPRTdeficient ENCDCs (EGFP-negative) migrated indistinguishably from neighboring HPRTexpressing EGFP-positive cells (Figure 3.4G). Furthermore, consistent with competence to
migrate, the proportion of EGFP-negative ENCDCs with lamellipodia in Hprt+/− cultures was
not reduced (Figure 3.4I). Thus, while DNA synthesis, cell migration, and lamellipodia are all
affected by GTP depletion and require HPRT for guanosine rescue, only effects on DNA
synthesis are cell-autonomous with respect to GTP pools. ENCDC with adequate GTP fully
rescue the ability of adjacent GTP-depleted ENCDC to migrate in culture. Consistent with these
results, time-lapse imaging of isolated ENCDCs confirmed that MPA does not reduce cell
motility. However, in explant cultures where dense clusters of ENCDCs migrate outward, timelapse imaging confirmed slower migration of MPA treated ENCDCs (Supplemental Figure 3.8).
Because ENCDC proliferation also drives migration in vivo (27), these data suggest that the
primary defect that causes HSCR-like delays in ENCDC migration after MPA/MMF treatment is
reduced cell proliferation that secondarily reduces ENCDC colonization of distal bowel.
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Figure 3.4
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Figure 3.4
Mosaic analysis reveals that effects of GTP depletion on migration and lamellipodia
are non-cell autonomous. (A) Schematic of the mating scheme, genotypes, HPRT and EGFP
expression patterns, and the GTP depletion status of each population when cultured in the
presence of both MPA and guanosine. These conditions create mixed cultures of GTP-depleted
and EGFP-marked, guanosine-rescued ENCDCs in X-EGFP+, Hprt+/− explants, allowing
migration of individual GTP-depleted ENCDCs to be examined in the context of a field of
rescued ENCDCs. (B-D) BrdU labeling reveals that guanosine rescues DNA synthesis in all
ENCDCs in X-EGFP+, Hprt+/+ explants (B) but only rescues DNA synthesis within the HPRTexpressing ENCDCs marked by EGFP in X-EGFP+, Hprt+/− explants (C). As expected,
guanosine fails to rescue DNA synthesis in Hprt−/Y ENCDCs (D). Filled arrowheads = BrdU,
EGFP double positive ENCDCs, empty arrowheads = BrdU positive/GFP negative ENCDCs,
scale bar = 50 µm. (E) Quantification of BrdU labeling in mosaic explants (paired t-test). (F)
ENCDC migration out of explants was impaired in Hprt−/Y explants, as expected, but Hprt+/+ and
Hprt+/− explants produced similar ENCDC migration distances (ANOVA). (G) Quantification of
migration within the depleted (EGFP-negative) and rescued (EGFP-positive) populations of
female Hprt+/− cells demonstrated that GTP-depleted cells did not migrate any less efficiently
than rescued cells (Wilcoxon signed-rank test) when surrounded by rescued cells. (H) Similarly,
while lamellipodia were reduced in Hprt−/Y explants (t-test), they were not reduced (I) within the
GTP-depleted ENCDC population in Hprt+/− explant cultures (paired t-test). *** = P < 0.001, ns
= not significant.
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3.3.6 MMF increased penetrance and extent of aganglionosis
MPA is teratogenic (31) in humans and some MPA-associated malformations are
plausibly due to defective neural crest-derived cell development (32). However, aganglionosis
has not been described in MPA-exposed children or animals. We hypothesized that MPA’s
effects on perinatal ENS structure might be more dramatic when combined with predisposing but
incompletely penetrant mutations, and that HSCR might only be induced by MPA when such
mutations are present. We therefore exposed the developing ENS of Sox10LacZ/+ mice to MPA.
Sox10LacZ/+ mice have partially penetrant aganglionosis and hypoganglionosis (33), modeling
high-penetrance HSCR in Waardenburg syndrome type IV. Explant cultures of Sox10LacZ/+ E12.5
bowel had equivalent ENCDC migration and BrdU labeling to wild-type under control
conditions. Importantly, MPA had similar effects on WT and Sox10LacZ/+ ENCDC (Figure 3.5AB). Thus, in this short-term culture, MPA was not more toxic to mutant than to wild-type
ENCDCs.
Next, we examined the interaction between MMF and Sox10 in vivo. Since Sox10 is
haploinsufficient in the developing ENS, we crossed Sox10LacZ/+ males with B6 females (34) and
treated with MMF throughout prenatal ENS development (E7.5-E18.5). We attempted postnatal
evaluation, but some MMF-treated pups had exencephaly and died immediately after birth. To
avoid missing more severely affected animals, we harvested E18.5 fetuses. Occasionally, control
dams delivered at E18.5, but ENS structure was similar to fetuses that had not delivered. Wholemount immunohistochemistry for neuronal processes (TuJ1) and somata (HuC/D) demonstrated
that Sox10 mutations and MMF individually caused partially-penetrant colonic hypoganglionosis
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and aganglionosis (Figure 3.5C). The combination of Sox10 mutation and MMF resulted in
extensive bowel aganglionosis.
We next tested MPA on Ret+/− ENCDCs in culture, since RET is mutated in most human
HSCR (2) cases. Ret+/− mice, however, are never aganglionic or hypoganglionic (35).

In

contrast to Sox10LacZ/+, Ret+/− ENCDCs did not migrate as efficiently as WT in culture, although
BrdU labeling was unaffected by Ret genotype (Figure 3.5D-E). MPA and Ret heterozygosity
had additive effects on distance migrated, consistent with known roles for RET in ENCDC
migration (11, 36) and MPA’s primary effect on proliferation.
Since heterozygous null Ret mutations do not delay ENCDC colonization of fetal bowel
(35) and only slightly alter adult ENS structure (37), we used a hypomorphic allele, Ret9, that
causes partially penetrant aganglionosis (38) to test MMF effects in vivo. Ret+/9 males were bred
to Ret+/− females on a B6 background and pregnant dams were treated with MMF from E7.5 to
E18.5. We expected Ret9/− fetuses to have partially penetrant aganglionosis even without MMF
(26), but found no aganglionosis and only one mouse with obvious hypoganglionosis (Figure
3.5F, H). Other genotypes did not have detectable ENS abnormalities in control fetuses. In
contrast, two of six MMF-treated Ret+/+ fetuses had hypoganglionic or aganglionic colons
(Figure 3.5F, I). Furthermore, MMF-treated Ret9/+ and Ret+/− fetuses had longer regions of
aganglionic colon than wild-type, demonstrating a synergistic effect. (Figure 3.5F, J, K).
Strikingly, all eight MMF treated Ret9/− fetuses had aganglionosis, often extending into small
bowel (Figure 3.5F, L). These findings are remarkable since the Ret9/- genotype closely mimics
heterozygous RET mutations that underlie more than 25% of human HSCR. Unlike human
HSCR, however, sex did not affect the penetrance or the extent of ENS abnormalities in MMF
treated Ret mutant mice.
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Thus MMF treatment from E7.5 onward caused Hirschsprung-like aganglionosis that was
significantly worse in genetically susceptible mice. We also tested the hypothesis that a more
limited period of MMF exposure might cause permanent distal bowel aganglionosis. ENCDCs
normally first enter the bowel at E9.5 (39) and reach the end of the colon by E13.5, but the colon
becomes less permissive (40, 41) to ENCDC migration at E14.5. To determine if MMF treatment
during the critical period of ENCDC migration caused permanent or transient distal bowel
aganglionosis, we switched dams carrying Sox10 and Ret litters from PBS to MMF for the
interval from E9.5-E14.5 and then allowed them to recover on PBS from E14.5 to E18.5. For
Sox10 and Ret matings (Figure 3.5C and 3.5F), the colons of all wild-type fetuses and
intermediate Ret genotype fetuses were completely colonized at E18.5, though one Sox10+/+
fetus had a hypoganglionic terminal colon. In contrast, aganglionosis was highly though not
universally penetrant in Ret9/- fetuses treated with MMF from E9.5-E14.5 and was confined to
the colon (Figure 3.5F). Furthermore, although the penetrance of aganglionosis in Sox10LacZ/+
fetuses treated with MMF from E9.5-E18.5 was very similar to those treated with MMF from
E7.5-E18.5, the aganglionic segments were shorter on average if mice did not receive MMF
before E9.5 and after E14.5. Collectively, these data suggest that significant ENCDC migration
delays may be reversible, but the most susceptible genotypes lack the capacity to recover from
transient MMF exposure.
It is important to note that the preceding data described colonization of the bowel by
ENCDC derived from the vagal region of the neural crest. Interestingly, in mice with aganglionic
bowel, the terminal third of the colon often had single neurons or isolated clumps of neurons
(<150 neurons per colon) associated with extrinsic nerve bundles and separated from vagal
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Figure 3.5

Figure 3.5
MMF treatment interacts with Ret and Sox10 mutations to increase penetrance and
severity of HSCR-like pathology. MPA treatment in 24-hour explant cultures reveals that (A,
D) neither Ret nor Sox10 heterozygosity impacts BrdU incorporation. (B, E) In contrast, Ret but
not Sox10 heterozygosity reduces ENCDC migration distance and MPA treatment has an
additive effect on ENCDC migration distance (two-way ANOVA, interaction terms were not
statistically significant). (C, F) Pregnant dams were provided MMF or control PBS in drinking
water and the ENS was examined at E18.5 with neuronal fiber (TuJ1) and soma (HuC/HuD)
markers. The position of the most caudal soma within the intestine is plotted as a dot, and the
region of hypoganglionosis is plotted as a line. Mean positions of aganglionosis are indicated
with black lines. Groups without abnormal fetuses are summarized as one dot and number.
Treatment with MMF from E7.5-E18.5 resulted in hypoganglionosis and aganglionosis with
genotype-dependant penetrance and severity. Treatment with MMF from E9.5 to E14.5 to test
whether MMF-induced developmental delays are reversible demonstrates genotype-dependent
reversal. (G-L) Representative maximum-intensity projections are shown of myenteric plexus in
the mid-small bowel, terminal ileum, proximal colon, and terminal colon from PBS-exposed
wild-type and Ret9/− fetuses and all MMF-treated Ret genotypes (scale bar = 100 µm). The PBSexposed Ret9/− colon shown (H) displays distal hypoganglionosis. TuJ1 staining demonstrates
thick nerve bundles in the aganglionic terminal colons of J-L and disorganized fibers in
hypoganglionic regions. *** = P < 0.001, ns = not significant.
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ENCDC by long segments of bowel that were completely devoid of enteric neurons. These rare
neurons are likely to arise from ENCDCs derived from the sacral region of the neural crest.
In addition to ENS defects, MMF treated mice were small, had reduced bowel length
(Supplemental Figure 3.9), exencephaly and congenital heart defects. MMF-induced
exencephaly was unaffected by genotype but was only present in litters treated with MMF from
E7.5-E18.5 (Supplemental Table 3.2). Most heart defects occurred in Sox10 or Ret mutant
fetuses in the E7.5-E18.5 treatment group. Although the number of fetuses was small, the
infrequent heart defects in MMF treated control mice raises the possibility that Sox10 or Ret may
have unappreciated roles in cardiac crest development that are only demonstrable with additional
genetic or environmental insults. We also observed 6 MMF-exposed fetuses with orofacial
clefting and three with iris colobomas. These defects are similar to those reported in MMF
exposed human infants (31).

3.4 Discussion
Hirschsprung disease and other problems with ENS development are known to occur in
individuals with many well established genetic defects (2) suggesting that these disorders are not
preventable. The gene defects and chromosomal anomalies that predispose to HSCR, however,
are all partially penetrant and cause variable degrees of aganglionosis. In part this variation in
phenotype in individuals who share the same underlying primary genetic defect is thought to
occur because of interactions between genes needed for normal development. Our current data
provide the first direct evidence that specific medicines impact enteric nervous system
development to cause distal bowel aganglionosis in mice and fish that mimics human
Hirschsprung disease.

In addition, the data show dramatic gene-environment interactions.
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Importantly, these studies suggest the possibility that any factor that reduces ENCDC
proliferation might increase the risk of distal bowel aganglionosis and that some cases of
Hirschsprung disease might be prevented by careful optimization of non-genetic risk factors
during early pregnancy.
Most compounds found to inhibit distal bowel colonization by ENCDCs in fish lack
obvious links to previously recognized ENS developmental pathways. Furthermore, because we
tested only one drug concentration, many additional medications are probably detrimental to the
developing ENS. Two medications in addition to MPA deserve comment. Mevinolin is a
commonly used inhibitor of the rate limiting step in de novo cholesterol biosynthesis (HMGCoA reductase), which is interesting because DHCR7 mutations disrupt the final step in
cholesterol biosynthesis, causing HSCR as a component of Smith–Lemli–Opitz syndrome (42).
Artesunate is a common malaria treatment that may increase reactive oxygen species (ROS), and
in Tcof1 mutant mice, additional oxidative stress delays ENCDC migration (43). These findings
highlight the many complex pathways needed for ENCDC colonization of fetal bowel and the
potential for diverse medicine classes to increase HSCR occurrence. This is especially important
since families with one child with HSCR have a 50- to 1600-fold increased risk of having
another child with the same life-threatening disease (2).
We investigated the immunosuppressant mycophenolic acid in more detail because MPA
profoundly inhibited zebrafish ENS development at concentrations in the low human therapeutic
range and because MPA is the only drug identified associated with specific patterns of human
birth defects (31). Despite inhibiting the ubiquitous process of GMP biosynthesis, some MPA
associated defects (cardiac defects, craniofacial defects, coloboma) suggest that IMPDH
inhibition disproportionately affects neural crest-derived cells (32). Interestingly, Drosophila
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IMPDH mutations (raspberry) cause mis-targeting of photoreceptor axons (44), and MPA
impairs cranial nerve development in rat embryos (45) demonstrating that defects in other neural
cell types can be caused by abnormal purine metabolism. We are not aware of human ENS
malformations reported after MPA or MMF exposure, but HSCR occurrence after exposure
likely requires predisposing gene mutations. Here we show that MPA caused dose-dependent
distal ENS malformations in fish and mice, that MPA impairs ENCDC migration by depleting
guanine nucleotides and reducing proliferation, and that mutations that model HSCRpredisposition dramatically increased MMF’s teratogenic effects on distal bowel colonization by
ENCDCs.
The unique way that the ENS develops that may explain why ENCDCs are particularly
sensitive to MPA/MMF. One possibility is that the relatively high rate of ENCDC proliferation
compared to neighboring mesenchymal cells requires ENCDC to synthesize guanine nucleotides
more rapidly via IMPDH and the de novo synthesis pathway. The elevated levels of IMPDH in
ENCDC compared to adjacent cells are consistent with this hypothesis, as are the different
effects of MMF in different cell types. As expected, MPA/MMF dramatically reduced BrdU
incorporation and mitotic figures in ENCDC. Remarkably, MPA/MMF effects in neighboring
mesenchyme were more complex. In contrast to ENCDC, a higher proportion of mesenchymal
cells incorporate BrdU after MPA/MMF treatment, but without a concomitant increase in
mitoses. This might occur if MMF-treated mesenchymal cells have enough guanine nucleotide to
enter S-phase, but have a prolonged period of DNA synthesis because of limited dGTP
availability. Alternatively, guanine nucleotide depletion could cause DNA damage, and the
elevated levels of BrdU incorporation reflect DNA repair. In any case, the effect on mammalian
development of blocking a ubiquitous enzyme like IMPDH depends not only on how the drug
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affects the biology of individual cells, but also on how important that perturbation is for
particular aspects of development.

For example, proliferation is essential for ENCDC to

efficiently colonize the distal bowel (27). Reduced proliferation of other cell types might lead to
smaller organs, but might not cause a structural defect because proliferation is not essential to
build that structure during the interval of drug exposure.
For our studies it was important to determine if distal bowel aganglionosis in MPA/MMF
treated mice occurred because of reduced ENCDC proliferation (27) or if depletion of guanine
nucleotides directly affected proteins needed for cell migration. In mesangial (46) and
endothelial (47) cells, for example, MPA-mediated GTP depletion led to reduced levels of active
(GTP-bound) Rho-family GTPases including RAC1, a key regulator of the actin cytoskeleton.
Our experiments, however, strongly suggested that MPA/MMF in the doses tested did not
directly impair cell migration. Specifically, we found that random motility of EYFP-labeled
ENCDCs was unchanged by MPA (Supplemental Figure 3.8) when cells were cultured at a
density that reduced cell-cell contact. Furthermore, using X-inactivation mosaicism we deleted
HPRT and depleted GTP in single ENCDCs that were surrounded by “normal” guanosine
rescued ENCDCs. In these cultures, the non-rescued ENCDCs remain BrdU negative, excluding
cell-to-cell transfer of any significant amount of guanine nucleotide, but the GTP depleted cells
appear to migrate essentially normally. Thus, with two different approaches we demonstrate that
GTP-depleted ENCDC can move at normal speeds, but fail to migrate effectively unless they are
surrounded by adjacent normally proliferating ENCDC. This result is conceptually related to the
findings that Sox10 and Ednrb mutations have non-cell autonomous effects on ENCDC
migration in aggregation chimeras (48, 49) and that proliferation inhibitors (27) or mechanical
reduction of ENCDC density (35) can reduce ENCDC colonization of cultured bowel. The
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molecular mechanisms that allow ENCDCs to sense and react to local ENCDC density or that
control the unpredictable trajectories of individual ENCDCs remain unknown, though in other
neural-crest cells both diffusible (50) and contact-mediated signals are involved (51).
We therefore propose that reduced ENCDC proliferation parsimoniously explains all
other observed effects of MPA on the developing ENS. These results suggest the possibility that
any condition that reduces ENCDC proliferation could increase the risk of Hirschsprung disease.
In addition to the risk of bowel aganglionosis in wild-type mice after MPA/MMF treatment, our
data show dramatic gene-environment interactions between MMF and either Sox10 or Ret
mutations at term. MMF caused distal bowel aganglionosis both when administered for the entire
period of prenatal neural crest development (E7.5-E18.5) or during the period of ENCDC
migration (E9.5-E14.5). Interestingly, ENCDCs were able to recover from a transient MMFinduced developmental delay in wild-type mice and in mice with “mild” Ret genotypes, but not
in Sox10LacZ/+ or Ret9/− fetuses. Furthermore, MPA/MMF appeared to inhibit bowel colonization
by both vagal and sacral neural crest. The sacral neural crest normally migrates proximally
through terminal colon and forms 10-20% of the distal colonic ENS (52). Although we observed
isolated neurons in each aganglionic colon, sacral ENCDC derivatives, if present, are greatly
diminished in number by MMF and/or the genetic lesions evaluated (i.e., less than 2% of
anticipated sacral-derived neurons in this region). If the same phenomena occur in humans, then
many potentially detrimental drug exposures will only cause Hirschsprung disease in children
with underlying predisposing mutations.
A few interesting differences were noted between in vivo versus explant culture results
for Ret and Sox10 mutant animals. In vivo, Ret+/+ and Ret+/− ENCDC migrate at the same rate
through the colon (35), but we noted reduced migration of Ret+/− ENCDC from cultured gut
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explants compared to WT cells. This may occur because the supraphysiologic level of GDNF
used in culture saturates all RET receptors, whereas in vivo GDNF is limiting even in Ret+/−
mice (37). In contrast, Sox10 mutant and WT ENCDC migrated an equal distance from gut
explants in vitro, while the same Sox10 mutation impaired distal bowel colonization in vivo.
This illustrates the importance of coupling in vitro and in vivo studies since some defects will not
be detected in the culture system currently in use. Differences that might be required to detect
Sox10-mediated defects include the much longer time that ENCDCs migrate in vivo, the diverse
set of factors affecting stem cell renewal, differentiation, and migration, and the three
dimensional environment in vivo that requires degradation of the extracellular matrix (53) and
may engage alternate integrin or adherence protein signaling.
Collectively, this work provides the first strong evidence that medicines may impact ENS
development and that potent gene-environment interactions dramatically alter the risk of
Hirschsprung-like disease. Combined with our previous demonstration that vitamin A deficiency
increases HSCR-like defects in concert with Ret mutations (12), this work adds credibility to the
hypothesis that unappreciated maternal non-genetic factors influence HSCR risk. Oral MMF may
also be a valuable experimental tool to probe for genetic factors that predispose to ENS
abnormalities but that are not severe enough to cause disease in the absence of additional defects.
Finally, these studies demonstrate a profound linkage between basic processes in cell
metabolism and specific mammalian ENS developmental defects. This work supports the idea
that any stressor that reduces the efficiency of ENCDC proliferation might increase HSCR
occurrence and severity in children with predisposing mutations, even without altering
“classical” ENS developmental pathways. De novo purine biosynthesis, for example, is a
multistep process where enzymes require nicotinamide, folate, and vitamin B12. Focused
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investigation of clinically-relevant antimetabolic stressors such as folate and B12 deficiency,
anti-folate medicines (trimethoprim, methotrexate), and other antimetabolites (e.g. azathioprine,
6-mercaptopurine) may identify immediate candidate interventions for reducing the incidence
and severity of HSCR in genetically predisposed children. In parallel with work in model
systems, these studies suggest that human case-control epidemiologic investigation is appropriate
and may uncover avoidable maternal exposures or health conditions that could reduce the risk of
dangerous neural crest-dependent birth defects like HSCR.

3.5 Materials and Methods
3.5.1 Zebrafish
Wild type (AB) in vitro fertilized embryos were treated (N ≥ 6 embryos per drug) with 10
µM drug and 1% DMSO in E3 Screening Media (54) from 34-96 hpf. 1% DMSO did not induce
any defects but may increase sensitivity as 2% DMSO alone inhibited ENCDC migration.
Distance from most caudal neuron (Elavl3/4-positive) to bowel terminus was measured (N >
9000 larvae) using a micrometer-calibrated eyepiece grid. Compounds were retested if mean
uncolonized distance was >125 microns, results were consistent between experiments, and the
compound might cross the placenta in mammals. Drugs causing death at 10 µM were retested at
lower concentrations. Larvae with >100 microns of uncolonized bowel were considered as
affected for the TD50 calculations.
3.5.2 Mice
Vaginal plug day was considered E0.5. Mice were from Charles River (CF1), or the
Jackson Laboratory: C57Bl/6J (referred to as B6), C3HeBFe/J (C3Fe), 129X1Sv/J (129X1),
Tg(Wnt1-cre)11Rth (55) referred to as Tg(Wnt1-Cre), Gt(ROSA)26Sortm1(EYFP)Cos (56) referred to
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as Rosa26EYFP, and Tg(CAG-EGFP)D4Nagy/J (30) referred to as X-EGFP+. Other mouse strains
and genetic backgrounds used were Rettm1Jmi: a null allele referred to as RetTGM (57) on a B6
background, Sox10tm1Weg: a null allele referred to as Sox10LacZ (33) on a C3Fe background, and
Rettm2(RET)Jmi: a hypomorphic allele referred to as Ret9 (38) and backcrossed to 129X1 for 2-5
generations. Wnt1-Cre Rosa26EYFP/EYFP and Hprtb-m3 (28) (referred to as Hprt−) were on a mixed
background. PCR genotyping (58) for Sox10LacZ and Wnt1-Cre used published primers (58).
Other primers are listed in Supplemental Table 3.3.
3.5.3 MPA and MMF treatment
Dams were injected daily with MPA (Sigma #M3536) in DMSO or DMSO alone (1.24
µL/gram body weight, 31.25-250 mM MPA, intraperitoneal), or given prodrug MMF (Accord
Healthcare, NDC #16729-094) at 1 mg/mL in 0.25X PBS adjusted to pH 3.6 as drinking water
(23). MMF and PBS groups drank equal amounts. Cardiovascular anatomy at E18.5 was
visualized under a dissection stereomicroscope by left ventricle injection with India ink (Windsor
Newton) diluted 1/10 in water).
3.5.4 Primary ENCDC culture
300–500 micron slices of E12.5 small bowel were cultured on fibronectin-coated (250
µg/mL, Life Technologies) Lab-Tek Permanox chamber slides (Thermo Fisher) in DMEM (high
glucose), 200 mM L-glutamine, 100 IU/mL penicillin, 100 g/mL streptomycin, 1X B-27
supplement (Life Technologies), and MPA in DMSO (0.01% final concentration). Four hours
after plating, GDNF (59) at 50 ng/mL was added to trigger migration. Cultures were maintained
for an additional 16 or 24 hours (37ºC/5% CO2). BrdU (10 µM) was added five hours before
fixation when appropriate. All culture experiments not involving mutant mice used CF1 fetuses.
Sox10, Ret, and Hprt fetuses were cultured individually and genotyped.
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For measuring neurite lengths, E12.5 bowel was enzymatically dissociated into a singlecell suspension (22) and cells were cultured in Neurobasal media supplemented with 1X B-27,
200 mM L-glutamine, 100 IU/mL penicillin, and 100 g/mL streptomycin. Cultures were plated at
a density 1250 cells per cm2 on glass chamber slides (Lab-Tek) coated with poly-D-lysine (100
µg/mL, Sigma) and laminin (BD Biosciences) and cultured for 48 hours before fixation. BrdU
(10 µM), DMSO or MPA (5 µM final), and GDNF (50 ng/mL) were added at plating. For timelapse EYFP microscopy, E12.5 Wnt1-Cre Rosa26EYFP/+ midguts were cultured as dissociated
cells or slices as described above and plated on fibronectin-coated glass chamber slides (Thermo
Fisher). Both cells and slices were cultured in phenol red-free DMEM supplemented with B-27,
L-glutamine, and antibiotics as described above. All other culture conditions were identical to
those of explant cultures.
3.5.5 X-inactivation mosaic analysis
X-EGFP+ male mice were bred to Hprt+/− females. E12.5 midgut explants resulting from
these matings were cultured for 16 hours in the presence of both MPA (5 µM) and guanosine
(100 µM) to rescue all wild-type cells while GTP-depleting all cells that do not express HPRT.
Since both Hprt and the EGFP transgene are subject to mosaic X-inactivation, in Hprt+/−
explants EGFP marks wild-type (rescued) cells but not mutant (depleted) cells. EGFP expression
from the transgene was weak and visualization required immunohistochemistry.
3.5.6 Immunohistochemistry
Zebrafish were fixed and then stained in whole-mount as previously described (19) with
anti-HuC/HuD monoclonal 16A11 (250 ng/mL, Life Technologies) and Alexa Fluor 594 antimouse secondary (1:250, Life Technologies) before mounting in 50% glycerol/PBS.
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E18.5 mouse bowel flushed with PBS was fixed (4% paraformaldehyde/PBS for 30
minutes at 25ºC), washed (PBS), and permeabilized/blocked (1 hour at 25°C) in TBST (Trisbuffered saline with 0.1% Triton-X 100), 1% cold water fish skin gelatin (Sigma), 100 mM
glycine, and 5% normal serum matching secondary species (Jackson ImmunoResearch). Primary
antibodies (Supplemental Table 3.4) were incubated overnight in blocking solution at 4ºC.
Fluorophore-conjugated secondary (Alexa 488 and 594 donkey anti-rabbit, Alexa 488 and 594
donkey anti-goat, Alexa 647 goat anti-rabbit, or Alexa 647 donkey anti-goat, Life Technologies)
incubation was for 1 hour at 25ºC. When desired, DAPI (100 ng/mL) and/or Alexa 594 or Alexa
488-conjugated phalloidin (4 units/mL, Life Technologies) were added during secondary
incubation.
An acid treatment (4N HCl, 5 minutes, 25ºC) step was required for BrdU and RET
staining and was performed after blocking (for TuJ1 co-staining) or after antibody staining and a
post-fixation step (4% paraformaldehyde/PBS for 10 minutes) for co-staining of other antigens.
Samples were washed twice with TBS and blocked again between acid treatment and primary
antibody incubation.
E18.5 mouse bowel anti-HuC/HuD staining required an alternate procedure. Fixed
samples were treated with 3% H2O2/PBS (20 minutes at room temperature) before blocking in
PBST (phosphate-buffered saline pH 7.4, 1% Triton-X 100), 10% normal donkey serum, 1%
cold water fish skin gelatin, and 100 mM glycine. Endogenous biotin was blocked
(Streptavidin/biotin blocking kit, Vector Labs) before an overnight 4ºC incubation with biotinXX conjugated anti-HuC/HuD (400 ng/uL, Life Technologies #A21272) in blocking solution.
After 6 PBST washes, tissue was incubated with Alexa–594 streptavidin (1:2000, Life
technologies) in PBST (15 minutes at 37ºC).
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3.5.7 Quantitative Reverse Transcriptase PCR (qRT-PCR)
Intestines (from stomach to colon) were harvested from E13.5 fetuses treated with PBS or
MMF (E10.5-E13.5) and individually homogenized in 800 µL of Trizol (Life Technology) by
passage through a 26-guage needle. RNA was isolated according to manufacturer’s instructions
with 200 µg of RNA-grade glycogen (Thermo Scientific) added as a carrier. 1 µg of each RNA
sample was treated with RQ1 DNAse (Promega) in a total volume of 10 µL to degrade genomic
DNA according to manufacturer’s instructions. 1 µL of this treated RNA solution was reversetranscribed with 200 units of SuperScript II Reverse Transcriptase (Life Technologies) according
to manufacturer’s instructions using 250 ng of random hexamers in a total volume of 21.1 µL.
qPCR reactions were performed on the equivalent of 1.6 ng of input RNA using Power SYBR
Green PCR Master Mix (Applied Biosystems) and 20 µM of each oligonucleotide in a 25 µL
reaction on a Stratagene Mx3005P thermocyler using the following cycling parameters: 10
minutes at 95ºC followed by 40 cycles of 30 seconds at 95ºC, 1 minute at 55ºC, and 1 minute at
72ºC. Oligonucleotide sequences for Gdnf, Ece1 (60), and Gapdh (61) were described
previously, and sequences for Edn3 were 5’ TCACCAGTTATTCCGGGAGAG 3’ and 5’
TAAGGCCGGTGGGCTTTATC 3’. No-template controls and no-RT enzyme controls were
performed for each primer-pair. Three replicate reactions were run for each sample-amplicon
combination and average PCR efficiencies for each amplicon were calculated using LinRegPCR
software (62) which were then used to calculate efficiency-corrected fold changes (63) using
Gapdh as a reference gene.
3.5.8 Microscopy and Quantification
Micrographs were acquired with Olympus BX60 or IX71 microscopes, Axiocam CCD
camera, and Axiovision software or with an Olympus FV1000 confocal microscope and
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Fluoview software. ImageJ was used for image processing limited to cropping, stitching multiple
fields (64), rotating, and uniform contrast adjustments. Confocal micrographs are presented as
single optical sections or maximum intensity projections.
Uncolonized zebrafish bowel was measured using micrometer-calibrated gridded
eyepieces. Mouse bowel colonization was measured with ImageJ. E18.5 bowel was considered
hypoganglionic when gaps between myenteric ganglia became perceptibly larger and ganglia
contained fewer neurons. For explant cultures, we measured the distance between gut edges and
cell bodies of the most distant ENCDC in 8 sectors per explant. In X-inactivation mosaic
experiments, overall, EGFP-positive, and EGFP-negative migration were measured. Time-lapse
images were acquired every 3 minutes on an AxioObserver.Z1 microscope (Zeiss) equipped with
motorized stage, incubator, and CO2 controller. Cells were tracked with MTrackJ software (65).
All experiments were performed in at least triplicate with separate embryos or separate
pools of embryos in culture. For drug treated pregnant mice, at least three litters were collected
per treatment. Mean ± SEM are plotted unless otherwise indicated. Analyses were performed by
observers blind to genotype and treatment status.
3.5.9 Statistical Analysis
We used SigmaPlot 11 (Systat Software) or R (R Foundation) for analysis. For fetal
bowel colonization, Student’s t-test or one-way ANOVA was used. For wild-type explants,
repeated measures ANOVA was used unless noted. For mutant explants, two-way ANOVA was
used to test influence of genotype, treatment, and interactions. Paired t-tests or Wilcoxon signedrank tests (when data were non-normally distributed) were used for mosaic analyses. Other
parameters were compared with one-way ANOVA, t-test, rank-sum test, or KolmogorovSmirnov test as indicated. For all analyses, P < 0.05 was considered significant and two-tailed
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tests were performed. P values were adjusted for multiple comparisons by the Holm-Bonferroni
procedure based on numbers of planned comparisons. When colonization was normalized to
bowel length, absolute length of aganglionic (or abnormal) segments were also tested and always
agreed with the normalized results.
3.5.10 Study Approval
Animal experiments were approved by the Washington University Animal Studies
Committee.
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3.6 Supplemental Data
Supplemental Figure 3.1
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Supplemental Figure 3.1
The de novo and salvage purine synthesis pathways are shown converging on GMP
synthesis (A). Enzymes and intermediates not involved in MPA action and/or guanosine salvage
are omitted for simplicity. A model (B) for the individual and synergistic effects of MPA (or
other similar antiproliferative insults) and HSCR-predisposing mutations on the developing ENS.
Normally, the ENCDCs that migrate into the developing bowel complete their colonization of
the terminal colon with relatively little time remaining before the bowel microenvironment
becomes more resistant to colonization. Either defects in classical ENS development genes or
prolonged exposure to antimetabolites (e.g. MPA) can result in partially penetrant aganglionosis
because of this developmental window. ENCDCs may be individually more sensitive to MPA
than other bowel cells and or simply cannot migrate effectively if proliferation of all cells slows.
MPA interacts with genes both affecting proliferation (Ret) and other aspects of ENS
development (Sox10) suggesting that multiplicative effects on disease penetrance and severity
can result from two hits in converging but largely separate signaling pathways. Transient
environmental insults that are removed as the ENCDC migration window closes can result in
phenotypes ranging from complete recovery to lethal aganglionosis dependent on genotype.
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Supplemental Figure 3.2
IMPDH is ubiquitously expressed in the bowel at the time that ENCDCs colonize the
colon. Since we anticipated that IMPDH levels might vary by position within the bowel and
ENS, we first used whole mount IMPDH immunohistochemistry to visualize and quantify the
expression in situ. (A) IMPDH reactivity was diffusely cytoplasmic with rod and ring
aggregates. Since ENCDCs appeared to have more intense cytoplasmic immunoreactivity for
IMPDH, we measured the average fluorescence signal intensity in 2.17 micron thick rings (B)
(represented by the shaded green region) around mesenchymal and ENCDC (SOX10-positive)
nuclei (blue ovals). This strategy was designed to minimize overlap with the cytoplasm of
neighboring cells (black lines). (C) Intensity values. Each dot is mean fluorescence intensity
from a single cell. Measurements are from optical sections of three separate E11.5 colons from
the CF1 strain. Thick line = median; thin lines = 25th and 75th percentile. Values have extensive
overlap, but ENCDCs have a statistically significant increase in average IMPDH fluorescence
intensity. ** = P < 0.01, rank-sum test. Since whole bowel staining did not reveal any obvious
differences in anti-IMPDH reactivity between regions of the bowel, we quantified (D) total
cellular anti-IMPDH reactivity in cells dissociated from six E12.5 Tg(Wnt1-Cre); Rosa26EYFP
bowels that were cultured for 3 hours on fibronectin-coated glass at a density of 3.1×104
cells/cm2 before fixation and staining. Total-cellular anti-IMPDH fluorescence for each cell was
quantified with ImageJ and is shown for EYFP-negative and EYFP-positive populations as
histograms.
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Supplemental Figure 3.3
MPA/MMF treatment from E10.5-E13.5 reduced colon lengths at E13.5. (A) Higher
doses of MPA significantly reduced the length of CF1-strain colons at E13.5 (P < .001, KruskalWallis test) while lower doses of MPA and oral MMF significantly reduced the length of Wnt1Cre Rosa26EYFP-strain colons (t-tests). Lower doses of MPA did not significantly affect bowel
length in C57Bl/6 fetuses, though variability was high (Kruskal-Wallis test). Thick line =
median; thin lines = 25th and 75th percentile. *** = P < 0.001, * = P < .05. (B,C) Plots of ENS
colonization extent assessed with double-stained E13.5 Wnt1-Cre Rosa26EYFP-strain colons. (B)
Cellular markers such as neural-crest lineage marker EYFP or SOX10 have near-perfect
concordance for ENS colonization extent measurements. The most caudal TuJ1+ process also
reliably indicates colonization extent, albeit with some random error. MPA treatment does not
appear to have any systematic effect on the extension of neuronal processes up to ENCDCs at the
wavefront.
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Supplemental Figure 3.4
Cleaved caspase 3 staining of 24-hour explant cultures reveals that MPA induces
apoptosis in cultured ENCDCs. *** = P < 0.001, t-test.

Supplemental Figure 3.5
MPA did not alter neurite growth in post-mitotic neurons. Data show the length of the
longest neurite on each TuJ1+ cell that did not incorporate BrdU over the course of 48 hours in
culture with GDNF, (n>150 cells/group).
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Supplemental Figure 3.6
MMF treatment at doses that significantly reduced ENCDC proliferation and bowel
colonization in vivo did not cause premature differentiation at E13.5. 8 µm-thick maximumintensity projections of SOX10 (pseudocolored green) and RET (pseudocolored red) distal small
intestine (A,B, scale bar = 100 µm) and quantification of each cell population within total
ENCDCs (C) demonstrate the expected reduction in the percentage of SOX10, RET double
positive progenitor cells within the ENCDC population as we move from distal (e.g. more
recently colonized) to proximal. Concomitantly, the RET+, SOX10− and SOX10+, RET− single
positive populations increase in proportion as the double-positive proportion falls. Since enteric
neurons already exist at this time and are known to lose SOX10 and retain RET expression, the
RET single-positive population is very likely a neuronal lineage. Increased differentiation would
manifest as a reduction in the proportion of double-positive cells. MMF treatment did not
significantly change the percentage of SOX10+, RET+ progenitor cells within the ENCDC
population (two-way ANOVA, interaction term was not significant). (D) qRT-PCR analysis of
mRNAs encoding mesenchyme derived factors important for ENS colonization. RNA was
isolated from E13.5 bowels after treatment from E10.5-E13.5 with PBS (5 embryos) or MMF (4
embryos). Gapdh is used as an internal reference gene for relative quantitation (t-tests). *** = P
< 0.001, ns = not significant.
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Supplemental Figure 3.7
MMF treatment at doses that significantly reduced ENCDC proliferation and bowel
colonization in vivo did not cause detectable canonical caspase-mediated ENCDC apoptosis.
Cleaved-caspase 3 reactivity was readily detected in the interdigital web of E13.5 mice (C) but
was infrequently detected in ENCDCs or non-neural crest mesenchymal cells with or without
MMF treatment (A-B,D) ns = not significant, t-test). Bowels shown in (A-B) are the same as in
Figure 3E-F.
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Supplemental Figure 3.8
Time lapse imaging of isolated ENCDC and bowel explant cultures reveals that (A, C)
MPA does not alter the speeds or migration distance of individual ENCDCs when they are
cultured at low density (Kolmogorov-Smirnov test), but does reduce (B, D) the speed and
migration of ENCDCs migrating from bowel explants (t-test on log-transformed speeds).
Isolated ENCDCs were prepared from the same region of Wnt1-Cre Rosa26EYFP bowel as were
the explants (small intestine) and were plated at low density (3125 cells/cm2) to minimize cellcell collisions. Migrating EYFP+ cells were randomly selected for tracking at 8 hours after
GDNF addition and tracked for the duration of culture that they remained in the field of view,
alive, and non-dividing. Measurements from the middle third (approximately hours 6-11) of 16hour time-courses were chosen for analysis because most chosen cells stayed in field for this
interval. ns = not significant, *** = P <.05. Thick lines in A-B = median. Thin lines in A-B= 25th
and 75th percentile. Thick lines and shaded region in C-D = Mean and 95% confidence interval.
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Supplemental Figure 3.9
MMF treatment during gestation reduces intestine length at E18.5 in (A) Sox10 and (B)
Ret interaction experiments. Data are shown with all genotypes pooled since Ret or Sox10
genotype did not affect intestine length. Black lines = mean, *** = P < 0.001, ns = not
significant, statistical test: Welch ANOVA.
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Supplemental Table 3.2: Incidence of neural tube and heart defects in the offspring of
MMF treated dams
Heart /
Paternal
Maternal
Fetus
N
Great
Strain /
Strain /
Treatment
Exencephaly
Genotype Fetuses
Vessel
Genotype Genotype
Defects
Sox10+/+

11

0 (0%)

0 (0%)

Sox10+/LacZ

16

0 (0%)

0 (0%)

MMF
1 mg/mL
E7.5-E18.5

Sox10+/+

10

4 (40%)

1 (10%)

Sox10+/LacZ

17

6 (35%)

4 (23%)

MMF
1 mg/mL
E9.5-E14.5

Sox10+/+

9

0 (0%)

0 (0%)

Sox10+/LacZ

13

0 (0%)

1 (8%)A

Ret+/+

7

0 (0%)

0 (0%)

Ret9/+

6

0 (0%)

0 (0%)

Ret+/−

6

0 (0%)

0 (0%)

Ret9/−

8

0 (0%)

0 (0%)

Ret+/+

5

3 (60%)

0 (0%)

Ret9/+

4

2 (50%)

0 (0%)

Ret+/−

4

2 (50%)

0 (0%)

Ret9/−

8

5 (63%)

3 (38%)

Ret+/+

9

0 (0%)

0 (0%)

Ret9/+

4

0 (0%)

0 (0%)

Ret+/−

5

0 (0%)

0 (0%)

Ret9/−

14

0 (0%)

0 (0%)

0.25X PBS
E7.5-E18.5
C3HFe/J
Sox10+/LacZ

C57Bl/6

0.25X PBS
E7.5-E18.5

B6;129X1
Ret9/+

C57Bl/6
RetTGM/+

MMF
1 mg/mL
E7.5-E18.5

MMF
1 mg/mL
E9.5-E14.5

A – Affected fetus was much smaller than littermates
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Supplemental Table 3.3: Genotyping oligonucleotides
Gene

Allele

Direction

Ret

common

Forward

Ret

wild-type 1

Reverse

Ret

RetTGM

Reverse

Ret

wild-type 2

Reverse

Ret

Ret9

Reverse

Hprt

wild-type

Forward

Hprt

Hprtb-m3

Forward

Hprt

common

Reverse

Sry

N/A

Forward

Sry

N/A

Reverse

N/A

Forward

N/A

Reverse

EGFP
/EYFP
EGFP
/EYFP

Amplicon
Size (bp)

Sequence
5’CAG CGC AGG TCT CTC ATC AGT ACC GC
AAC C3’
5’ACG TCG CTT TCG CCA TCG CCC GTG
CGC GCG3’
5’CCC TGA GCA TGA TCT TCC ATC ACG
TCG AAC3’
5’GCG CAG CAG CTA GCC GCA GCG ACC
CGG TTC3’
5’CCC AGT AAG CAT CCC TCG AGA AGT
AGA GGC3’
5’TCT GGT TTT ATA TGG GTA CTG GGG GAT
CT3’

multipleA

5’AGC ATT CCT GCC CCA ACA ATG ATT C3’

288

5’CAT GCA GGC ACT CAC ACA TAC AAG
TAA AAA3’
5’TTG TCT AGA GAG CAT GGA GGG CCA
TGT CAA3’
5’CCA CTC CTC TGT GAC ACT TTA GCC CTC
CGA3’
5’GCA CGA CTT CTT CAA GTC CGC CAT
GCC3’
5’GCG GAT CTT GAA GTT CAC CTT GAT
GCC3’

multipleB

230
290
450
320
218

273

265

A – To detect Ret+ and RetTGM, a PCR reaction was performed with three primers
(common, wild-type 1, and TGM). To distinguish Ret+ and Ret9, an analogous reaction was used
(common, wild-type 2, and Ret9).
B – To detect Hprt genotype, two separate PCR reactions were performed for wild-type
(wild-type and common) and b-m3 (b-m3 and common).
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Supplemental Table 3.4: Primary antibodies
Antibody
rabbit anti-TuJ1
goat anti-RET
rabbit anti-p75NTR
chicken anti-GFP
goat anti-SOX10
rabbit anti-SoxE

Manufacturer /
Investigator
Covance (PRB-435P)
Neuromics (GT15002)
Promega (G323A)
Aves Labs (GFP-1020)
Santa Cruz Biotechnology
Craig Smith, MRCI,
Australia

Dilution used
1:10000
1:200
1:200
1:1000
1:200
1:4000

rabbit anti-IMPDH

Proteintech (12948-1-AP)

rabbit anti-cleaved Caspase 3
Alexa 594-conjugated
mouse anti-BrdU
biotin-XX conjugated
anti-HuC/HuD

Cell Signaling (#9661)

1:100 on bowel; 1:200 on
cells
1:250

Life Technologies (PRB–1)

1:50

Life Technologies (A21272)

400 ng/mL
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Chapter 4: Neural crest requires Impdh2 for
development of the enteric nervous system, great
vessels, and craniofacial skeleton
4.1 Summary
Mutations that impair the proliferation of enteric neural crest-derived cells
(ENCDC) cause Hirschsprung disease, a potentially lethal birth defect where the enteric
nervous system (ENS) is absent from distal bowel. Inosine 5’ monophosphate
dehydrogenase (IMPDH) activity is essential for de novo GMP synthesis, and chemical
inhibition of IMPDH induces Hirschsprung disease-like pathology in mouse models by
reducing ENCDC proliferation. Two IMPDH isoforms are ubiquitously expressed in the
embryo, but only IMPDH2 is required for life. To further understand the role of IMPDH2
in ENS and neural crest development, we characterized a conditional Impdh2 mutant
mouse. Deletion of Impdh2 in the early neural crest using the Wnt1-Cre transgene
produced defects in multiple neural crest derivatives including highly penetrant intestinal
aganglionosis, agenesis of the craniofacial skeleton, and cardiac outflow tract and great
vessel malformations. Analysis using a Rosa26 reporter mouse suggested that some or
all of the remaining ENS in Impdh2 conditional-knockout animals was derived from cells
that escaped Wnt1-Cre mediated DNA recombination. These data suggest that IMPDH2
mediated guanine nucleotide synthesis is essential for normal development of the ENS
and other neural crest derivatives.
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4.2 Introduction
The enteric nervous system (ENS) is a network of ganglia distributed throughout
the digestive tract that autonomously controls motility, secretion, and blood flow (1). The
ENS develops from migratory neural crest-derived cells that invade, migrate through, and
colonize the nascent bowel while dividing rapidly, eventually reorganizing into discrete
ganglia, and differentiating into glia or one of more than fifteen functional classes of
neuron (2–4). A complete and functional ENS is required for life. Incomplete
colonization of the bowel by ENS precursors results in Hirschsprung disease (HSCR), a
life-threatening oligogenic birth defect where a segment of distal bowel is devoid of
enteric neurons (aganglionosis). Bowel colonization critically requires that ENCDC
proliferate efficiently (5, 6). For this reason, many of the mutations that cause HSCR
impair ENS precursor proliferation or self-renewal (2, 7). Inhibition of ENCDC
proliferation with the antimetabolite immunosuppressant mycophenolic acid (MPA) also
causes aganglionosis in mice (6) and enhances the penetrance and phenotypic severity of
mutations that model HSCR. MPA blocks the rate-limiting step of de novo guanine
nucleotide synthesis by inhibiting inosine 5’ monophosphate dehydrogenase (IMPDH), a
ubiquitous metabolic enzyme whose expression is relatively enriched in ENCDC (6).
Prenatal MPA exposure in humans is also associated with a specific pattern of birth
defects (8), some of which are plausibly due to disruptions in neural crest development
(9).
Relatively little is known about the developmental roles of IMPDH, which is
present in two isoforms encoded by separate genes in vertebrates. IMPDH2 is widely
expressed and is enriched in activated lymphocytes, tumor cells, fetal tissues, and other
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proliferative cells (10–12). Homozygous Impdh2 deletion in mice results in early lethality
prior to embryo implantation, while heterozygous deletion results in a subtle reduction in
the IMPDH activity of splenic lymphocytes (13). IMPDH1 is also ubiquitously expressed,
but does not appear to be regulated by proliferative demand, and has a specialized but
poorly-understood role in the retina (12, 14–17), where missense mutations in IMPDH1
cause a form of autosomal dominant retinitis pigmentosa in humans. In mice, Impdh1 is
dispensable for life and its deletion results in a relatively mild retinal phenotype (16, 18).
Our previous experiments with the non-selective IMPDH inhibitor mycophenolic
acid did not target IMPDH inhibition to neural crest derivatives, nor did they indicate
whether IMPDH1 and IMPDH2 have redundant roles or whether one isoform is uniquely
required for neural crest development. Since Impdh1 homozygous mutant mice are viable
and fertile and thus must form a complete and functional ENS, we hypothesized that
Impdh2 is required within the neural-crest lineage for ENCDCs to proliferate efficiently
and colonize the bowel. To further explore the role for this basic metabolic pathway in
development, we deleted Impdh2 in the early neural crest of mice using a Cre/loxP
system and Wnt1-Cre mice.
Here we demonstrate that Impdh2 expression is required in the neural crest for
development of the craniofacial skeleton, cardiac outflow tract, and enteric nervous
system. In the ENS, loss of Impdh2 results in extensive bowel aganglionosis.
Furthermore, ENCDC that do colonize the bowel in Impdh2 conditional mutant mice are
delayed and demonstrate incomplete Cre/loxP recombination, indicating a strong
selective pressure against Impdh2 deletion. Collectively these data support the need for
de-novo guanine nucleotide synthesis and cell proliferation during neural crest
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development and are consistent with the hypothesis that IMPDH1 does not adequately
supply metabolic guanine nucleotide needs for these neural crest-derived cell populations.

4.3 Results
4.3.1 Impdh2 deletion in the neural crest results in craniofacial and cardiac defects.
Guanine nucleotides can be produced either de novo via IMPDH1/IMPDH2 or by
the purine salvage pathway. To determine whether Impdh2 was required within the neural
crest lineage for ENS development or whether Impdh1 and/or purine salvage from
adjacent tissue could provide adequate GMP once embryonic lethality was bypassed, we
used the well-characterized Wnt1-Cre transgene (19) to delete a conditional Impdh2loxP
allele (Supplemental Figure 4.1) in the early neural crest. As expected, both
Impdh2loxP/loxP and Impdh2loxP/Del mice lacking Wnt1-Cre survived to adulthood and were
fertile. While Wnt1-Cre Impdh2loxP/+ mice appeared normal, Wnt1-Cre Impdh2loxP/loxP
mice did not survive after birth, though they did develop to term. At E18.5, Wnt1-Cre
Impdh2loxP/loxP fetuses had profound malformations of the anterior head (Figure 4.1A,E)
including a near-total absence of the jaw and a protruding brain that was not covered by
bone. Eyes were sometimes open, and ear pinnae were rudimentary. Bone and cartilage
staining revealed that most skeletal structures anterior to the parietal (dorsal) or
basisphenoid (ventral) bones were reduced or ablated, and the remaining structures
consisted of irregular spicules of bone and cartilage (Figure 4.1B-D,F-H). Notably, these
structures are normally neural crest-derived. Several posterior elements of the skull that
are neural crest-derived are also reduced or missing in Wnt1-Cre Impdh2loxP/loxP fetuses,
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Figure 4.1: Impdh2 deletion by Wnt1-Cre results in craniofacial and cardiac defects
at term.
At embronic day 18.5 (E18.5), (A, E) Wnt1-Cre Impdh2loxP/loxP fetuses lack a jaw,
external ear, or any mineralized bone in the anterior head. (B, F) superior, (C, G) inferior,
and (D, H) lateral views of bone and cartilage stained skulls show that Wnt1-Cre
Impdh2loxP/loxP fetuses have missing or severely reduced neural-crest derived skeletal
structures of the head, including most structures anterior to the parietal and basiosphenoid
bones as well as the neural crest derived interparietal bone and tympanic rings. bo =
basiooccipital bone, bs = basisphenoid bone, eo = exooccipital bone, f = frontal bone, m
= mandible, n = nasal bone, p = parietal bone, px = premaxilla, ip = interparietal bone, so
= supraoccipital bone, tr = tymanic ring, x = maxilla, * = remnant or abnormal structure.
scale bars in panels A-H = 5 mm. Injection of ink into the ventricles of control Wnt1-Cre
Impdh2loxP/+ hearts (I) reveals normal anatomy of the great arteries. Wnt1-Cre
Impdh2loxP/loxP hearts (J and K) show representative malformations of the great vessels
and outflow tract: J shows an interrupted aortic arch, where the left subclavian (ls) arises
from the pulmonary artery instead of the aorta. In K, the pulmonary artery fails to label
with ink despite ink injection into the right ventricle, indicating pulmonic stenosis or
atresia. a = aorta, p = pulmonary artery, b = brachiocephalic trunk, lc = left common
carotid artery, ls = left subclavian artery, p* = atretic pulmonary artery. Scale bar = 2 mm.
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such as the interparietal bone and tympanic rings (20, 21). Since our previous
experiments with IMPDH inhibition also revealed heart defects in exposed fetuses, we
examined hearts at E18.5 using dye injection into the left ventricle and observed outflow
tract and great vessel defects in 4 of 8 Wnt1-Cre Impdh2loxP/loxP fetuses (Figure 4.1I-K).
4.3.2 Neural crest-specific deletion of Impdh2 results in bowel aganglionosis.
Examination of enteric neurons in E18.5 fetal bowel using ANNA–1 (antiHuC/HuD) staining revealed normal colonization in Impdh2loxP/+ fetuses while deletion
of Impdh2 in the neural crest of Impdh2loxP/loxP fetuses resulted in severe defects of the
ENS including highly-penetrant aganglionosis of variable length (Figure 4.2A-C) ranging
from very short colonic aganglionosis to total intestinal aganglionosis. In bowels that had
normally-innervated regions, those regions were always oral to hypoganglionic and
aganglionic regions, strongly suggesting that Impdh2 deletion causes a vagal ENCDC
colonization defect. Some isolated enteric neurons were found in the walls of otherwise
aganglionic colons and are possibly of sacral neural crest origin. We were concerned that
the variable phenotype seen in the conditional knockout was due to the presence of two
“floxed” alleles of Impdh, resulting in either incomplete recombination or a failure to
reduce IMPDH2 protein levels quickly enough to produce a complete phenotype in the
ENS. To address this concern, we converted one copy of Impdh2loxP to the deleted allele
Impdh2Del in the germline and examined the phenotype of Wnt1-Cre Impdh2loxP/Del
fetuses. This configuration requires only a single recombination event to delete Impdh2.
This strategy greatly increased the severity of the ENS phenotype. (Figure 4.2A,D).
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Figure 4.2: Impdh2 deletion by Wnt1-Cre causes highly penetrant aganglionosis of
variable length at term.
(A) At E18.5, all Wnt1-Cre Impdh2loxP/+ bowels are fully colonized by neurons, while
Wnt1-Cre Impdh2loxP/loxP and Wnt1-Cre Impdh2loxP/Del intestines demonstrate distal
aganglionosis reminiscent of Hirschsprung disease. Proximal to aganglionic bowel there
is a hypoganglionic transition zone and eventually, in many cases, regions of relatively
normal bowel. Dots = position of the most caudal enteric neuron in each intestine, grey
lines = hypoganglionic regions. vertical lines = mean positions of the most caudal
ENCDC. (B) ANNA–1 (anti-HuC/HuD) staining of enteric neuron somata reveals that
Wnt1-Cre Impdh2loxP/+ bowels contain a dense network of enteric neurons throughout the
bowel while (C-D) conditional knockout genotypes contain aganglionic (distal colon),
hypoganglionic (C, proximal colon) and relatively normal regions of the ENS (proximal
small intestine). ANNA–1 photomicrographs are maximum intensity projections of 20
micron-thick volumes. Scale bar = 100 µm.
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4.3.3 Impdh2 deleted ENCDCs colonize the bowel abnormally
Because of the distal aganglionosis apparent at E18.5, we examined the effects of
Impdh2 deletion as the ENCDC migration process nears completion at E13.5 using a
mouse strain that expresses EYFP after Cre-induced DNA recombination, Rosa26EYFP.
The craniofacial defects that result from Impdh2 deletion were readily apparent at E13.5.
While lineage-marked EYFP+ cranial neural crest cells did migrate to the expected
regions of the anterior head in Wnt1-Cre Impdh2loxP/loxP and Wnt1-Cre Rosa26EYFP
Impdh2loxP/Del fetuses, the resulting structures were abnormal in Wnt1-Cre Rosa26EYFP
Impdh2loxP/loxP embryos and the pharyngeal arches were almost entirely absent in the
Impdh2loxP/Del genotype (Figure 4.3A,C,E). In the ENS, Wnt1-Cre Impdh2loxP/+ colons
were uniformly colonized at E13.5 as indicated by EYFP fluorescence or SOX10 staining.
In contrast, both Wnt1-Cre Impdh2loxP/loxP and Wnt1-Cre Impdh2loxP/Del genotypes showed
severe colonization defects at E13.5 (Figure 4.3B,D,F-G) and colonization in the Wnt1Cre Impdh2loxP/Del genotype was slightly but significantly reduced relative to Wnt1-Cre
Impdh2loxP/loxP (Figure 4.3G). The structure of the proximal colonized regions of the ENS
was also abnormal in both conditional knockout genotypes. In Impdh2loxP/+ fetuses, the
ENCDCs immediately behind the wavefront were organized into chains of cells (Figure
4.3B), quickly transitioning into a high-density network more proximally. In contrast,
Wnt1-Cre Impdh2loxP/loxP and Wnt1-Cre Impdh2loxP/Del bowel contained long stretches of
low-density ENCDC strands and even isolated ENCDCs (Figure 4.3D,F). Notably, the
proximal colonized areas of E18.5 bowel appeared essentially normal (Figure 4.2),
indicating that these sparse strands of ENCDCs did expand between E13.5 and E18.5 to
populate the colonized regions of the proximal bowel. In an effort to determine the fate of
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Figure 4.3: Impdh2 conditional knockout fetuses have cranial neural crest and
ENCDC abnormalities at E13.5
(A, C, E) EYFP-positive neural crest derivatives have migrated to the anterior head in all
genotypes, but in (C) Wnt1-Cre Rosa26EYFP Impdh2loxP/loxP fetuses, EYFP-positive tissue
is reduced in size and has not fused at the midline. In (E) Wnt1-Cre Rosa26EYFP
Impdh2loxP/Del fetuses, EYFP-positive tissue is still present anterolaterally but does not
form recognizable branchial arch structures. Scale bar = 1 mm. In (B) control bowel,
SOX10-positive enteric neural crest-derived cells (ENCDCs) have colonized almost the
entire bowel and have accumulated to a high density in colonized regions (small intestine
and proximal colon). In (D) Wnt1-Cre Impdh2loxP/loxP and (F) Impdh2loxP/Del intestine,
colonized regions are both significantly shorter and contain fewer cells, indicating a
profound inability for ENCDCs to efficiently populate the intestine. Scale bar = 100 µm.
Measurements (G) of colonization extent as well as colonized regions of bowel
containing an unusually low ENCDC density reveal that Wnt1-Cre Impdh2loxP/Del
intestine has a significantly worse colonization defect than Wnt1-Cre Impdh2loxP/loxP. Dots
= position of the most caudal ENCDC in each intestine as indicated by EYFP expression
in Rosa26EYFP bowels or SOX10 staining in Rosa26+ bowels. Grey lines = regions of low
ENCDC density. Vertical lines = mean positions of the most caudal ENCDC. * = P< .05,
*** = P < .001 by Welch’s t-test on the most-caudal ENCDC positions.
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Impdh2-deficient ENCDCs, we measured DNA synthesis and apoptosis at E13.5 using
BrdU labeling and cleaved-caspase 3 staining. We did not detect significant numbers of
cleaved-caspase 3 reactive ENCDCs of any genotype and found that BrdU incorporation
in the EYFP-positive cells of E13.5 Impdh2loxP/Del bowel was not significantly reduced
relative to EYFP-positive cells at the migration wavefront in Impdh2loxP/+ fetuses
(Supplemental Figure 4.2).
4.3.4 Wnt1-Cre incompletely recombines the Rosa26EYFP reporter in the ENS of
Impdh2 conditional knockouts
E18.5 fetuses that also carried the Rosa26EYFP reporter displayed an unexpected
phenotype. In Wnt1-Cre Impdh2loxP/+ bowel, all neurons were EYFP-positive (Figure
4.4A), as expected given the Wnt1-Cre fate map (20). However, in every Impdh2loxP/loxP
Rosa26EYFP fetus (N=4 EYFP-positive samples), mixtures of varying numbers of EYFPpositive and EYFP-negative neurons were clearly visible (Figure 4.4B-C). The degree of
incomplete recombination varied both between animals and between regions of a single
bowel, reflecting the clonal mixing that occurs during ENS development (22–24). When
we examined heterozygous Wnt1-Cre Impdh2loxP/+ Rosa26EYFP bowels at E18.5, (N=4
EYFP-positive samples), we were unable to find any EYFP-negative neurons. Similarly,
when we examined Wnt1-Cre Impdh2loxP/+ and Wnt1-Cre Impdh2loxP/Del bowels carrying
the Rosa26EYFP reporter at E13.5 and stained for SOX10, we observed many EYFPnegative ENCDCs in the Impdh2loxP/Del genotype (2 of 4 embryos, Figure 4.4D-E). After
searching the colonized regions of Wnt1-Cre Impdh2loxP/+ bowels marked by EYFP
(N=6), we found only a few scattered EYFP-negative SOX10-positive ENCDCs in a
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Figure 4.4: Residual enteric neurons and ENCDCs in Impdh2 conditional knockouts
display incomplete recombination.
In (A) Wnt1-Cre Impdh2loxP/+ Rosa26EYFP control fetuses, all ANNA–1-positive (antiHuC/HuD, red) enteric neurons are EYFP-positive (green) at E18.5, demonstrating that
under normal circumstances Wnt1-Cre efficiently recombines the ancestors of essentially
all ENCDCs. In (B-C) Wnt1-Cre Rosa26EYFP Impdh2loxP/loxP colon (B) and small intestine
(C), many enteric neurons are not EYFP-positive, and the degree of incomplete labeling
varies. (D-E) A similar phenomenon is already visible in the small intestine at E13.5.
ENCDCs (SOX10-positive, red) are always EYFP-positive (green) in (D) control Wnt1Cre Rosa26EYFP Impdh2loxP/+ bowel, but in Wnt1-Cre Rosa26EYFP Impdh2loxP/Del bowel,
many SOX10-positive ENCDCs are EYFP-negative (E). Dashed boxes = magnified
insets. All scale bars = 100 µm. All photomicrographs are maximum intensity projections
of 20 micron-thick volumes.
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single embryo (Supplemental Figure 4.3), indicating that while Wnt1-Cre mediated
recombination in the ENS is highly efficient, it is not universal.

4.4 Discussion
4.4.1 A neural-crest autonomous requirement for Impdh2
Deletion of Impdh2 in the early neural crest results in craniofacial defects
including near-total ablation of skull structures derived from the neural crest (20, 25).
This includes the skeleton anterior to the basisphenoid and parietal bones as well as the
tympanic rings and the interparietal bone in the posterior skull (Figure 4.1). In addition,
conditional knockout fetuses demonstrated cardiac outflow tract and great vessel defects.
These phenotypes bear a striking resemblance to the pan-neural crest defects that result
from experimental ablation of the Wnt1-Cre fate map using Cre recombinase-triggered
expression of diphtheria toxin fragment-A (26) or HSV-Tk followed by ganciclovir
treatment (27), which suggests that neural crest derivatives lacking Impdh2 fail to expand,
survive, or differentiate properly. Taken together with the catastrophic results of Impdh2
deletion in the ENS, these results reinforce our previous findings that global IMPDH
inhibition results in cardiac and ENS defects (6). Our previous work could not separate
the effects of IMPDH inhibition on ENCDCs and non-neural crest tissues such as the
bowel mesenchyme, which manifested as global growth restriction and reduced intestinal
length in exposed fetuses. These experiments clearly show that Impdh2 is required in
ENCDCs and that the resulting ENS defects occur in the context of an entirely normal
bowel microenvironment. Moreover, guanine salvage from this normal neighboring
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tissue and any residual GMP synthesis by IMPDH1 clearly cannot compensate for the
loss of IMPDH2.
4.4.2 Incomplete recombination in conditional deletion of Impdh2
The aganglionosis observed in Impdh2 conditional knockout bowel demonstrates
the necessity of IMPDH2 for ENS development, while the incomplete recombination
seen in the ENS (Figure 4.4) of these fetuses provides indirect evidence that loss of
Impdh2 selects against neural crest cells populating the bowel. The Wnt1-Cre transgene
has been used extensively to delete genes in and mark the cells of the ENS (28–31), and
we are unaware of any previous instances where incomplete recombination has been
demonstrated in Wnt1-Cre mice, although it has been suggested that it may account for
some otherwise contradictory results (32, 33). Indeed, we observed only rare instances of
incomplete recombination of the EYFP reporter in E13.5 Impdh2loxP/+ Rosa26EYFP fetuses
(Supplemental Figure 4.3), suggesting that Cre-induced recombination is nearly complete
in the ENS of Wnt1-Cre mice. The Impdh2loxP/loxP conditional knockout, on the other
hand, shows clear evidence of incomplete recombination of the Rosa26 reporter. Since
each Cre-catalyzed recombination event is independent, when reporter recombination is
obviously incomplete we can no longer assert with confidence that every EYFP-positive
cell has recombined the gene of interest. Because the Wnt1-Cre transgene is very
efficient in conditional heterozygotes, we suspect that cells escaping recombination had a
strong selective advantage early in neural crest development, leading to their
overrepresentation in the ENS of conditional knockout fetuses. We also suspected that
incomplete deletion of Impdh2 could account for the variability in ENS phenotype. Since
the Impdh2 allele used in this study lacks an internal recombination reporter and all
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available anti-IMPDH antibodies suitable for immunohistochemistry lack specificity for
IMPDH2, we attempted to circumvent this problem by using the Impdh2loxP/Del
Rosa26EYFP genotype, reasoning that reducing the number of required recombination
events from 3 to 2 might make both deletion and lineage marking more uniform.
However, examination of the ENCDC population indicates that this was not entirely
successful, since many SOX10-positive cells in Impdh2loxP/Del Rosa26EYFP bowels still
escaped recombination at the Rosa26 locus. Using the Impdh2loxP/Del genotype likely
increased deletion efficiency and reduced the number of proliferation competent cells
entering the bowel since the migration phenotype in Impdh2loxP/Del embryos at E13.5 was
significantly worse than in mice with the ImpdhLoxP/LoxP genotype and ENCDC migration
depends largely on population size and proliferation (5, 34). The relatively normal BrdU
labeling index in Wnt1-Cre Impdh2loxP/Del ENCDCs is also easily accounted for if the
ENCDCs that do colonize the bowel in Impdh conditional mutant mice have
preferentially not undergone recombination at the Impdh2 locus despite sporadically
recombining the Rosa26EYFP reporter.
The defect in ENCDC colonization of Impdh2 conditional knockout fetuses is
severe at E13.5, with long stretches of very sparsely populated bowel (Figure 4.3).
Continued expansion of this remnant ENCDC population must occur to produce the
relatively normal-appearing ENS present in the colonized regions of bowel at E18.5
(Figure 4.2), which also supports the idea that this sparsely colonized network is made up
of fugitive ENCDCs whose ancestors escaped recombination and then adaptively expand
to fill the underpopulated bowel (35). To our knowledge, it is not known how long Cre
expression from the Wnt1-Cre transgene lasts in the migratory neural crest. Expression of
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a similar Tg(Wnt1-LacZ) transgene in the developing ENS was lost after E11.5 (36),
suggesting that the rare ENCDC that had not yet recombined at that time would
permanently escape Cre-mediated DNA recombination. As other studies have shown,
reducing the number of ENCDCs that enter the bowel is sufficient to cause aganglionosis
even if the remaining ENCDCs are healthy (34), which accounts for the failure of these
remaining cells to colonize the more distal portions of the bowel. It is also possible that
non-recombined cells support the migration of Impdh2-deleted cells through the bowel,
since non-cell autonomous rescue of ENCDC migration occurs in aggregation chimeras
(37, 38) and in tissue culture (6). In the absence of a method to directly detect Impdh2
recombination on a cell-by-cell basis, we cannot determine if all ENCDC that colonize
the bowel in mutant mice retain IMPDH2 expression.

4.5 Conclusions
Taken together with our prior study demonstrating that chemical inhibition of
IMPDH results in aganglionosis by reducing ENCDC proliferation (6), these experiments
identify IMPDH2 as uniquely required for the development of the ENS. This is especially
interesting since human genetic studies have independently identified a risk locus at 3p21
in Hirschsprung disease (39), and the IMPDH2 gene is located at 3p21. In that analysis,
the 3p21 risk allele appeared to enhance the effect of RET mutations, the primary
causative mutation in most cases of Hirschsprung disease (7). A subsequent study has
mapped this risk locus to an interval 0.6 megabases from IMPDH2 (40). Other modifier
mutations are well-appreciated contributors to Hirschsprung disease (41–43), and future
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studies will investigate whether known (44) or novel genetic variation in human IMPDH2
is associated with Hirschsprung disease.
Because IMPDH inhibition impairs ENS development and the Impdh2 gene is
indispensable for embryonic survival, we examined whether Impdh2 is required in the
neural crest lineage for its proper development. Wnt1-Cre-mediated deletion of Impdh2
resulted in severe craniofacial, heart, and extensive aganglionosis of the ENS. During
initial ENS development, ENCDC colonization in conditional knockout fetuses was
impaired and the remaining colonized regions were abnormally hypocellular.
Furthermore, both the developing and definitive ENS showed evidence of incomplete
recombination that was specific to the conditional knockout genotype, demonstrating that
Impdh2 deletion is strongly selected against in the neural crest cells that eventually
become the ENS. These results confirm a critical role for de novo guanine nucleotide
synthesis and IMPDH2 in the neural crest lineage, and indicate that IMPDH1 and the
salvage pathway cannot compensate for IMPDH2 loss even when other tissues in the
developing embryo are normal.

4.6 Materials and Methods
4.6.1 Impdh2 Gene Targeting
The pOSfrt-loxP vector (Provided by Randy Thresher, Lineberger Comprehensive
Cancer Center Animal Models Core) containing a FRT-flanked positive selection marker
(MC1-Neo) and a negative selection marker (PGK-TK) was used to assemble the Impdh2
targeting construct from a 129/SV derived mouse genomic Impdh2 clone (Agilent
Lambda FIX II). A XbaI/XbaI fragment containing Impdh2 exons 10-14 and 3’ flanking
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region (4.6 kb ‘long arm’) was filled-in using T4 DNA polymerase (Promega) and cloned
into the PmeI site of pOSfrt-loxP using T4 DNA ligase (NEB) 3’ to the FRT-flanked
MC1-Neo cassette. A second 3.5 kb fragment was synthesized by PCR using one primer
located in intron 1 (5’ AAG GGT ACC CAT ATG TGA AGC AGG GGC AGG GGT
TTA GAG G 3’) and a second loxP sequence-containing primer located in intron 9 (5’
CCG GGT ACC ATA ACT TCG TAT AAT GTA TGC TAT ACG AAG TTA TAG
AGA TGC CAA GTC AGG CCT TGC C 3’). KpnI restriction sites at both ends of the
amplified product were utilized to clone the fragment into the KpnI site of pOSfrt-loxP
between the FRT-flanked MC1-Neo cassette and the 4.6 kb “long arm”. The entire PCR
insert was sequenced and confirmed to be void of mutations. To complete the targeting
construct, a 3.3 kb XbaI/NdeI fragment containing the 5’ end of Impdh2 (5’ flanking
sequence through exon 1, ‘short arm’) was filled-in and ligated into the PmlI site of
pOSfrt-loxP containing the other two fragments, between the PGK-TK gene and the
FRT-flanked MC1-Neo cassette. Sequencing of the completed targeting vector revealed
that the most 5’ portion of this fragment was phage vector DNA located between Impdh2
genomic sequences and the PGK-TK cassette, and that the homologous ‘short arm’ was
1.3 kb long.
Transfection and selection of E14TG2a (129/Ola) ES cells and generation of
chimeras was performed by the Animal Models Core of the UNC-Lineberger
Comprehensive Cancer Center. A single correctly targeted ES cell clone was identified
using PCR screening and sequencing, and the resulting agouti male chimeras were bred
to C57Bl/6 females to accomplish germline transmission. The MC1-Neo cassette was
excised by mating to Flp-recombinase expressing mice to produce the Impdh2loxP allele.

146

4.6.2 Animals and Genotyping
Animal experiments were approved by the Washington University Animal
Studies. Animal procedures were conducted in accordance with animal research protocols
approved by the University of North Carolina – Chapel Hill’s Institutional Animal Care
and Use Committee. All mice were maintained on mixed genetic backgrounds with
functional HPRT-mediated purine salvage. Since E14TG2a ES cells carry the Hprtb-m3
null mutation, PCR was used to confirm that the Impdh2loxP strain did not carry Hprtb-m3
(6) prior to experimental matings. Cre-mediated recombination of the Impdh2loxP allele
results in a frameshift after codon 32 and a premature stop after codon 48, preventing
expression of the catalytic domain. To produce a conventional knock-out allele,
Impdh2loxP/+ mice were bred to Tg(ACTB-cre)2Mrt/J “Actin-Cre” mice (45) resulting in
pups carrying germline deletions of Impdh2, referred to as Impdh2Del. Actin-Cre was then
removed through further breeding prior to experimental matings. Impdh2loxP mice were
bred to Gt(ROSA)26Sortm1(EYFP)Cos (46) mice (referred to as Rosa26EYFP) which
permanently marks all Cre-expressing cells and their descendants with EYFP expression.
Impdh2loxP and Impdh2Del mice were bred to Tg(Wnt1-cre)11Rth (19) mice, (referred to
as Wnt1-Cre), which drives loxP recombination in the entire neural crest and the dorsal
tissues of the neural tube of the midbrain and hindbrain (20). These strains were
intercrossed as indicated using timed matings to produce Wnt1-Cre Impdh2loxP/+
conditional heterozygotes (control animals) and the two conditional knockout genotypes
Wnt1-Cre Impdh2loxP/loxP and Wnt1-Cre Impdh2loxP/Del with and without the Rosa26EYFP
reporter.

147

The vaginal plug day was counted as embryonic day 0.5. For collection of fetal
samples, dams were euthanized with CO2 according to institutionally-approved
procedures. Embryonic day 18.5 (E18.5) fetuses were euthanized by decapitation except
for fetuses to be processed for bone and cartilage staining, which were anesthetized prior
to immersion fixation. Tail DNA was prepared using the HotSHOT method (47) and
genotyped using a previously described PCR genotyping protocol (48). Genotyping
reactions for Cre recombinase-containing transgenes and Rosa26EYFP used previously
described primers (6, 48). The Impdh2+ and Impdh2loxP alleles were genotyped using
primer pair Impdh2-F: 5’GAC TAC CTG ATT AGC GGA GGC ACC TCT TAC3’ and
Impdh–5FRTlox-R: 5’CAC GCT AAC ATA TTC CAC ATA TCC AGA GAA3‘,
producing a 320 bp band from the wild-type allele and a 450 bp band from the
conditional allele. The Impdh2Del allele was genotyped with primer pair Impdh2-F and
Impdh–3lox-R: 5’CTG AAA GAC ACC TAT ACC AAG TCC ATA GCC3’ resulting in
a 650 bp band indicating the presence of the deleted allele. All analyzed mice were
hemizygous for the Wnt1-Cre transgene and heterozygous for Rosa26EYFP if it was
present.
4.6.3 Bone and Cartilage Staining
Simultaneous staining with alizarin red S and alcian blue was performed
essentially as described in (49). E18.5 mouse fetuses were fixed in 95% ethanol for two
hours, after which skin and organs were removed and fixation was continued for one
week. Samples were moved to acetone for two days and then stained for 3 days at 37 ºC
in 0.015% alcian blue (Sigma #A5268), 0.005% alizarin red S (Sigma #5533), 5% glacial
acetic acid, and 70% ethanol. Samples were washed with water and rocked in a 1% KOH
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solution at room temperature until skeletons became visible after 48 hours. Samples were
then passed through a graded series of 20–80% glycerol/1% KOH baths over the course
of several weeks until tissues cleared. Skeletal preparations were stored and
photographed in 100% glycerol.
4.6.4 Whole-mount Immunofluorescent Staining
Enteric neurons were labeled in E18.5 fetal mouse bowel using human ANNA–1
antiserum (A gift of Vanda Lennon, Mayo Clinic), which stains the somas of all enteric
neurons (50) with the same pattern as the anti HuC/HuD monoclonal antibody used in
previous studies (6). Fetal bowel was harvested, flushed with PBS, fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 30 minutes at room
temperature, and then incubated in blocking solution for 1 hour at 37 ºC: 5% normal goat
serum (Jackson ImmunoResearch #005–000–121), 1% cold water fish-skin gelatin
(Sigma #G7765), 100 mM Glycine in Tris-buffered saline pH 7.5 with 1% Triton-X 100
(TBST). Samples were then incubated overnight at 4 ºC in ANNA–1 antiserum diluted
1:2000 in ANNA–1 diluent (5% normal goat serum, 1% bovine serum albumin, and 0.2%
sodium azide in PBS.) Samples were washed 3 times with PBS and incubated with
Alexa–594 conjugated goat anti-human secondary antibody (1:400, Life Technologies
#A–11014) at 37 ºC for 1 hour in PBS. After 3 washes with PBS, samples with the
Rosa26EYFP reporter were incubated overnight at 4 ºC with chicken anti-GFP (1:1000,
Aves Labs #GFP–1020) in blocking solution, washed 3 times with TBST, incubated for 1
hour at 37 ºC with Alexa–488 conjugated goat-anti-chicken (1:400, Life Technologies
#A–11039), and washed 3 times with PBS.

149

Embryonic day 13.5 (E13.5) fetuses were pulse-labeled by maternal
intraperitoneal bromodeoxyuridine (BrdU) injections (100 µg/gram body weight) with a
one-hour chase. Fetal bowel was harvested, processed, and stained for EYFP (Aves Labs
GFP-1020), cleaved-caspase 3 (Cell Signaling #9661) or for SOX10 (rabbit anti-SoxE,
Craig Smith, MRCI Australia) exactly as described (6), except that rat anti-BrdU (1:400,
BU1/75, Abcam #ab6326) and Alexa–594 conjugated donkey anti-rat (1:400, Life
Technologies A–21209) was used to visualize BrdU incorporation instead of a
fluorophore-conjugated primary antibody. All samples were mounted on slides and
visualized in 50% glycerol/PBS.
4.6.5 Microscopy and Measurement
Photographs of whole fetuses, skeletal preparations, and hearts were acquired on
an Olympus SZ–40 stereomicroscope. EYFP fluorescent micrographs of whole fetuses
were acquired on a Nikon SMZ1500 stereomicroscope using a GFP-B epifluoresence
filter. Measurements of colonization, aganglionosis and hypoganglionosis were
conducted on an IX71 epifluoresence microscope guided by ANNA–1 staining at E18.5
or by SOX10 and EYFP staining at E13.5. Images of fluorescent whole-mount bowel
were acquired as wide-field fluorescent micrographs on a Zeiss Axio Observer.Z1 or as
multiple optical sections using either a Zeiss Apotome.2 structured illumination device or
an Olympus FV1000 point-scanning confocal microscope. BrdU positivity within EYFPpositive cells was manually counted from confocal volumes. All optically sectioned
samples are presented as maximum intensity projections through 20 micron-thick
volumes unless otherwise indicated. Image processing was performed in ImageJ software
(51) and was limited to stitching of multiple fields (52), rotation, cropping, uniform
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brightness and contrast adjustments, and maximum intensity projection of volumes, with
the exception of EYFP fluorescent micrographs of whole E13.5 fetuses, which were
subjected to local contrast enhancement using contrast limited adaptive histogram
equalization (CLAHE) (53) to improve the contrast of EYFP-containing tissue.
4.6.6 Statistical Analysis
Statistical tests were performed using the R software package (54). Student’s t test
was used to compare E13.5 bowel colonization and rates of BrdU incorporation within
ENCDCs. Multiple comparison adjustments were performed with the Holm-Boniferroni
method based on the number of planned comparisons.
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4.5 Supplemental Data

Supplemental Figure 4.1: Production and structure of the Impdh2loxP and Impdh2Del
alleles.
(A) The Impdh2 targeting construct, shown above the corresponding wild-type Impdh2
locus, contains loxP sequences (red triangles) in intron 1 and intron 9 while FRT
sequences (hollow triangles) flank a MC1-Neo cassette immediately preceding the first
loxP site. Flp-mediated recombination excises the MC1-Neo cassette (B) from the
targeted allele to produce the conditional Impdh2loxP allele. Cre-mediated recombination
produces the Impdh2Del allele, which results in a frameshift (asterix) and premature
termination codon in the exon 3’ to the recombination. After Cre-mediated DNA
recombination, the IMPDH catalytic domain will be not be produced.
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Supplemental Figure 4.2: BrdU incorporation in ENCDCs of Impdh2 conditional
knockout fetuses.
(A) Immediately behind the migration wavefront in Wnt1-Cre Rosa26EYFP Impdh2loxP/+
bowel, many EYFP-positive ENCDCs (green) incorporate bromodeoxyuridine (BrdU,
red and merge). (B) At this time point, very few ENCDCs are present in the small
intestine of Wnt1-Cre Rosa26EYFP Impdh2loxP/Del fetuses. Scale bar = 100 µm. Pictures are
maximum intensity projections of 12 µm-thick volumes. (C) Quantification of BrdU
incorporating nuclei within the EYFP-marked ENCDC population does not demonstrate a
significant difference in BrdU incorporation between Impdh2loxP/+ (N = 5) and
Impdh2loxP/Del (N = 4) genotypes. Note that different regions of the bowel are being
compared, since each contains the migration wavefront in its respective genotype. ns =
not significant by pooled-variance t-test. Error bars are s.e.m.
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Supplemental Figure 4.3: Incomplete Rosa26EYFP recombination by Wnt1-Cre in the
absence of selective pressure.
In Wnt1-Cre Impdh2loxP/+ Rosa26EYFP fetuses, Cre/loxP recombination of the EYFP
reporter allele is not entirely complete. Individual SOX10-positive, EYFP-negative cells
(inset, arrowheads) can be seen, likely representing a clone of ENCDCs derived from a
rare neural crest cell that escaped recombination.
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Chapter 5: IMPDH2 variation in a Hirschsprung
Disease Cohort
5.1 Summary
In the mouse, IMPDH activity and the Impdh2 gene are required for normal development
of the enteric nervous system. In humans, the IMPDH2 gene is located at 3p21, a region linked
to Hirschsprung disease susceptibility and and genetic interactions with RET. These observations
suggested the possibility that mutations in IMPDH2 predispose to Hirschsprung disease. We
therefore sequenced the IMPDH1 and IMPDH2 genes in a cohort of Hirschsprung disease
patients and detected one rare nonsynonymous variant that moderately reduced the enzymatic
activity of recombinant IMPDH2. Common variants that may affect IMPDH activity were
detected at normal frequencies. In parallel, we investigated whether heterozygous loss of Impdh2
could affect the penetrance of mutations that model Hirschsprung disease in mice, and
determined that Impdh2 interacted with neither the Sox10 nor the Ret mutant alleles tested.
Together these results suggest that IMPDH2 is unlikely to be the Hirschsprung disease
susceptibility locus previously mapped to 3p21.

5.2 Introduction
Several factors prompted us to search for one or more mutations in IMPDH2, the gene
encoding one of the two IMDPH isoforms (1), as possible risk factors for Hirschsprung disease
(HSCR). We have shown that IMPDH proteins are enriched in ENCDCs, that IMPDH inhibition
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impairs ENS development in vertebrates, and that IMPDH inhibition interacts with Ret in a
mouse model of HSCR. These findings suggest that mutations that reduce IMPDH activity or
expression could interact with established HSCR-predisposing mutations in a manner analogous
to the effects of mycophenolic acid (MPA). Furthermore, we have demonstrated that Impdh2 is
required in neural crest-derivatives for the formation of the ENS, while the survival and
relatively normal phenotype of Impdh1-knockout mice (2) indicates that Impdh1 is dispensable
for ENS development. Most intriguingly, IMPDH2 is located in a chromosomal region that has
been linked to HSCR (3). Specifically, a region in 3p21 was identified along with RET and
another unidentified locus at 19q12 in a genome-wide linkage study of families with shortsegment HSCR. The model that best fit the data indicated that the 3p21 and 19q12 risk alleles
modify the effect of a RET mutations. More recent work has replicated this association between
HSCR and 3p21 in a different population (4), but the causative gene has not yet been identified.
This region is rich in genes, and these mapping studies have detected association with two
different intervals in this region. IMPDH2 is located between the regions identified in these two
studies (Figure 5.1). To date, no other approaches have been used to identify the gene
responsible, refine the interval, or rule out candidates in humans or using model systems.
Genetic variation in both IMPDH2 and IMPDH1 has been studied in several contexts.
IMPDH1 (OMIM 146690, RP10, LCA11) mutations cause blindness in autosomal dominant
retinitis pigmentosa (adRP) (5, 6) and Leber congential amaurosis (7), two genetically
heterogeneous disorders affecting the retina. These mutations do not affect enzymatic activity,
though they may cause aggregation (8, 9) or decrease IMPDH1’s ability to bind nucleotides (7,
10) which has as-yet unknown functional significance, but may be involved in transcription (11)
or translation (12). Though the mechanism by which these mutations cause disease is not
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Figure 5.1: Intervals in the 3p21 region linked to HSCR
Using linkage analysis in two different populations, Hirschsprung disease has been linked to two intervals (red blocks) in the 3p21
region. The lack of overlap indicates that the regions that crossed the significance cutoffs in each study were not overlapping, and does
not necessarily demonstrate separate loci. IMPDH2 (green) is located between these two association blocks, while IMPDH1 is located
at 7q31.2, a region not associated with HSCR.

completely understood, failure to synthesize GMP can be excluded as a possible reason, since
Impdh1 knockout mice only develop a late-onset and mild retinopathy that is very different from
adRP (8). In contrast, introducing RP10-mutant IMPDH1 to normal mouse retina using viral
vectors is toxic to photoreceptors, while overexpression of normal human IMPDH1 causes no
pathology (13). This demonstrates that RP10 IMPDH1 mutations that cause retinitis pigmentosa
are dominant and probably not due to a simple loss of GMP synthesis.
Variation in IMPDH2 and IMPDH1 have also been investigated in human patients for
polymorphisms related to clinical outcomes and therapeutic drug monitoring in mycophenolate
mofetil (MMF) / mycophenolate sodium (MPS) immuno-suppression. Two intronic IMPDH1
SNPs (rs2278293 and rs2278294) were associated with biopsy-proven acute rejection in kidney
transplants (14). rs2278294 was also associated with the risk of acute graft-versus-host disease in
allogeneic hematopoetic stem-cell transplant recipients (15). Only rs2278294 was associated
with rejection of kidney grafts and leukopenia in a subsequent study (16), while conversely only
rs2278293 was associated with subclincal acute rejection in a third study of kidney transplant
patients (17). Two other groups have failed to find any association with renal transplantation
outcomes at either SNP (18, 19). In IMPDH2, the minor allele at one common SNP
(rs11706052) has been associated with biopsy-proven acute rejection in kidney transplant (20),
higher IMPDH2 activity after transplantation (21), MPA resistance in activated lymphocytes (22),
and reduced incidence of lymphopenia (23). However, two other studies have failed to confirm
this SNP’s association with rejection (14, 16) while a third found only a weak association (18). A
rare variant (24) is located in the IMPDH2 promoter (IMPDH2:c.–96T>G) within a putative
cyclic-AMP response element. This variant reduced the expression of reporter constructs relative
to the wild-type promoter, but this variant is rare and has not been detected subsequently (25).
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Still another rare variant, rs72639214, is intronic and associated with lower IMPDH2 mRNA
levels (26). Electrophoretic mobility shift assays showed that the minor allele abolishes binding
to nuclear extract, suggesting that this variant impairs binding of a transcription factor. The
alleles that may provide reduced rejection or graft-vs-host disease risk are hypothesized to act by
reducing the abundance of IMPDH1/IMPDH2 at the transcriptional or posttranscriptional level
and allowing more complete immunosuppression for a given level of MPA, while
simultaneously predisposing to side-effects like leukopenia. Rare nonsynonymous variants with
functional consequences have also been detected in IMPDH1 and IMPDH2. In IMPDH1,
excluding mutations linked to retinal disease, one nonsynonymous mutation (rs72624960,
IMPDH1:p.S275L) has been detected that reduces enzyme activity largely through increased
protein degradation and lower steady-state protein levels (26). In IMPDH2, the rare variant
rs121434586 (IMPDH2:p.L263F) demonstrated 10% of the activity of wild-type enzyme (27)
and this phenotype also seems to be related to lower protein levels and accelerated degradation
(26).
Exhaustively sequencing a human gene even in a small group of patients is a major
undertaking using traditional methods, but second-generation sequencing coupled to an
appropriate data analysis pipeline allows for detection of single nucleotide variants at singleallele frequencies in pools of hundreds of alleles (28), an approach generally referred to as
“amplicon-seq”. New analysis strategies have extended this approach to allow for identification
of both missense mutations and small insertions and deletions (indels) with high sensitivity and
specificity (29). This strategy estimates minor allele frequencies in a pool but does not identify
which individuals have a mutation nor the allelic configuration within any single individual, so
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individual DNA samples must be genotyped using other methods if interesting variants are
detected.
Using this sequencing strategy, we scanned IMPDH2 and IMPDH1 in 51 HSCR patient
samples for single-nucleotide variants and short indels. We detected one nonsynonymous variant
in IMPDH2, IMPDH2:p.P123R (rs142797363), and examined its effect on IMPDH activity in
recombinant enzyme preparations. We also demonstrate that heterozygous loss of Impdh2 does
not enhance the phenotype of mouse models of HSCR.

5.3 Results
5.3.1 Pooled Resequencing
The pooled sequencing reaction provided good coverage (>30 reads per strand per allele,
Figure 5.2B) of all targeted regions of IMPDH2 and control sequences. Most exons of IMPDH1
were also adequately covered, with the exception of exons 1, 4, and 12 (Figure 5.2A) likely due
to the GC-richness of their immediate flanking sequences (70-80%). The SPLINTER algorithm
detected all four positive control polymorphisms that were present at simulated frequencies of
10/102, and detected 12 of the 13 variants present at 1/102 simulated alleles, indicating high but
not perfect sensitivity.
5.3.2 Variation in IMPDH1 and IMPDH2
Only one nonsynonymous variant was detected in the pooled DNA from individuals with
Hirschsprung disease: IMPDH2:c.368C>G or IMPDH2:p.P123R, which we confirmed by PCRRFLP assay and conventional sequencing to be present in one individual in the heterozygous
configuration. Neither the L263F IMPDH2 variant nor the IMPDH1 S275L variant were
detected. Minor alleles at the possibly relevant noncoding SNPs rs2278293, rs2278294, and
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Figure 5.2: Sequencing coverage of IMPDH1 and IMPDH2
Pooled-sequencing coverage plots of all targeted regions in A) IMPDH2 and B) IMPDH1. For
all analyses and this plot, reads were truncated to 22 base pairs before alignment. Coverage of
IMPDH2 noncoding regions is more complete since IMPDH2 is a much shorter gene. The cutoff
for confident variant detection was set at 30 reads/allele in either orientation, though coverage
was generally very similar in each direction.
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rs11706052 were present at frequencies comparable to previous findings, and the two rarer
noncoding IMPDH2 variants (rs72639214 and c.–96T>G) were not detected (Table 5.1). Other
variation was generally intronic and did not appear to be obviously deleterious. Several detected
variants were changes in the number of bases in repetitive regions. The IMPDH2 P123R allele
(rs142797363) has been previously detected (38) but nothing is known about its functional
consequences.
5.3.3 Activity of the P123R IMPDH2 variant is reduced relative to wild-type.
To determine whether the P123R variant affected enzyme activity, we expressed wildtype, P123R, and known deleterious mutant L263F human IMPDH2 fused to an N-terminal
6xHis tag using an E. coli expression system as has been done for IMPDH1 (8) yielding
enzymatically active protein. Purified protein yields for wild-type IMPDH2 were consistently
higher than those for P123R. L263F produced even less protein, as reported previously in
bacterial (27) and mammalian expression systems (26). Activity assays revealed significant
differences (Figure 5.3) between wild-type and both variant enzymes. The P123R variant
demonstrated a modest but significant reduction in turnover number (Kcat) and an increase in Km
for both IMP and NAD+ substrates (Table 5.2). The L263F variant resulted in larger changes in
Kcat and both Km, though the reduction in activity was not as severe as was previously reported
(26, 27).
5.3.4 Heterzygous loss of Impdh2 does not enhance Ret or Sox10 mutations.
Activated splenic lymphocytes from Impdh2+/– mice have reduced total IMPDH activity
(39), indicating that heterozygous deletion of Impdh2 effectively simulates a partial loss of
activity and can reasonably simulate a loss-of-function mutation. We applied this genetic stressor
to the same two mouse models of HSCR that pharmacologic IMPDH inhibition potentiated but
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Gene

HGVS Name

IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1
IMPDH1

NM_000883.3:c.146+109A>T
NM_000883.3:c.147-52G>T
NM_000883.3:c.147-35G>A
NM_000883.3:c.505-34C>A
NM_000883.3:c.579+119G>A
NM_000883.3:c.580-106G>A
NM_000883.3:c.987G>C
NM_000883.3:c.1075-129C>A
NM_000883.3:c.1405+33C>T
NM_000883.3:c.1551-114T>G
NM_000883.3:c.1575G>A
NM_000883.3:c.1694+43G>A
NM_000883.3:c.1779-407G>C
NM_000883.3:c.1779-131G>T

Type

Intron
Intron
Intron
Intron
Intron
Intron
Synonymous
Intron
Intron
Intron
Synonymous
Intron
Intron
Intron
5' Flanking
IMPDH2 NT_022517.18:g.49007307A>G
(run of As)
NT_022517.18:g.49007304delA 5' Flanking
IMPDH2
and g.49007304delAinsAA
(run of As)
IMPDH2 NM_000884.2:c.368C>G
Pro123Arg
IMPDH2 NM_000884.2:c.532-177T>C
Intron
IMPDH2 NM_000884.2:c.532-169T>C
Intron
IMPDH2 NM_000884.2:c.532-168G>A
Intron
IMPDH2 NM_000884.2:c.532-161G>A
Intron
IMPDH2 NM_000884.2:c.532-160C>T
Intron
IMPDH2 NM_000884.2:c.532-159C>T
Intron
IMPDH2 NM_000884.2:c.532-156G>A
Intron
IMPDH2 NM_000884.2:c.532-139C>T
Intron
IMPDH2 NM_000884.2:c.532-138C>T
Intron
IMPDH2 NM_000884.2:c.532-137G>A
Intron
IMPDH2 NM_000884.2:c.532-120delA
Intron
IMPDH2 NM_000884.2:c.532-96G>A
Intron
IMPDH2 NM_000884.2:c.819+10T>C
Intron
NM_000884.2:c.*26Tdel and
3' UTR (run
IMPDH2
c.*25_26TinsT
of Ts)

SNP id
rs2288553
rs2288552
rs2288551
rs72624952
rs2278293*
rs2278294*
rs2288550
novel
rs28580600
rs4731447
rs2228075
rs72624969
rs78763502
novel
adjacent to
rs71641216

Minor allele
freq.
dbSNP HSCR
0.121
0.061
0.077
0.041
0.077
0.061
0.010
0.061
0.444
0.500
0.400
0.408
0.126
0.133
N/A
0.020
0.101
0.133
0.175
0.061
0.279
0.428
0.122
0.071
0.090
0.133
N/A
0.020
N/A

0.082

rs71641216

no data

0.102

rs142797363
novel
novel
novel
novel
novel
novel
novel
novel
novel
novel
novel
rs72624911
rs11706052*

no data
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.016
0.073

0.041
0.010
0.031
0.010
0.020
0.020
0.020
0.020
0.031
0.031
0.071
0.010
0.031
0.092

rs200887858 no data

0.020

Table 5.1: Variation detected in IMPDH2 and IMPDH1 in a HSCR cohort
Known variants were queried using NCBI human variation search tool (as of September 2013)
(www.ncbi.nlm.nih.gov/projects/SNP/tranSNP). * = SNPs correlated with human phenotypes.
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IMPDH
Variant
Wild-type
P123R
L263F

Kcat (s-1)

Km IMP (µM)

Km NAD+ (µM)

0.524 (± 0.015)
0.477 (± 0.017) *
0.431 (± 0.026) **

36.4 (± 3.44)
47.1 (± 3.92) *
63.5 (± 10.20) *

95.1602 (± 6.52)
125.8893 (± 10.21) *
187.4732 (± 24.32) **

Table 5.2: Kinetic parameters of recombinant IMPDH2 variants
* = P<.05, ** = P<.01, two-tailed t-test against wild-type parameter. All values are ± standard
error. Ki for substrate inhibition by NAD+ was estimated at 279 (± 57.51) µM

168

Figure 5.3: IMPDH activity of IMPDH2 variants is reduced
IMPDH activity was measured by monitoring the production of NADH by 15 nM (908 ng/mL)
of each IMPDH variant (wild-type = green, P123R = blue, L263F = red) in the presence of the
indicated concentrations of (A) IMP and (B) NAD+ and 400 µM of the other substrate. The
reduction in velocity seen at high concentrations of NAD+ (B) is typical of substrate inhibition.
Both variants appear to have reduced enzymatic activity.
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these crosses resulted in no effect on the penetrance of ENS malformations or the length of
bowel affected in either Sox10 or Ret mutant mice (Figure 5.4).

5.4 Discussion
5.4.1 Expected Characteristics of a 3p21 HSCR Modifier Allele
Using the population prevalence of HSCR (1 in 5000), the risk ratio estimate for the
modifier allele at 3p21 (4.2), and estimates of the baseline population frequency (3) of the 3p21
modifier allele (4% allele frequency and thus 7.5% heterozygote frequency) we can estimate that
about 24% of HSCR patients in the originally studied population were heterozygotes for the
3p21 modifier allele (Figure 5.5). Linkage to 3p21 was identified in short-segment HSCR
families and the 3p21 risk allele is a RET modifier gene, so we do not expect it to be
overrepresented in syndromic cases of HSCR associated with other genes (EDNRB, PHOX2B,
SOX10, KIAA1279, or ZFHX1B). Because of the methods used to identify and enroll patients in
the PHIS/BDS study, we lack detailed diagnostic information for each patient. It is a reasonable
assumption that isolated (non-syndromic) HSCR requires some form of RET mutation, since
linkage to the RET locus is seen even in the absence of identified functional mutations (3, 40).
Since HSCR appears as an isolated trait in 70% of patients and short-segment disease represents
80% of HCSR patients (41), we can estimate the likelihood of a randomly-selected HSCR patient
carrying the 3p21 risk allele as about 13.5% and thus sampling a group of as few as 21 HSCR
patients is 95% likely to include at least 1 occurrence of the 3p21 mutation. Thus if mutations in
IMPDH2 are the causative lesions at RET modifier locus 3p21 we would be able to detect them
even in a small cohort of HSCR patients. Because IMPDH1 contains significant variation in the
human population, we included canonical IMPDH1 exons in the sequencing library.
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Figure 5.4: No effect of heterozygous loss of Impdh2 on the ENS of Ret and Sox10 mutants
Impdh2+/Del mice were bred to (A) Ret and (B) Sox10 models of Hirschsprung disease and the
neonatal (postnatal day zero) bowels were examined for aganglionosis and hypoganglionosis.
The most caudal neuronal soma in each animal identified using ANNA-1 (anti-HuC/HuD)
immunofluoresence is shown as a point, and the hypoganglionic region is shown with a line
projecting to the left. Data are abbreviated with a number indicating sample size when no animal
in a group was aganglionic or hypoganglionic. The Ret9/– genotype (A, bottom) has low
penetrance and severity on its own, and Impdh2 heterozygosity did not appear to worsen its
associated phenotype. The more penetrant Sox10+/– phenotype was similarly not enhanced by
Impdh2 heterozygosity (B). Though the penetrance of Sox10+/– appeared possibly reduced by
Impdh2Del, this difference was not statistically significant when considering either aganglionosis
or hypoganglionosis (Fisher’s exact test).
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Figure 5.5: Estimating proportion of 3p21 risk carriers within HSCR patients.
Gabriel et al. (3) estimated a risk ratio of 4.2 and population allele frequency of .04 for the 3p21
RET modifier allele. To estimate the proportion of allele carriers within the population, we first
calculate the frequency of heterozygotes assuming Hardy-Weinberg equilibrium (.077). This
allows the calculation of non-carrier non-affected (b) from the disease incidence (1/5000.) a/c,
the carrier frequency within an affected cohort, can then be calculated. This assumes that
homozyogosity is not selected against, but the numbers are very similar if homozygosity is lethal.
This estimate does depend on the assumption that the results of one study in HSCR families with
multiple cases of disease in each family can be generalized to the population at large.
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5.4.2 Prevalence of the IMPDH2:p.P123R Nonsynonymous Substitution
We did detect one nonsynonymous variant that reduces the enzymatic activity of
IMPDH2 (IMPDH2:p.P123R), but this variant was present in only in one individual. Allele
frequencies calculated by SPLINTER are vulnerable to errors in DNA quantification and pooling,
likely accounting for the discrepancy between the number of P123R alleles detected (4/102) by
pooled sequencing and those confirmed by individual genotyping (1/102). This variant was also
detected by the NHLBI Exome Sequencing Project (ESP), but it was extremely rare. P123R was
detected only once in 8600 alleles in a European-American population and was absent from a
4406-allele African-American population. The cohorts included in the ESP contain both normal
controls and several cardiac and pulmonary disease cohorts and it was not possible at this time to
determine which NHLBI cohort contained the variant. In any case, we expect the 3p21 risk allele
previously identified to be present in the general population at a significantly higher frequency
than P123R, making IMPDH2 nonsynonymous variants poor candidates for the 3p21 risk factor.
Our mutation scan also did not detect major overrepresentation or underrepresentation of any
IMPDH2 or IMPDH1 variants that have been previously associated with transplantation
outcomes and/or IMPDH activity (Table 5.1), nor did we detect the L263F variant.
5.4.3 Functional Consequences of the IMPDH2:p.P123R Variant
Both PolyPhen2 (42) and MutPred (43) phenotype prediction programs suggest that the
proline to arginine amino acid substitution might be deleterious, and alignment of IMPDH2
orthologs and IMPDH1 reveals that proline 123 is highly conserved despite many changes in
flanking residues (Figure 5.6A). This amino acid, however, is located in the first cystathionine βsynthase (CBS) domain, which is involved in nucleotide binding and is unnecessary for
IMPDH’s catalytic activity (44). The region containing P123 is generally disordered in crystal
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structures of IMPDH1 and IMPDH2 but a structure of S. pyogenes IMPDH (PDB: 1ZFJ, 45)
does resolve this region and shows that the homologous proline residue (P106) initiates a turn
(Figure 5.6B) within the first CBS domain, suggesting that a substitution may have structural
consequences. As a control mutation for enzyme kinetics, we used the L263F variant of
IMPDH2, assuming that it would produce nearly inactive enzyme. Somewhat surprisingly,
IMPDH2 L263F retained a much larger proportion of wild-type catalytic activity in this study
than in either a previous study using recombinant IMPDH2 from E. coli or affinity-tagged
IMPDH2 expressed in mammalian cells (26, 27). Kinetic parameters for both wild-type and
L263F enzyme also differed from previously published values, especially the Km for NAD+ and
IMP. Since previous studies used either C-terminal affinity tags or untagged protein, it is
possible that the N-terminal affinity tag alters the stability and kinetic properties of the enzyme.
5.4.4 The Haplosufficiency of Impdh2 in Mouse HSCR Models
Importantly, the hypothesis that IMPDH2 might be the HSCR susceptibility locus at 3p21
was formulated based on our previous finding that IMPDH inhibition impairs ENS development
and interacts with Ret and Sox10 (Chapter 3). To examine the plausibility that a loss-of-function
variant could have an effect similar to global IMPDH inhibition, we tested if Impdh2
heterozygosity increased bowel aganglionosis in mice with mutations in Ret and Sox10. While no
association between 3p21 and SOX10 has been documented in HSCR, Sox10 was included as a
potential interactor because IMPDH inhibition strongly enhances Sox10 phenotypes and because
Sox10LacZ/+ has a much greater penetrance in the ENS than even the highest risk Ret9/– genotype.
We detected no enhancement of either the Ret or Sox10 ENS phenotype by Impdh2
heterozygosity. Furthermore the Ret+/– Impdh2+/Del compound heterozygotes generated as part of
the breeding scheme survived to adulthood and were fertile. It seems likely that heterozygosity
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Figure 5.6: Multispecies IMPDH2 alignment in context of P123R mutation
A: Proline 123 is highly conserved across isoforms of human IMPDH and across species,
including prokaryotes, despite poor conservation in the rest of this CBS domain at the aminoacid level. B: While P123 or its immediate neighbors is generally missing from crystal structures
of mammalian IMPDH, the homologous residue (blue section of backbone ribbon) is resolved in
a structure of S. pyogenes IMPDH, showing that this residue initiates a turn.
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for a null allele is a more severe defect than heterozygous P123R or even L263F mutations
would create based on our in vitro enzyme kinetics studies, though we cannot discount the
possibility

that

these

mutations

could

have

a

dominant

negative

effect

through

heterotetramerization, cellular toxicity from aggregation, or disruption of one of the noncatalytic
roles of IMPDH. Others have speculated that homozygosity for L263F might be incompatible
with life (27), but even if P123R or L263F homozygosity were possible, such individuals would
be vanishingly rare in the general population given the allele frequencies.
IMPDH2 may have roles in the cell unrelated to its enzymatic activity, which are
suggested by its ability to bind single-stranded nucleic acids, which mediates its association with
translating polysomes and its role as a transcription factor in Drosophila (11, 12, 46). The CBS
domain where the P123 residue is located is important for nucleic acid binding activity (46), and
our study does not address whether the P123R substitution affects nucleic acid binding. However,
any possible disruption to these functions is not directly related to the antiproliferative effects of
IMPDH inhibitors that prompted us to examine IMPDH2 and thus lacks a plausible mechanism
to cause ENS-specific disease.

5.5 Conclusion
The 3p21 RET modifier locus has thus far eluded identification (3, 4). Mutation scans of
IMPDH2 in a HSCR cohort revealed one rare variant (rs142797363 or IMPDH2:p.P123R) with
reduced enzymatic activity. However, other variants that could possibly reduce IMPDH activity
were not overrepresented in the sequenced HSCR cohort compared to control populations.
Moreover, heterozygous deletion of Impdh2 did not increase the penetrance or severity of mouse
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HSCR models. Based on these findings, it is unlikely that a mutation in IMPDH2 is the RET
modifier allele identified through linkage studies.

5.6 Materials and Methods
5.6.1 Isolation of Human Genomic DNA
Cases of Hirschsprung disease were identified by the Pregnancy Health Interview Study
(Birth Defects Study), an ongoing case-control surveillance study of birth defects in North
America (30). Anonymized human genomic DNA samples were obtained either as isolated DNA
in TE buffer or as buccal cells collected and frozen on nylon brushes. DNA was isolated from
brushes using the Gentra Puregene Buccal Cell Kit (Qiagen) using a procedure modified to
enhance the recovery of low-abundance (<2 µg) samples. Brushes were incubated in cell lysis
solution with proteinase K (Qiagen) for 1 hour at 65 ºC. After this incubation, lysis buffer
containing DNA and debris was recovered from brushes by embedding the brush in a sterile
plastic micropipette tip and forcing liquid out with air driven by a syringe. Subsequent isolation
steps were performed according to manufacturers instructions, after which the DNA/glycogen
pellet was resuspended in 20 µL of DNA hydration solution (Qiagen) and quantified on a
Nanodrop spectrophotometer (Thermo Scientific).
5.6.2 Quantification and Whole-Genome Amplification of Human Genomic DNA
Because buccal-derived DNA samples contain variable amounts of microbial DNA, the
amount of human DNA in each sample was quantified using a qPCR assay designed against the
human-specific Yd6 subfamily of the Alu element retrotransposable element. qPCR reactions
consisted of 0.1 µM forward and reverse intra-Yd6 primers (31), 1X SYBR Master Mix (Applied
Biosystems), and 1 µL of sample DNA in a total reaction volume of 25 µL. DNA samples were
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compared to a standard curve of control human genomic DNA to determine the linear range of
the assay and the amount of amplifiable human DNA in each sample. Samples containing too
little DNA for pooled sequencing or undetectable amounts of DNA were subjected to wholegenome amplification using the REPLI-g system (Qiagen) according to manufacturer’s protocol.
51 HSCR samples were of sufficient quantity to include in the pooled sequencing procedure.
5.6.3 Pooled Variant Detection in IMPDH2 and IMPDH1
PCR amplicons were designed using to include all exons and splice sites of IMPDH1
(NM_000883.3) and IMPDH2 (NM_000884.2) except the retina-specific exon 13b of IMPDH1
(32). All variation coordinates are relative to these cDNA sequences, except for variation in the
promoter of IMPDH2, which is presented relative to the genomic sequence NT_022517.18. At
least 75 bp of all 3’ intron sequences and the core promoter of IMPDH2 (1) were included to
capture functional noncoding elements. Primers (Table 5.3) were designed not to overlap any
sequence of interest and were selected using Primer3 software (33). DNA samples were pooled
to a total weight of 0.4 µg, with 10 ng of the pool used in each subsequent PCR reaction,
ensuring that 60 haploid genomes per pooled individual were present in each reaction. To
construct a positive control pool simulating unique heterozygous variants in a pool of 51
individuals, plasmids containing defined mutant copies of TP53 exon 9 were pooled in amounts
corresponding to either one allele (13 variants) or ten alleles (4 variants) out of a total of 104
alleles, with the difference made up by wild-type sequence. The negative control DNA used to
construct the error model was M13mp18 phage DNA (New England Biolabs). All pooled PCR
reactions were performed and products were purified as previously described in (29) and Table
5.3. Purified PCR products were pooled in equimolar amounts, ligated into concatamers, and
fragmented by sonication on a Bioruptor XL (Diagenode) as described in (29). A single-end
178

Amplicon

Primer Sequences

IMPDH2
Amplicon 1

Fwd: 5’GATGGATGGACCCTGGAGGGAATCT3’
Rev: 5’GCTCACCTTGATGTTCAGGACCCAA3’
Fwd: 5’GGGTCCTGGGTGGCTGGATGTAG3’
Rev: 5’CGCGCACCTAGGGGTACGAGACC3’
Fwd: 5’TGGTGGTCCATAGAACTTCACCCCTG3’
Rev: 5’CCCCTATTGGAGGGCTCTATTGTCCC3’
Fwd: 5’GGCTGCTAAGACTGCATGTGCCTGA3’
Rev: 5’TGAGGGTGCTGTTTTTGTGTGCATC3’
Fwd: 5’GTAGGGACACCTCTCCCCCTCATCC3’
Rev: 5’CAAATCCTCTGGACCGGAAGGACAG3’
Fwd: 5’GCGCGGCTGAGCCCTTTGT3’
Rev: 5’CGCGCACCTAGGGGTACGAGACC3’
Fwd: 5’GGGGGCTGTAGCCTCTGCTCCTCTA3’
Rev: 5’GCCCCTGAGCAAGAAGTCAGCCTCT3’
Fwd: 5’GTCATCTTGAGCATATGTCCTGTGTCTG3’
Rev: 5’GCTGTGAAGGAACAACGGGACTGTG3’
Fwd: 5’GCTGTCACCTAGTGGCTGACTGGGG3’
Rev: 5’CTGCTGAACCACTCATCCATCTCCC 3’
Fwd: 5’TTTCAGGGAAGCAGTCCCCTTTGAG3’
Rev: 5’ATACATCTGGGGAACAAAGGCGAGG3’
Fwd: 5’ATCCAGCCCTGTCCCTTTTCCTGA3’
Rev: 5’TCAGCTTGACCTCAGAACCCTGGC3’
Fwd: 5’CAGGCCTAAGGCTGCCCCATTTTAG3’
Rev: 5’GAGCAGTCCTGACTCTGCAGGGGAT3’

IMPDH2
Amplicon 2
IMPDH2
Amplicon 3
IMPDH2
Amplicon 4
IMPDH1
Amplicon 1
IMPDH1
Amplicon 2
IMPDH1
Amplicon 3
IMPDH1
Amplicon 4
IMPDH1
Amplicon 5
IMPDH1
Amplicon 6
IMPDH1
Amplicon 7
IMPDH1
Amplicon 8

Table 5.3: Primers and amplification conditions for pooled sequencing
A: Denaturation temperature was raised to 96°C for this GC-rich amplicon
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Size
(bp)

Annealing
Temp (°C)

1394

59

970

59A

1074

64

1289

64

1139

61

392

57

248

59

1296

64

384

59

692

65

1200

59

695

64

sequencing library was constructed from the fragmented concatamers using genomic DNA
library construction reagents (Illumina) according to manufacturer’s instructions. The library was
sequenced on a Genome Analyzer using one lane of a sequencing flow-cell. 24 bp reads were
aligned to reference sequences allowing for two mismatches/indels per read and aligned reads
were analyzed unknown variants using SPLINTER software using the positive control sequence
and expected variants to set confidence cutoffs (29). Primer binding sites were masked and
positions within 5 bp of the 3’ end of primer binding sites were excluded because of
disproportionately high coverage. Variation in low-coverage (less than 30 reads/allele) regions
was also excluded.
5.6.4 PCR-Restriction Fragment Length Polymorphism Genotyping Assay
The P123R (rs142797363) minor allele results in the creation of a MwoI restriction site.
PCR primers were designed to produce a 182 bp amplicon for restriction digestion containing the
polymorphic site. Presence of the P123R variant is indicated by cleavage of the amplicon into
111 and 71 bp fragments. P123-Forward: 5’GCT TCA GAT CAA GAG CCT GAT GAA AGT
AGT3‘, P123-Reverse: 5’GTC TGT GAT TGG GAT ACC GCA GAA AC3’. A positive control
product containing the rs142797363 minor allele was amplified from control genomic DNA in
two overlapping amplicons using 1) P123-Forward and mutated reverse primer P123R-OE-R:
5’CGA TCC TTG CGG CTG AGG ACC ACA GGG TCT3’ and 2) mutated forward primer
P123R-OE-F: 5’GTC CTC AGC CGC AAG GAT CGC GTG CGG GAT3’ and P123-Reverse.
The two purified amplicons were fused and full length product was synthesized in a PCR
reactions using the P123-Forward and P123-Reverse primers. Negative control product was
amplified from control genomic DNA using the same primers and was mixed in equimolar
amounts with positive control product to simulate heterozygosity. PCR reactions on individual
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samples were performed in the following conditions: 5 ng genomic DNA sample, 200 µM
dNTPs, 0.2 µM each primer, 1.3 M Betaine, 1X Klentaq LA Buffer pH 9.2, 0.1% (v/v) Klentaq
LA polymerase mix in a total reaction volume of 20 µL. Cycling conditions were as follows: 94
ºC for 3‘, 40 cycles of [94 ºC for 1“, 52 ºC for 45”, and 68 ºC for 1’], and 68 ºC for 5’. PCR
products were digested with MwoI by adding 5 µL of a solution containing 0.2 units/µL MwoI in
1X NEBuffer #4 (New England Biolabs) and incubating at 60 ºC for 2 hours. Digested products
were separated on a 2% sodium borate-agarose gel. Heterozygous samples were confirmed by
automated dye-terminator sequencing of purified PCR products.
5.6.5 Plasmids
Human IMPDH2 cDNA was amplified from IMAGE clone 3447994 (34) using primers
KpnI-EK-IMPDH2-F: 5’CGG GGT ACC GAC GAC GAC GAC AAG ATG GCC GAC TAC
CTG ATT AG3’ and SacI-IMPDH2-R: 5’CGC GAG CTC TCA GAA AAG CCG CTT CTC
ATA3‘. Purified PCR products were double-digested with KpnI and SacI restriction enzymes
(New England Biolabs) and ligated into pET30a(+) bacterial expression vector (Novagen)
digested with KpnI and SacI and treated with Shrimp Alkaline Phosphatase (Promega, producing
full-length human IMPDH2 with an N-terminal 6xHis-S-FLAG tag (pET30a-IMPDH2). P123RIMPDH2 was produced in two amplicons by amplifying the original IMPDH2 clone using 1)
KpnI-EK-IMPDH2-F and P123R-OE-R primers and 2) P123R-OE-F and SacI-IMPDH2-R
primers. The two purified amplicons were fused using PCR with KpnI-EK-IMPDH2-F and SacIIMPDH2-R primers, and the resulting product was ligated into pET30a(+) using the same
procedure as wild-type IMPDH2 to produce pET30a-P123R-IMPDH2. pET30a-L263F-IMPDH2
was derived from pET30a-IMPDH2 by a linear amplification-based site-directed mutagenesis
procedure (35) using L263F-OE-F: 5’GGA CTT GTT CGC CCA GGC TGG TG3’ and 5’TGG
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GCG AAC AAG TCC AGC CTA TAC TTG TC3’ primers. The fidelity of all constructs was
confirmed by sequencing.
5.6.6 Production of Recombinant Human IMPDH2 in E. coli
The production and purification procedure was modified from (32). pET30a-IMPDH and
variant plasmids were transformed into Rosetta (DE3) pLysS E. coli (Novagen) and grown in
100 mL LB media with 30 µg/mL kanamycin and 34 µg/mL chloramphenicol. Cultures were
grown on a shaker incubator at 37 ºC until reaching an OD600 of 0.5–0.6. Cultures were cooled to
room temperature and were induced with 1 mM IPTG for 14–16 hours while shaking at room
temperature. Bacteria were pelleted and resuspended in 6 mL of lysis buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole, 10% glycerol v/v, pH 8.0) supplemented with Complete Mini
protease inhibitor cocktail (Roche), 1 mg/mL lysozyme, 10 µg/mL RNAse A, and 5 µg/mL
DNAse I (Sigma). Suspensions were sonicated with a probe sonicator on ice for a total of 60
seconds in 10 second pulses with 10 second rest periods at a power of 250 W. Lysates were
incubated on ice for 15 minutes and then cleared by centrifugation for 30 minutes at 10,000 g at
4 ºC. The resulting supernatant was incubated with constant rotation with 1.5 mL of a 50% slurry
of Ni-NTA Superflow resin (Qiagen) for 30 minutes at 4 ºC. Resin and lysate was decanted into
gravity-flow chromatography columns, lysates were allowed to flow through, and the resin was
washed twice with 6 mL wash buffer (lysis buffer with an imidazole concentration of 20 mM).
Bound protein was eluted with four 0.5 mL volumes of elution buffer (lysis buffer with an
imidazole concentration of 250 mM). The fractions containing protein (as indicated by UV
absorbance at 280 nm) were pooled and dialyzed twice against 1 L of storage buffer (Tris-Cl 100
mM, KCl 100 mM, 20% glycerol v/v, pH 8.0) overnight at 4 ºC. Coomassie stained SDS-PAGE
gels revealed a single band at the expected size (60.5 kD). Attempts to enzymatically remove the
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6xHis-S-FLAG tag with enterokinase were not successful on-resin or in solution without
degrading the protein so tagged protein was used in subsequent assays. Protein concentrations
were measured using the Bradford method (Bio-Rad Protein Assay) and protein was stored at
−80 ºC until it was assayed.
5.6.7 IMPDH Activity Assay
IMPDH activity for each protein preparation was measured using a procedure modified
from (27). Enzymatic activity was measured at 37 ºC in 100 mM Tris-Cl, 10 mM KCl, 3 mM
EDTA, 2 mM DTT by monitoring production of reduced nicotinamide adenine dinucleotide
(NADH) using absorbance at 340 nm (extinction coefficient 6,220 M−1cm−1). 15 nM of enzyme
in a 200 µL volume was used for each reaction. Reactions were performed in 96-well plates and
NADH production was monitored over a 30 minute period using a Synergy2 temperaturecontrolled plate reader (Bio-Tek) using an absorbance path length calculated from plate well
dimensions. Inosine monophosphate (IMP) or nicotinamide adenine dinucleotide (NAD+)
concentration was varied from 1–400 µM in the presence of 400 µM of the other substrate. The
rate of NADH production did not change appreciably in any reaction over the course of 30
minutes, so average rate was assumed to accurately represent initial rate.
5.6.8 Curve Fitting
NADH production rates were fit to standard kinetic models using nonlinear least-squares
regression in the R software package (R Foundation for Statistical Computing.) Apparent kinetic
parameters for IMP were determined using the model v = Vmax × [IMP]/(Km+[IMP]). Since the
experiment in which NAD+ concentration was varied revealed significant substrate inhibition at
400 µM, an alternative model including substrate inhibition for NAD+ was used: v = Vmax ×
[NAD]/(Km+[NAD+]+[NAD+]2/Ki) (36). Ki for NAD+ was assumed to be identical between
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variants. Differences in each model parameter (Vmax and Km) between wild-type and each variant
were tested for statistical significance using two-tailed t-tests (37). Reported Kcat is calculated
from the Vmax of the IMP experiment.
5.6.9 Animals and Whole-Mount Immunofluorescence
Impdh2Del, Sox10LacZ (Sox10–), RetTGM (Ret–), and Ret9 pups were genotyped as
previously described in Chapter 3 and 4. Impdh2+/Del Sox10LacZ/+ pups were produced by mating
heterozygote animals. Impdh2+/Del Ret9/– pups were produced by first breeding Impdh2+/Del and
Ret+/– heterozygotes. Impdh2+/Del Ret+/– mice survived normally and were then bred to Ret9/+
mice. Postnatal day zero pups were euthanized by decapitation and intestines were collected,
fixed, and stained with ANNA–1 antiserum and as previously described in Chapter 4. Bowels
were then incubated overnight at 4 ºC with rabbit anti-Tuj1 (1:1000, Covance #PRB-435P) in
blocking solution: Tris-buffered saline pH 7.5 with 1% Triton-X 100 (TBST), 5% normal
donkey serum (Jackson ImmunoResearch), 1% cold water fish skin gelatin (Sigma #G7765), 100
mM Glycine. Samples were washed 3 times with TBST and incubated for 1 hour at 37 ºC with
Alexa-488 donkey anti-rabbit secondary antibody (1:400, Life Technologies # A-21206) in
TBST. Bowels were washed 3 times with TBST before mounting and visualization in 50%
glycerol/PBS. Aganglionic and hypoganglionic regions were measured using the same methods
described in Chapters 3 and 4.
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Chapter 6: Conclusions and Future Research
Directions
6.1 Environmental factors affecting ENS development
Through a chemical screen in zebrafish and subsequent studies in primary culture
and in vivo in mice, we determined that the antimetabolite immunosuppressant
mycophenolic acid (MPA) and its prodrug mycophenolate mofetil (MMF) impair ENS
development and interact with Ret and Sox10, genes that cause Hirschsprung disease
(HSCR) in humans and similar ENS defects in mice. To our knowledge, this is also the
first chemical screen in which effects on ENS development were assessed. While our
laboratory has previously demonstrated that Vitamin A deficiency impairs ENS
development and interacts with Ret mutations, Vitamin A depletion in mice required both
genetic and environmental manipulations of Vitamin A metabolism where the genetic
insult was sufficient to interact with Ret even when dietary Vitamin A was abundant (1).
Mycophenolate exposure is the first solely environmental factor that impacts the
development of the ENS in an animal model. Future work will focus on drug exposures
that are more likely to occur in pregnancy, since MPA/MMF is already recognized as a
hazard (2, 3).
In the chemical screen we identified several other interesting compounds that
impaired ENS development, and preliminary work by others in the laboratory indicates
that many of them affect murine ENCDCs in culture. Artesunate has become an
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important part of combination malaria therapy (4) and pregnant women are likely being
exposed to it regularly without apparent harm, though studies have demonstrated
teratogenic effects in animals (5). Since this is likely to be a common exposure, it will be
important to determine whether it interacts with mild HSCR-predisposing mutations such
as RET polymorphisms (6), which can be relatively common in the general population.
Mevinolin, a widely used cholesterol lowering drug, is contraindicated during pregnancy
due to the results of animal studies, case reports of malformations and out of an
abundance of caution (7). Separate from the likelihood of exposure and the possibility of
adverse events, detecting a drug that affects cholesterol synthesis in our assay highlights
the developmental importance of this pathway and suggests that ENS development
should be studied in mice lacking Dhcr7, a cholesterol synthesis gene implicated in
Smith-Lemli-Opitz syndrome, which can include Hirschsprung disease as a component.
The chemical library used in this screen is relatively small (9), and does not cover even
the modest 2200 compounds approved by the FDA (10). Also, our screen examined only
a single, somewhat arbitrarily chosen dose of 10 µM. Use of a range of doses and
expansion of the library to encompass both overlooked pharmaceuticals and bioactive
natural products that may be present in the environment or deliberately used will likely
yield additional ‘hits’ for further investigation.
Further investigation of a class of drugs, toxins, exposures, and nutritional
deficiencies is prompted by the fact that MPA/MMF impairs ENS development through
its antiproliferative effects. Many other exposures could plausibly reduce proliferation in
ENS precursors, contributing to the failure of ENS development during the critical period
in which precursor migration is possible. Our data suggest that such insults might also
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increase the likelihood that a RET mutation will result in penetrant disease. Interestingly,
flubendazole has recently been shown to act as an inhibitor of microtubule
polymerization in tumor cells and delays the growth of leukemia xenografts (8),
suggesting that it may also act on the developing ENS through an antiproliferative
mechanism. More common exposures that might modulate cell proliferation include
Vitamin B12 and folic acid deficiencies, as well as commonly used antifolate drugs such
as trimethoprim/sulfamethoxazole. These and other exposures are amenable to
experimental testing against HSCR animal models analogous to the experiments
performed using MMF.
MPA/MMF itself may prove to be a useful experimental tool in the search for
candidate genes affecting the ENS. Much as MMF treatment was capable of uncovering
the phenotype of low penetrance and nonpenetrant Ret genotypes, this simple
pharmacological manipulation might induce aganglionosis in the context of mutations
such as Phox2b and Zfhx1b that, like Ret, cause no ENS phenotype in the heterozygous
state in the mouse but result in HSCR in humans.

6.2 Requirement of Impdh2 for ENS Development
Prompted by the effects of MPA/MMF on ENS development, we then
demonstrated that Impdh2 is required within the neural crest for the development of the
ENS and other neural crest derivatives using a tissue specific knockout mouse model.
Impdh2 deletion ablated most ENS precursors and appeared to provide a selective
advantage to neural crest cells that did not efficiently express Cre. Implicitly, this shows
that IMPDH1 is insufficient to substitute for IMPDH2 and that salvage cannot substitute
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for de novo guanine nucleotide synthesis, even when neighboring non-neural crest tissues
are normal.
Given the reduction in the number of ENS precursors, it is somewhat surprising
that we were able to detect neither a reduction in proliferation nor apoptosis in EYFP
marked ENS precursors at embryonic day 13.5 (E13.5). It is possible that these cells are
dying through non-apoptotic processes or have already been eliminated before entering
the bowel. Wnt1-Cre probably begins to recombine loxP sites at E8 (11, 12), and our
current studies leave a large time interval unexplored. While the developing ENS at
embryonic day 12.5 and 11.5 was already hypocellular, examination of the pre-enteric
migratory streams of vagal neural crest cells at a time point such as E9.5 (13) will
probably be necessary to determine the fate of recombined cells. At this time, given the
evidence of incomplete recombination and the defects in multiple neural crest derivatives,
we cannot exclude the possibility that Impdh2 deletion is lethal to all cells, and the cells
that are in the bowel at E13.5 appear normal because they escaped Cre-mediated
recombination.
In parallel with the studies performed in vivo, we established a mouse embryonic
fibroblast (MEF) cell line from an Impdh2loxP/loxP Rosa26EYFP embryo. Preliminary
attempts at Cre-mediated deletion of Impdh2 in culture do not appear to have resulted in
adverse effects on these cells and thus suggest that not all cells require IMPDH2, but
more work is needed both to confirm complete recombination and analyze the phenotype
of these cells. In vivo, PCR analysis of ENS precursors sorted using the EYFP reporter
would definitively determine whether any of the cells that enter the bowel have
recombined both copies of Impdh2.
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Alternatively, deletion of Impdh2 could be delayed until a later time using 4hydroxytamoxifen inducible Cre recombinase lines with activity in the developing ENS,
such as RetCreERT2 (14) or Tg(Sox10:iCreERT2) (15). Normally, at E12.5, enough ENS
precursors have entered the bowel to perform organotypic culture experiments
incorporating time lapse imaging capable of observing non-apoptotic/non-necrotic cell
death (13). Moreover, guanosine supplementation experiments performed on these cells
could definitively determine whether or not any of the proposed nonenzymatic functions
of IMPDH2 are important for ENS development.

6.3 Hirschsprung Disease Genetics: IMPDH2 and 3p21
Because human IMPDH2 is located in a genomic region associated with HSCR,
we sequenced IMPDH1 and IMPDH2 in a cohort of patient samples. While we found one
heterozygous IMPDH2 variant that moderately reduced the activity of recombinant
IMPDH2, we did not observe any differences in the frequency of common variants
associated with IMPDH function. Moreover, heterozygosity for loss of mouse Impdh2
did not influence the penetrance of ENS defects in Ret or Sox10 mutants.
Thus, IMPDH2 is unlikely to be the RET modifier locus at 3p21 and the causative
gene remains unidentified. Mapping studies have demarcated large regions containing
many genes, making a candidate approach difficult, and the relatively modest effect of
the variant combined with the requirement for a RET mutation for penetrant disease
complicates the human genetics. We could turn once again to the zebrafish for a higherthroughput system with which to test the large number of candidate genes. This system
has been successfully used to demonstrate genetic interactions between ret and the
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syndromic-HSCR associated genes bbs4/bbs5 using morpholino injections (16) and a
bowel colonization assay similar to the one used in our screen. This assay could be
scaled-up using fluorescent reporter strains (17) and a prioritized list of candidate genes
culled from the regions linked to HSCR. Such a screen could also be adapted to probe
gain-of-function mutations since overexpression within the developing zebrafish ENS
can be achieved through mRNA injection into the early embryo (18). Exome and genome
sequencing of patient samples will likely allow finer mapping intervals to be obtained
and may even identify specific candidate genetic lesions that can then be tested in animal
models.
In closing, these studies demonstrate that maternal medications can, in principle,
induce HSCR-like defects in isolation and in cooperation with permissive genetics.
Mycophenolic acid serves as a proof-of-concept environmental factor that modifies birth
defect penetrance and expressivity in susceptible genetic backgrounds by reducing ENS
precursor proliferation. Both pharmacologic inhibition of IMPDH and its genetic
disruption through the tissue-specific ablation of Impdh2 can impair ENS precursor
colonization of the bowel, implicating a requirement for de novo guanine nucleotide
synthesis in the developing ENS. However, IMPDH2 mutations probably do not
contribute to HSCR.
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